var title_f10_22_10592="Whooping cough no whoop";
var content_f10_22_10592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/55250/Whoop_cough_no_whoop_conv.mp4?title=Whooping+cough+no+whoop\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sound of a child with whooping cough without whooping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: file://www.whoopingcough.net/symptoms.htm. Copyright &copy; 2010 Dr. Doug Jenkinson.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10592=[""].join("\n");
var outline_f10_22_10592=null;
var title_f10_22_10593="Brown Sequard syndrome";
var content_f10_22_10593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Location of lesion in Brown-Sequard syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10593=[""].join("\n");
var outline_f10_22_10593=null;
var title_f10_22_10594="Exposing the upper vagina";
var content_f10_22_10594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54784&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vaginectomy: Exposing the upper vagina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 370px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFyAXMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACikZlUZYgD1JxS0AFFNDqWZdw3KASM8gHp/I06gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACignAyelc/pni/R9T8QtotlPJJfpaLespiZQIm2FckjqQ6nHXmgDoKKr390llZzXMv3IlLtjrgDJ/SuS+GHi+48WW+vLfwQ295pWqTafJHFnGEC4PJPOSR+FAFjx7HO50+MNi0uS9q2c7EnO14Hb0HmRhM+sgHetrRNZttXifyt0N1Dhbi0m+WWBvRl/kehHIJHNY914m0bVNYTw08TXU11GzSREcLFukUPn0JhfBHseMis3X/h3/bqNBqGuXklvt8tJfJjF3HH/cW4ADY+oJPfJ5oAhvJH1vxDO9lukhdPM4Py+TCsqK3X/lpLI4HqsTEVag8X/ZdA8NwRJ9o1LUoLSOKSZtsW+WJ2DORz0ifgDk4HGcjh9RsYvhd8UfAlroF1ff2Xr/m6ff291dPOJXRUEUuXJwwLAcYG0YAFdN4f+GXg3UNAH2zw9aeZKgtpwpdcmFigIwRtPynkYJzQBp+ND4nuvC2oQQwWNlIsRka9iu3YqEG7MabAd2VxgkAZzk4wZfhFrt54h8EWl5qcyT3iu8MjqoXJU45AJGfXn8ulcl41sNB+FWm6fqGmfaLHSb6/FlqiNPNcK8MsTgvtdmOUKqw284DDnNX/ANn/AFGSXwxeaTfwSWup6bceXPbywmFlBRdrbT0BwSOAMYwB0oA9A8RymDw9qcys6NHayuGQkMCEJyCO9R6BezXqXJuAQ0bxjBGMZhjcjH1Y1S8cOs+lJpCybZtUcW3DAFYusz89hGG59So71Y8Ilp9JN/IWLX8r3Yz2Rj+7H4RhBQBtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAEZBB718/2cj+Ffix4L1mdBDp+q2Enhu9lcnEd1AxVMk8LvMaAeuDX0BXI+JtAuXa7l0+ysNVs70g3ukaiQIZiBgSIxVgr8KCCCp2g/KckgGb4x1Q6zeXul6TELuOwhdb64V/kt3lBTZ8vzFxGZCQB8uVJ9K8t/tbxNY33iWTRtO1e6mlZYLiSwaOS4uURF8t3H3o5VSRY2lRX3AKQuRmuh8QqtxqNzLa6d/Yunad4enuYEsisDrexyOFQyRnDKu2TC/dO4k5yANj4NeZcavqt88hbzmkQgIAoKiFcZA5IIYd+nYAKACT4L+CdS0qe/8AE3imGK31vUFWKO0jORZ26hQsecnsijGTwoySxavVaKKAPC/2lpzYa/8ADPURIIzba4mSVzwWjJ57fd/KvUPAyvHZarHIWJXVrwjcScBpmYfh81eXftZMI/DvhqVmKiPVEbOcdBu9D6V6x4acf2h4jiDZMWo4IyON0EL9v96gDz74xxw69488C+GbhJJbaW7N3NGGITKfOpbH+xHOB9TUq+F9Ukuj4j0xpp7x57poZbW4SG4iheZysI8xWjmiPyttkxtYkqQCAKL6mt58ZvE+oiKTyPDems4lyrK7iLgAYyMb5gQTz+deq+GbOTT/AA5pVnMcy29rFE59WCAH9c0AcB4Z8K67quqXGq+K457eeeL7JJ9ouYpZTahg3kqIgI0DsMuw5IAX/ar1EDAwOlFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4b48l+y6F4ikVFD/YDGqM/Xfd3APPpjP0rqvhHbBRNcLKJ4/IwkoZmDZuJweST/cXjqPQdK4D4o3qPpb3RiR/PmtoEjcE5zNcPgYBycjAHQkivSfhDzogwMAW9uf9WE5kUz/dBO3/AF447dOetAHfUUUUAeF/tZBD4S0kyFAEnndS5x8y28hHrzkf/q6j0zwplfFPjRSGAbUIJASMZzZwLx6j5fzzXnv7TzQv4d0+1l2bpku9nmReYpIgbAPcHkYYA4P51r+G9YuLHTfGusXBAni0+1vj5hPDCxUkEfVaAMPwdHJrQ8eai7FbXV7+3sEGedrStkH32TqPwr2+vGvhbZNB4M8Kw+crtf6xJcPjoyQpIAfzhjP417LQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFB460AfL/wAbLaKfwpYRviWGS8tSMPtLN9muyNp4OcspHv8AmPoHwfaR2UF9DCqqkc6RAKcgeXBFHgfihrw/4iWbXMPgOxOA19q9jbsIzhQPsybmBOcr+86Hrz3xXung+Qz6O1wV2+fdXMo/3TM+0/8AfO2gDborM13XLDQo7J9Sm8oXt3FYwDGS80jbUUf56A1p0AePftBvGi6S9xEzQxWt/IXVWPlny0UMSv3R83XBHI6dRkePbryfhV4sk2r51zY6dBItsT8+dqOFPptDc+grd+OchjvtIZX2v9hv1GVyMMIV65GDzxg88jpmuU+Pdz9h0W2sx5KyTyWQKyfL5vlwXDYHIBbdswM4J456EA7P4WaeIdI+HsRMgNvoEl2yPywebySN3vzIK9TrkPDUKweLbqxVFVNM0ext129izTZH0wiV19ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRTJZVi2bgTuYKMepp9AHN+NPEjeHtOupo7cSyx2j3Me9tqMVdFCE9iTIOau+Er2fUfD9rd3SBJJN52j+6HYL/wCOgVxvxkAfQtVcvGRFZRQmKVgqMJrmMcknHSIj8a6rwDYrp3g3SLeP7ogEnb+P5+3H8XbigDfornbrxLp1reM17cLHCLg2cJ4PmSqpZyAOflwV+oI5JFbttK00KyNE8QYAhX4bGAeR2PtQBLRRRQAVBqEghsLmVuAkTMT9AanrH8YTGDwrqzqpZzbSIqgkEsykADHuRQB414ggK/EvwOCA8GmxXuoSRn+FobK3VSf+BDH517d4ftnstC062lOZYbeNHI7sFAJ/OvIbm0uL7x9ePG67VsZbQFh3vNSaPI/7ZWz/AIV7bQB8/wD7Ttl4j1PxN8PrTQjBsOoGSBHlKmS6XDKW4wAqqcH/AGjX0ADkAkY9q858b2jah8XvhzEMGK0TUb+Rf92OONT/AN9SivRqAPIvjSjXGpou8tFb6RdTSQlVwwLJ82TypG37w4H8XykmuX+LGm3+sfGjw9aRSstgsFkXQxExtuncOCV5B2qCMjbxgmt34wSs3ie9VHljkh0dPLdQQuXebILcYOEyPoc4HzCC5cXv7UsVniVhaabFOVDfIqqkuCRj+9Inf0oA9S0GKM6/4juVwXa5ihJ9kgjOPzc1u1k+GY0WzuZlRVa4u55GI/i/eMoJ/wCAqo/CtagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyb4b+Pbrxt431KzuLYJZ6e001s6/L91/K2sMnJ+8c+u4dMV6zXz38BtOGjfFfxXZ77lDKt1L5Ui/Idt2ULKenbBr3fW9Ri0nSrm+n5SFN23OCzdFUe5JA/GgDxr413cuoXFvo9lOouNV1SG3TAz+7twDnHcieYD/AID7V6/qlx/Y+hn7JGHljRYLaIn78hwiKfbJGT6ZryDwUX8T/E60uXdZIdLjkc5QDLKWDOO43yzO4Bx8sa+9dV8V/EEum28r2hX7VaKsVkrYxLfzhkiAHUmOPzJCo7MD2oAzPBFo2v8AxD1G4Zd+k+GD/ZtrMcq1xcnD3DsPunMmCcd0X3r1uub+HPhmLwj4O0/SIt5eJS8zu+9mkYlmJb+Lk4z6AVo32pR2j3LzTqkahYkG3d+9POOOSTuTj3HrQBoxukiK8bK6MMhlOQadTYk2Rqn90AVz2q+JW+2TaZ4dtP7V1eMfvF8zy7e3P/TaXB2nvtAZ/wDZxzQB0dcN488b+GdLjhsr/wAQaRBci8tzLDLeIHRFkV2JTOeikdO9VNV8KS38SXHj7WtU1KN22f2bpEc0FoCexSHMrjjq7lfYdKdZSaB4bneLSPCtlZWEYH72O0NqwPctviVevfec0Aee/D74keCLrUdOku/EVlb3CiN5DdkxANHAVA3MAOXuJjnP8Ne9aZqNjqtot1pd5bXtq33ZraVZEP0ZSRXD614tjvY47O40+9topSXLbYmcqOQyrIrIyHoW7Z4PeubufCOlarJLqOiYivfKJD6WpsLmMYID7EKmQ5/iDYPHysOCAdzYMl/8T9Wl2N/xK9OgtFYjjfM7SSAf8BSH8662vDF1vx/4MkWbzYfFGkynPlXkBgviB8uEkRAJGGMkMm/APAAzXovgP4g6H41jlTTJmhv4RumspwFlQdNw7Mmf4lJH48UAef8AxTUz67rqIjNJMlnZjKjaRvU7ScHI/e5IPA4I2n5q1dA+T47/ABB1WVwtrpul2cL+mWQyE/UBB+BFcJ4i1ywtviLrV/eXkdvFBr9ot4JchY442hUOcjGML1Ge3TjPomiMNX0PxR4gs7aS3j8T38MVqbldjSW2yG2WQqeQGAkdQedpU45oA77w1bm18PabC2dy26bs9d20Z/XNaVA4HFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcCLi90q+8V3L6nfXkWj2yzw287pscmFmIbCg9RQB31Fee654w1jSrPznt7Oa4t7ZL67toEZwkLsQv71mQAnY44ViSv3afr3iPWm8L+IdV06awtIrN7q3hR4y0yvC5QuSTtOSjELt+6VOT0oA7+iuHl8QarF4hk0hWtvtk1xDbrNIrGCMm3klYhAQxJ8vGN3cnPGDSvvHOprpM97bWtmgs9Ln1K4WTc3meS7KyRkEYDbCQxzgEcGgD0WisXxHqV1ZzaXaWAgW51G5NustwpaOPETyElQQWJEZAGR1Jzxg8pP441NrKe6gtbNEsrEXtwr7m83E0sbLGcjAPlFlY56jg5oA9ForF8Tandaf8A2XDYrAZr68FrvmBKxgxu27AIJxs6ZGfUVyH/AAnWs3DGDT9JS5u7WCSadUGVuClxNDiMl12KxgZtx3YDpkd6APSaK4Y+I9VuJkkaK2htP7ZOnR+XIxdwsjqS4IwAdvQfmOlUdC8T6/NoGjefLp0l9c6dNqL3E0bKjJH5YKYUjDEycsOFAHynNAHo9FcHB4y1C5uknjtbeLTxdWVs8Ugbzj9pjjYHOQFKmQcYOcdqr2HjjUrixl1K4sVttLlikaCZoi3lyCQIkbAPmQsSeAE2kY56gA9Eorz7S/Eep6jrum2t8jWs1tqs1lcIgCCZfsXnKSodwP8AWLxuPK546D0GgAooooAKKKKAPNfFfg7ULfxVbeJPDLCO8id3KbA6tvXDo6FlzGxw2VO5W3HDbsDj/ipqviG2t4dRvdKuNQaAs1slwqWunWcqRNKZnQu0k7KsblSwCKVHAYiveq8V/aW1RYPB+tKJCTb2KQ+Up5Z7mZU49xFFP+DGgCf9nJrmP4f3fiDX7lZJbmR55bpyCxUZd2Zh6M7jHYKB7VQXy/EHxk8MaZcuguNOSbxBeRNE4YzSKqxqGPH7tTCMda63TbW28P8Aw18PaNcl4Y2tllu/3ZyI0Xzp9w7bsFDznMnevBNJ1aTTPi7Lq2rpd2txfYuvt0LAeRJMv+q/efLkiMDYx+7uAwcEAH1lreoppWmy3TRtM4wkUKfelkYhUQe5YgZ6DOTxXm3h55/FHxAVDM1xpegxn7TLGwEVxfNJuYAAAkIyDGenljrnNctrvjCe+1uytdF/tfVNbvojbQXcnlxpZLIjZkhhQ/f4+aR/uZXsxFdvcxzfDr4f2en6NEtz4i1KdLO1EhLK93IMbnPXZGqlj/sxnuc0AXNW1q+8TeL7zwp4ene0s7CNG1nU4ziSMuCUt4D2kI5Z+dinj5iCOq8OW2k2WlRWnh9bVLCAmNVtmDKrDrkjq2eSTyTyeapeBtC07w54ei0zTJvtIidzc3LNukuLgnMskjd3LZz6dO2K27e3hto/Ltoo4Y852xqFH5CgChdaubW4kSXTtRMKY/fxwiRT9ApL/wDjtTaXq1hqsbPYXUcxX76A4eM+jKfmU+xANXqz9R0bT9RcSXdpG8y/dmXKSp/uuuGH4GgB81tHLZmG8toZou6KgIPuAenese5GgXNlI5gbEDrvMUTrPbsMgOQBvU9fm9PUVu2Fu1pbLC9xNc7c4kmIL47AkAZx0z19c1FqOmW9/seQPHcR/wCrnibZInXow7c9DkHuDQBws/i2yWeS1uVi1eDb5ZuRlTJHnjKgYPP8S8YyRjgNl3ngWx8WKNT0m+fTdahOYroD/SLRsZUkg/NzkHs4JB+bcx7rXkstPsrh/siRsbeRjdrFH8pwByMgktnsMdjjIzgeDLaylAvrO7ksbu0YR3VqXBiw2GXGedjKQV5OMjuCCAeU+BfD8+p+NvFOqeIls7jXbJbeW5kgiWRFn80jdD5mFG5YE6ckZHGa9I8IXlxr+uW99crN9pkmLTrIhEapCjLiEnqnmSIcHDAqc54J4f4ZBLrxF421G94s7i8mmm2ou5wtsgwAeCf9K4B4Oa9X8F6faW+pXbWjyTLbwQwmZ9w3SOokdgpPyllMJPqeTk5NAHX0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAVm79HuLnUbbdp8twyAXsWUZimMASjrjBI+btWlXmZ+H9+1reWryQOStyIbt7yUlhK+8q8O3aA3AYhjnBOOcAA6Fr3whrgvLi7j0i6t9MZbdru4WJ4k3KrbVc5GPmAPTnir88PhoXK3VxHo32jUQYVmdYt10CMFAx5fIwMc1yuo6Vqmn37a7c21qZf7Tjuls7bz7hSBaGDkpCWBBywOwjtxnIzbHwPqd1o9nJPBGRcab9juLKW8ktfKHmySZBRGJyJACpCkbF59ADvtQ0zw7ZaZImoWWkW+nNsDrPFGkRx90HIxx2qrJeaDJrqeH1sba4mlsgsirHEUS2YNtRgSCyNsYbVDD1ABzU/iTTby7u9KvdPS1nmsZXf7PdSGONw0bJncFYhhng7TwWHfNZ3g7wrLoWoNPO9vKv9mWlmpQHKvG9wz4GOExMgXnOFwcYGQDQl1DQtcvr7Q79bS4mtpxE9pdqjeYwijl3KhzuAWReccHNQ6df+GtSs7EKunR/2jaqkNrOsaySwc7U2d1HzccjrWbL4Z1KXxHfTMtithcatBqi3AlYzqIreKPy9mzAy0bc7/useOaxv+EH17+ztNsXubSSG1Sy2lbuWIRNDKHf5FT97nHBcjB7DqQDpvED+H9d1rT9D1CWG6uIJHvTbApIqmNdpEqnOBiXIGO3tTFufB+rw3EUkGj3Fjo4RfNljiaCEMOAjHIXoAelYdx4H1a5tWsXmsYoEtNQt0ulkdpJTcsrBnTaAOh3YY5zxipdQ8I6xqF1NfyfYbW4+1291HbW91IEcRwvEVMgjBX74YEKcFRxQB2K/2OUt9v8AZ5SWUXMONmHkYkiRfViSTuHJzTZPDuiSQ+VJo+mvF5pn2NaoV8w9Xxj7x9etc/4c8Hiw1azvbq0swLe1ljRPNa4aOV7hpSyu6g4OevHPGMAV2lAFZtPsnd2a0t2Z5EmYmJSWdMbWPHJG0YPUYFVW8P6M09zM2kaeZrpWSeQ2ybplb7wc4+YHAyD1rTooAoWWi6XY7PsWm2VtskMq+TAqbXKbCwwOu0Bc+gx0q/RRQAUUUUAFFFFABXzr8UrdPFXjjwzoDTFl1HV31CZU2/LFCy26deWBWO4Ixn7xOK9716+OmaJf3yJve3geVU/vMFJA/E4FeG+DYYpPjNqN1cMkln4X037OsgySBEgjbg9y5uDn6euaAO0+IEi6le3dsSyrKV0tXYkKi4E875XpwIV57jFdJ4V0izuNFvJrywt2j1ab7RLDJGGR0VVjjJU8cpFGcHoTXMWZvLo3Nm1sYLi5iS0klfGUmuSZ7gLg9VRiOnVF7V6dFGkMSRRKEjRQqqOgA6CgClpei6XpO/8AsrTbKx8z7/2aBIt312gZrjbkDWfi0ZPPjUaDZG3tEkXcPtlwu+RsAgnbCsfcf64+vPoNedfC8Lf3+o6yqHbezXF2HY5LeZO0S4PoIrSH86AO/s7aCztore0iSGCJdqRoMBR6CpqKKACiiigAooooAgvYVuLdonD7WIB2HBxkfp6juK878WGbwlfXGoW0H2iF7WaRYUTmQKjNJCPTb/rUGc488DqK9LrzD4gXaXWv6ZZbZnt9SnhtcqM7XSYFhgHKYUvkkcgleQRgAytUs5fCl/YaH4XTR7e/1crDNLfM06KfJeS6maMNn5UhtwASFO4DpVP4H382m+KLjS7++mvn17TYdcF3cMQ805J3jafunyXtzsHCheBis3xPcy6x448R2kU4W4mRdJg2ncY5L2UQs4GOCtvZO+c9GNbGsT2Fl4h0vWIo4I5bbUI/sxSPO23wkLhOeB5EiFu3ydutAHtVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJvMMMnkFBLtOwuCV3ds47U26uYbWISXMqRRlgu5zgZJwBn61LQB43o3inWfC+sXNpryzS+WgmvLSS4MrW8edvnwyPzJATgbjgr0kCt8zet6bfW2pWUV3YzLNbyjKuv6gjqCDwQeQeDWf4m8PWniC1iS4aSC6t2821vIMCW2k/vKSCPYqQVYcEEcV5lZ3eseB9dkt/s0RaZmllsosrDeIBzNa5JIIH3oiSU7ZTaVAPZqKoaHq9lrmmQ3+mzLNbSjgjqD3BHYj0q/QAUUUUAFFFFABRRRQBzHxA1BLHSrXzGARrlZZBjJMcIaeQY91hI/GvI/hlDcLoeuXGrJIY727htppXxkxqr3VyWI6gq7LnvxXZfGa+ZLa4hgLpcR2XlJIDja1xKq5B7ERwz/nXGRXdpp3g2M3TrBcahOYRJ5q7DLdzEth/ujbb2wOemH7A8AHofw7aDWLiPVI0ijJjN7PFG5kVbqfg4J6FY0HHT94a9BrC8GW/l6KtwzFnvJGud2MZU8R8e0YQfhW7QBX1G5Flp91dNjbBE0p3HA+UE8nt0rz74KPJJodsUaNrZNK06M4GGWb7OJHB45z5oOcnkkdq7DxoCfB2ugAk/YJ8Af9c2riPg6ZFsbJ4Gikhns4fNRDgKFjWNGAz6xyBu+WWgD1CiiigAooooAKKKKACuE8V/ZtL8XWGqSzxxWlvDNe3MKpl5pVUQxbcDJZhIRjksY0x92u1vLu2soGnvbiG3gX70krhFH1J4ryTX/EEaeMdP8SF4ZdEtLyJJ7hmK+TbyCa2jcdsC4aUsT0XbQBg+DW0seLvD8FlZxT65p2myzT3BnULJqE67yJAASwRTcAPzjcVHJ51fFumedpHiK00KG5Dtp84trcfLLGGBbgOB5S7sjLfw5Cbifl80+H9xZ638VjqmuwqFN462ZinmReDO8i7shCwaRSQThflA4ave1kmkE8ek6bq9pDcgubWK0t4ULHqzSnI56k8nnjPSgDqvDuorrHh/TNTjKlLy1iuVK9CHQNx+daFch8INw+FnhNXPzJpsCdc4wgGP0rr6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAI7iJJ4JIZUR0kUqyuu5SCOhHce1eZ+Lby88KOlrpGoI2o3Iza6XauzSS4DEBInEgReDlsogxyRWt8V/HSeDdNs4LULJrWpyeRZoy5WMDG+Zx3RAQSOpJUcZyMT4UeDoZLG71jWgL+4vHli86dQzXMYcfvJDjJLFWwudoU7QMcUAJ4Z1r4l65a+fHD4PgQAZia/a4lXPTc0SlB+FW/ENv4k1fT3sfEOhQSwR4mjurCU745V6PE6t5sbjnDLGx7dCRXosltBLbtBJDG0LAKUKjBHpiuafwFo8a3J0x9R0uW4JLy2V7Ih5OeASVHI7CgDy7wpr97puotPZKsl68jxyQxriHVdq7m2gY8m6UDLwlVJ5dVIJWvafDmuWPiHSotQ0yXzIX+VlPDRsOqMOzD/64yCDXzx8YNB1LRtfmvrbWrqcfZkSaHUYwUuVViyHfE28Op3FZdoZCBg81a+Hfii9llTXdMbzdRO6LULVQFXUvLGW+QHbHdqAWIHDr86cb1AB9IUVm+HtasfEGlQ6hpkvmQSDoeGRu6sOzD0rSoAKKKKACiimyyLFE8khCogLMT2AoA8H+L2qrFqMdy9yfIN/M+N2MR28Ihx0wR5k03UgH8KyW8qaTwl4e0yS7gvCkNyZVhEsaJcZhBdTwuYIjjPTf71meOkHibVk0q3eSK6utPs4QWUjEt5O0rEc4yPOUnP92ut+H9qNY+N+sXkBC6ZpqyNCI2yjABLWNR2IX7PKR6Fj65oA9zhjSGJIokCRooVVUYAA4AFPoooA534i6vb6D4D1/U7twsVvZSsOcbmKkKo9yxAHuRXGfC+5him08SI0a3Vja3ULD5V3TWybh/tKxjPXkMn+0M7vxLt11e68M6A7Dy77UDPKhPDpbxPKFI7jzVh/DNYXhqKaw0DQLq1f7RPZIun7XOxWAO+FOeBuRgoP94x+hoA9VJwCcE47DvVPTtSttQV/s7kSRnEkTqUkjPoynkfyPbNRO51jSEm0u9e3MoEkUwQNgjsynt2K8HqMg8jKmks7ueCHxFbCy1JCFhuEkMayH/plKCDz/cJB9iOSAdNRVe0gmgASS5aeNUCgyKN5IzkkjAOeOw6VFqN1c2xj+zafNeBs7vKkjUr/AN9sKALEkcP2iOWQL5qBlRieQDjP8hWXqg0i3tIk1LUPs0KOZFaS/eIk89W3Akc9CcdPQVh+Lbi6vbGEyeHrgMsg2+dFbXDNnqqguQpIGc89OlcRrt3a6FsvLixigu4k82GOW2jBQKcFlVIopDjPXlecZGaAOnvdf8JwQvPoEMOvaijLHC9spvAkrMFTdMSVT5nGfmzzwDXmHxPvLrS9J1xIr2eWe7RdFt4Y4SzXkSYSQ5Hyo6yidy2DgTDqcVN8O/Fd94x13Wdav9WnfR/DqeZDbiONIvtMgdEIx8rFRu45G5l+Y8E8HfRa/wCMJ9G8P2VoLnSAzhRLEjJLJNdStJK053AEABGdSW3BgBliCAeofszeE/sJ1TVrvUobyeJV0+K1RHH2RNiSMCHwQxY4OVGfLBHHFeq+JNfn0hJLiP8AsxrKK3lmYS3LJOfKVi+yMId+APUVnp4StvDul2J0SzZ7y1jKSXkLgXUmfmZuflkywyUY45+XGAKyPiF4huZPh3r9tHCt1dzQf2cJoCEMctwRAm+JyHQ7pAcfN9aAOu8AW4tfAvh2Bc4j063XkYPEa1vVHbwpb28UMYxHGoRR6ADAqSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5l8U3Fx4m8dXV6XjurbUGksEBVtltYxyFcg/9NHXeWGeHUdcY+lLKIQ2cEQAUJGqgBQoGBjoOB+HFfLPhaN7HxNYrPMTK6yWu+MMRalHkWUMd3BQRqG4wqszj5sZ+qYAwgjEjbn2jc3HJx144oAfRRRQBn+INPj1XRb2wmtoLqO4iMbQzkqjg8EEjkfUcivlvxn4Rk8FBb2xiurOU3ptZ4Tch43CKJoZIZh8ySpklXYDGcH5SQfrSuA8baBLrsF/5bWwjsr5Lt47iMssu2BARkHj5Se3XHSgDz/wN4qurGVNWgC3KXEfn38UCiNbyEYBu4o+dki7gJI8/KSDkxurD0r4ieINSs/h7N4m8GyQXrWarfeUy7kurcf6xc9VO0lgRzlQO5FfL2r6Jc+DJ/CesaZeaxZXfnSxbrkKLeKRCyB4m6MCq7DG3LLxkDGPW/AXi2LSXmkuwieGL2RYb+ycErpdxJwkqFgCbSYDKkjA56EMKAPQ/hR8SdJ+JOhtfaXFc288OFubeaM/unPYPja4+nOMZAziu4ryS/0KH4TasniDw1bvF4QnEdvrOmxZZLUABVvUHJ+UACTqSvzHJBNesxuksayRsrowDKynIIPQg0AOrF8aSSJ4W1JIP9fPF9mi5x88pEa/qwrarn/GNx5MOlxlSUlv4y5A+6sQacn/AMhUAeJDU4rnxx4m1u8kzb+GHvtRhh3DY/kKIY145Kkorf70Yx0rpv2WrS/XwPdXuqtJ58lx9mQMwZdkY5ZcertJn1xXlsrlvBXiGS6hkY6lc2VgTIzBXZjJeTLx0GwICR0Ga+i/hJYvp/w28PQyhxI9qs7B/vAyZkIPuN2PwoA66iiigDz/AMTPFffFXR9NMzxPDoOoXBkjfa8PmS20YkU9iB5mDWH8Mbl2tbrSNdKSHzDYzhn+995oJRk9HG9Mg9YlxWlpq/avHmoeKfMJt49QGhxswxthSMq4B9DdMR/wEVRudKGma+81tGs0aRhHIPE9q3zJkjoU25VxyDE5/j5AO+0e8ktbj+ytT2Ldjc0EoGFu06lh23/3l/EcHh+vx3rxYgs7TUrNlKz2U+FMg/2ScqT/ALLYB9R3s2KE6dbvfukzRjzBLIqgjg4Y4yA2DyRx1xxV0EMAVIIPII70Acimv6hp3lRXVgggChVUxSQMpH8OQHi6d/MArqYpJJ7RJFQwyOoOyTDbfY7Tg/garS6xp0N81nPewQ3SqH8uVwhIPQjPUfSrwYFQwII9QaAMK80zVr5kV9cFsitl1tLRAx46AuXwe+RzXzZ8TL3S9D1e60bS765vgqhtZ1G6uTJJcBWyI8k/OUBPy5yckDG0Y9l+KPxHtNGhXR9Fdr7W7v5Alq2TEDgcsDhWbIAJI27tx4AB8k+HXhSBp7bVHltv7PgvZbe8tby3dWkk+ykSLx842iTYkZ3MSCcg8UAQWkM/hTQrmDxDcRQ2Meob7y0WeKJ7i7MAkhUpGCURVVE8snaSpfjbtb0n4MaTO2iCC7i8wW85lEe3y40Z0gkG0dQBNCSMA/erjvF1rB4z8c6D4UV7q5vdPMl1eSzSKREDOWSOYqMNIkY6g8fMMksa930a1t9M8QX1nbRGJJLaCSPqQQgMZA+gVP8AvqgC/o+qQ6lAhH7u5EYeW3Y/NEcspB+jIw/CuR+IMEGoeM/A2mfZ1eeW/e+lkCZZYbaMuMn085oPxxWhrmjvpupNrOkiZXkcPOibnCtgDeIx1DAAOqjJwrD5k5o+BJH8SeJdY8VzxItuqjSdPKksGjjYmeRT3VpsqDgZWFTgZoA7yig02N1kUNGysp6FTkGgB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfO2q20Hhn45anYSXHkjUyNV01RziacBJicgqATAcscfeTOVzXvHh2RJNFtPLRYwieWY1BAQrwVweVwRjB6dK8q/aR066s9N0fxjpiobnRpjFcbjtBtpSoYk+zKnY8MxrR8F+JTrmm2T6RMq213FE0kh4uYiJ0j8tsjn5fMw2M4AHO3cQD1WiioluIWZ1WaMmP74DD5fr6UAS1C9vD5c6mJWWbJkUjO84A5/AAVJFIk0SSwuskTqGV1OQwPQg9xSGaITiEyJ5xUuI9w3FQQCcemSOfegDybxT4Zi1j4ZW0GoRiRrG5lMsecKSxeNwfpv7elebab4Z1HwdY6Vd3s8mpaBf232eKKdVEMIJLPbT5ORDJliJOiOEc4BYH6Ya2srq2ubP91MiyfvUJ37XOJPmHr8ytg9iO2K8q8ZeEY7nwPp+nWF29tF9rnQxSnfEdqXBBweUPHVSPoaAL3wx12ON18I6mXudPngd9HuLtcNc26krJbSqRxLCQUZT2HTg1veAo28OX114NmLtb2afadJkfcd9mzY8rcSctCx2f7hi9TXhOkm/e5bRNVnmtNSWWO8s78pgWV392GfI4KPlYpBjGGQkA7jXuGkajc+MfD+n6paRxWfiTSbvyrq1dsCKVSFngY4J2shJU/7jdqAO8rzv4v3ktrYO8RwYNL1C5T5gv7zy0hTkkDOZz1r0SvH/jvJNdQSaVaI5ubqKCFZFZQYlMrzyMA3BOyzbAJAz3oA80sbGXVPhZ4ZlnuZH1C/vLy4O8FGMjMLJGYEE52Hr1yS2Tg5+p7aCO2tooIFCRRIERR2AGAK8Q03QtPv73QBYL+807V7e0lR33tD5Qe4MZbPzuG3O7EAEsNpwgz7nQAVz/jbXZNC0hDYxxT6veyrZ6fbyMVWW4YHAYjooAZ2P91T3xXQVwOkrbeNPFD69E4kt9Dv2s7IsmVbERE0iH/aaQLu5GIuPvHIBe8I6ZHd/DLTNPNwrXE+nxTSTgZbz5F8wzYPQ+YS496k8OIXns5HhmRcSbducW8mcS27D+5uG5SfTAIGAcuyvYNKkgjlDJb2yy6dMdpCS28bEKw9GjBBOcDazkZAzWpo8d/pGuzwXCXN3ZTqnl3Ma5UY+VS46lsBQzewOMH5QDp7e3it7dYIY1SFRhUHQD0A9PauS1F9I0uW4aDUrvQZIQcrsIgcDn5Y3BRsgfwfN71T1S51rw1qodLuS606RwzG6jBDbsjarAgK2cddoOeFJyasvf294Bc3enajZTTrgz2txhHxwOCyluCPvJigBJvEFje2qxTeJ/Cs8b4ys8YO4EZAKGauV8X+I/Cnh3Tr1VOjXmoyQZtbSy09QGkHQk/MGx1wOQB0rrPEXiXRfCfhq5m1LWoxdRwEw+cI2nDbQFAjjUZ5x27181+AvC58TatqmpazqFw2j3DzXS3byBrq2njYy+XJvBVvkXcUJ6MGHRtoBQ8Jwva6/GurNb2E8m1Mm6iC+YzFfKlUnMcY8xwSQQ3zblfIx6j4lWx8J+D4xBqnhCZ5rZYLS40/TjLey3GSryq/mttCksS/O0574B2tJurOy8NXZ+3rp9igt5NQa2WJlRLmPeJpXkUl4wWWMKpUhUJ4AGPMNM0vU/H/AIu01dc2XkssUMmo/ZLfYGtoiXwDwxZ/MwWPJLADGQAAemfBnw7D4U8Mvq+s6e06axCfMuYV88wwfwpKqjdgrjJGRx82DyfRLGUW5tby0lOsaVGHSK6t382WBT95WAP71eF6ZYFRkHk1b0LxFp9xDDAVjsWLGKGMkCOTHGI2wAT/ALBAYd1FUPGU/h/QNl9dWjHVrxjBbQ2BMd1eyHkIuwgn1JJ2r1JA5oAytd8U6hqCWvh/Sht1TVy0UOo2jqVt4lAM0xRiHRkVhgEEb2QZ5rudH0610fSrPTdPiENnaQpBDGOdqKAAPyFYHgjw5LpguNU1hjNr18B5zGd5ltogSVt42c52LkknjcxLYHAG14g1a30TSbi/uz8kS5Cjq7dlHuT/AI9KAMfxFq0kmvWGh2KpJJIRLckgN5a87OD3yrPkEEeX6kV00SCONUXO1QAMnJ/M9a8z8Ox3z6oszhjq1y5mmOwgRk4BDHOQEXbleMkRJ1VzXo2n2iWNnHbxNI6oPvyuXdiTkliepJJNAFiiiigAoqCS8to1uC9xEotxmYlx+7GM/N6cc80x7+Bb2C0BZ55lLgIM7UH8TegzwPU/jgAtUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAE4GaajB0V1zhhkZBB/I06qN9cGwLXUu9rXH71iyhYFAJL84+X15PbjrQAa9pVrrmiX+lX6b7S9ge3lX/AGWBBx78183fDe6u/C0yW5Mc6aNcy2GoTMxZ4SkwG6dQu5YsAssy5AyA4wAa+nkZXRXRgysMgg5BFeI/E7T7nwh8RIfFujps/tSEwSOEBAuo0O0PnjEkYK9uUHIzyAez6fdR31jBdQMjxTIHVkdXUgjsykg/UHFeReHbSa41OG8srWWYtqOrO3/EtkixBLJcFZPtBAEmcx4XnO8cfLkdl4V8YaTfaYgs4vs90rRrLaGMxbSzRqWUcjbmVTkdc+9avgqSIeH7e1jcNJaDyJFxgoR0BHbjBoA4LTJNet5fDkMNtqlo1qunW7xmG4dJoTHGJWOCIo9pZ1IYF8pn5Rg0y3TXd8d8kOtHWRo7x37yRSkJMZ4TKsG4bMhRIUCcHaDya9eooA8k+z6pbvqh0tNYi0m51oSSyyxXTXDxfYYFU8YnK+YpXK8gqAeA1aPhvQdRvLoW2qX+oy2lvpsUkbvbmGOa4lku1lZkYbtwRkyuR94ZHIr0qo7iR4oWeOJpnHSNSAT+ZA/WgDwzU9CfUjqySRMYIo7a4SB1wFfydrox4+V0bawbHDfeWo/DeuL4f1+HXjPNJbTCCz1gyA7pYHJW1vn9JEZWglP95CcdK9EsLmxuPGN9by3bw3N0k0caCQxudrBTs4BJHlscjOK8k17RJPDHivX7eRF1Dw9An2iaNuJPs1wgFzEecc7FkUgD95EowC+SAfSVeJ/FYyXPjmKMjMMNrOxXrytlcgHHfm5Ax7iu1+FGrTXWh3Gkahci51HRZRaSTgjFxEVDQTDHZ42U/UGuQ8ViWf4tT2RSLY9oZEctk5aSyiwR6fNx67jQBU+F+uXHin4jahc/K2niU6jDKsSrvkERgZQQPuoGC5bJLK56Gvca8u+FF/oeq+KvEw8LQCHStIkFipBJ86ZmLTMM87RtRVGccMRwa9RoA4r4qeJLHQtIsbK/vJrMazdLYCaHO9EYEuVI5DFQVBHIZlIBNT/abOCT+yPDrQ20rwo1u6t+7DIq+XHgfwsiEHHZT3xniv2r1tl+EVxdSofttteW0lnMv3oZfMA3D/gO8fjU3wj13SvG3haDJitdchyd0ZG9HG09uG27UGDn5VQ9GoA7C4h/tJUv7aGVVuHUXMaEebaTpkCQDuR9xh0ZcdRkHUtbCe0X+znjF3pcqsuWfDQgj7mD1TsOSRwORyLsklrp6faLtoYHndFkk+6ryHCrk+/AGfYelZWq/wBjanZz351FYFt4v3t3bzAFIz82GzkFSOzA9+9AFOGWG1mkh0/xEItiuWstUHmFAOSw3lZNo9SxGOleYeLvi9psltqWl2NhDq91bxL9nu7O08y3hOcPkyYAYADaBnJKgZ6Vxmr+Irzx5dXmlaVc6hf+HLOTesGQst2yk7VUkNIFyM8MB8oAAOdvZxeFfDNr4LuZtSlCw3VqWis4wsGS4CeWCx2l8bQRwCdrHjmgDhbPwNZaja6dextp8hLAvfCJmNxLu5jVCOVK7t0Ywyj5gK7TTpbC/wDCsqxS3ek6JZ+R9lgkhBe7lMjuiSyglZrYyoqqY8bs7dwBOcnT9DvZfCxafWotH0eNPsaXeoxeUzuu5TuiBxM6ZKFyBkLkM2N1dnq3jDS9L0yzl8S36NqEGkyyRWVvuiEzbykE8cWcoXQMeT8gYZIxmgDzz42ING8DWmj6jrMx186tJeTxW4MC3gYvL5roMhCXIVCSQdg9CF9V+BejWXhzwtay6isdrr+tFruVZUETsGY7UVSeBgA7Rzkkkc1x/wAMfA2oaxaS+JvF1/51wY0kEt/+9UlAOZPughQvUEY6Z+Vt/S6VrXijxnDfaZpEWl3+i52J4ivLc+UeQGMUJXFww+bDfLHkdW7gHQ/EG7sY7pNM0ywbUfFGoKGS0hbapQcebdHBUQjplwSeignpc8C+B7fw7JJqN/KNQ8QXAImvGTasSHnyoE6RxjA4HLEZYk9NHwZ4Q0jwfp722jwESTEPc3Up3TXLj+KRu/U4AwBnAAHFX9f1qx0HT3vNRm2RjhVAy8jdlUdyaAJdX1K00jTp77UZlhtoV3O7foAO5J4A715fe3GoeINatb25hlMqnfp+ngD9xnOJWB43leRnpy2Nq/PLqi6p4j1azuryCOSUOx0/SpGGy1YAZmnHJaQBhgEbVz64Db9hYJZC4gt7r50UnVNYdwDH0ZkVj0Y9Sf4RyedoABPoMLWdwYkuUSCCUC8uu08xOFgQtk7VLcnqWP8AeL12Nc3othFeyWt0LcQ6XaD/AIl1uVI7Y85geQSCQoPIBJPLYG5f3kNhaSXNyxWJMZwMkknAAHckkAAdSQKAJpHWONnkYKigszMcAAdzWKdVupdNjkgiRLq9kK2aNnhD0kcey5cjjsvU0mqOdUvINL2OlsYxc3jHAwmfliP+8Qc/7KsO4rOjvG1HUTPbkpNdRlbeUc+RaA5aU5PBcj5eP7n904AGWsUEs0NpBJ/oscjiFZFLG9uV5eaTHJRW78At9Fz09jaC2TLuZrlwBLOygNIR646Dk4HQZrN8NQCVH1IxLGs6rHapjBitl+4PYnlj9QD92tygAooooAKKKKACiiigAooooAKKKKACiiigArP13WtP0Kxa71W5S3hGQu45ZyATtVerHAJwOeDS315JZ3tmHRTaTt5TSd45D9zPsTkfUr6153NfX2q/ELxNqMUK3mn+HoYtKtrQDInuJlV5WY84VQ8YIwc7T/d5AEsvFV9pcgn03w3qkOizy5S1uyiHb/E8ABO0cg7GIB/hxzXSzX3hr4h6Hf6L9qim81Cstu2FngcEENsbkMrbWBwRkDrWnBH4gtImeaaz1K4ldRsVDaxQLg5IPzs3b/61cj4o8NR312bvXkltpVbzIL9JRJHbNxnEqqk0PfBB2jvnoQDyuBb3wj4in0jUZ4odcgjPkyCMLHdQf8s2jHAxmKAckkMG+Y4Fex+GdetDqLyRsB/aM7KqsdpJWRuQD1+SSDpng+1c/wCKtEj13SE0nxY5F3aoXttXKK01t23SBcB4jwC67eo3LGcNXm8urXPhHX4tE15P7P1R2Q27y+ZJaXu3CCWNx3I8pmzt2mPkEmgD6iRldVZGDKwyCDkEUted/D/xU8+nvBcQSSTrGPJghdTu2AKVXcwAOApxnkk/Su30u9kvoGlksbuywcBLkIGbjrhWP05x0oAu1Qm1IQXZiuLW5jj/AIbjYGjPGSSVJKjrywAq/RQB5xHo9nd+LdE2y2+oWcMDkvkSLJI/nF3HJAO4jnt0rmPEEUWm+NfEFlft51nqC2lrH9omY4VknbaJGB2lGjRhk8ZHIGSPSnsI08TSrYyJbXMsEk7vEi5DMY1UsD977j/r9a52OKGPxbdx68YWFzcLvfBMDMkJUDn7jYmjwCe3BJNAHmnwa10adq+liWTzJ7ac+Gb/AG5csnzSWUpIHO3bJDuOR8vXpnufFWnzWfxUXVJ4cWr2G+OUOvzFbqxJXHUEeXnPTDdc5rzu78NpoviXVV0eRxp+tfarSLIYPBfWsjTQAMSc8hUB4J3Ec9+9+IGux3/hjR9dUFI5tInmI2/MreZbMVwfdSKAMj9kCGY/DzUr26QCa71J5GfHMmUU7j/31Xu1eOfsoxtF8KI0kQoy3kilSeQQqA/qDXsdAHjf7U8Zl8A6UomWE/2xAVLYwWCSlQc9t23J5wMntXjFxpcPhZNI8UeCLyGa8toPtN5BbTBBCVjUYZCTuDAu2egJc4xla9d+Kc0fi/xbb6SzxPpGkSOsiyKWV7toWzJgfeECSIdo+80u3qK4my0LXtChfS7sxG1s5JL211WfAjWUv5awuwOVMbTPl+VypUc8gA2rb9ozSX0YSa9pksqSqkclobVlc7hncSd0bKRk9QePu1xmta9a/EXWIdP0W1kstNmYFI8uZ7xixYIrckAkcs2B2AwGYzXHhKz+dtdtZtKeSeQ3FtHOqxRqqod7w7cttGGJyAodQCNyEdhoXgy1sNNhFjPZyW6QfZpb2aQj7RGfnVPMUgrk42yLyBg8YIUA1/Avgz/hHoIZb6SN9bihCRyQ3DRxywtwgBPynJ2lW52OAvQjPP8AjJNR8Uanbx+D7uSSBWF1HBGywtazKHVnkyVVCXbG0nO45Xiu08VG8bR5YodsVrAk8vmOjtvTGHG0Z5XkvGQDlSwBGVqj4f0C4XTdTivnji8Q30On6rtsXHnmKKQnaNw/esoDfeBBLgHsSAO1e58L6Hc+HtR12VDbWmmRrpFuFZzeJ5bCaFYhhS+4wMdwIG1DxgkeOeE7d/Eusw6jqGmt4o8TSvGzwQR70sowoVImcYjQbVU5cg8kA7txrH+Lmualqmrap/b0mo3d8t21rp+mXkCxSx2bchjEqAozbVJOMn5MGvqL4OT20OgjTNO8N3+j2UI+0LJPaG3jkaVixUK2GLLnBOMcDBIxQAzRvA+p6vp8C/ES/hv41YSf2RZqUslIPG/PzSgD+Any8/w8CvQYYo4YUihRY4o1CoiDAUDgADsKfXKfEHxna+EbCACF73WL1/J0/ToeZLmT0A7KO56CgC54v8UWfhmzjadJLm+uG8u0soBuluJOyqPT1PQfkK8+s9P1XxJqgu7uZJb91BV4ydlsmefKOflX5ceYPmYj5Dx5oq+GfDV7qev3t7rMov8AXrgbLy73/ubWHJ/0aIdowcgkYMjZH3QxrutIMGrxT2mizSR6RE+251BDh7x8YZUcD7o4BdemNq4xkAElpEqC5ttMnIIz/aGsOADuGdyoehYc/wCymTnLZFS6ZYxarFCFg8rQYG3W8Dc/aznPmvnkrnLAHlj8x7U+1t49ZSKG3ijj8OQqFSNV4u8dOP8AnkP/AB//AHfvdJQAVhXc8dxqU1xcNt03SlMjN/C8u0kn3CL+req0ialN9nvr9ZFeOWUW9hESNrkHaDxz8zk8/wB0A8c1BfyRabbW2nys0kcKfa7yUHaWw+R7FpJM8ZGQGoAgv3ZNGWK4KwX+rybpxuwyRYzJ1yfliXbwPvY9agsrX7Y72iLMj6ntvL4vkGC3wBHbgfwkgbdowP8AWHqeee16+j134nmHTcXcujWjWbRrlf30zRu6lsH5Akce8joGK9WAr0fStPWwhfc5mupm8y4nYYMr4Az7DAAA7AAUAXQAAABgDtRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBV1Wxi1PTriznLrHMhUshwynsynsQcEHsRXk/gi6u/+EZ8UW0j+VfHxHcQ309u/lumZkDOvcBo9zA9QMYr2KvMtRFxYfE7VdOh2hNZsYtWswRjfd2zBJIx2+aPygSecZ9KAO0kudSvoIjpTWkBFzLFNJOhl2ojOowoZckkL34yetad5cQ20Bkum2w9GYjIGfX0HuawtFuoYtVfyZM2WrqLy1JzxJtAkT24Ctj1L+lTasV068hnj+3YlZmkMUhlVenJiJyV/wBwZHXGMmgCC90qKxG8Ps0yPMqsCTJZv3ZDz+7IzlTwB6qSBy/jLwhpN74fOj64scvh+62/ZrtQM6XctwrxE52RlsYGcKTt5RsL6FYGE28BsPJayZCUaM5HXjHbHWue/soaRNc2Rj+1+HNQyn2ExlxbFgd6rxjyiMnaehyBwQtAHgdt4hvfCeuL4V8axatJd2xUrcwXjoRHuws8ROVaNvl6/MhVgSMYr6O8MX2m3mnxSaZfveR3AadWlnMjEbipIyeFBBHHFcHq/hseINOuPDlzcwyeINMhNxo+o3EayCe1fgLIMYdePKkHOQEfqVxwnwm1V7hbiTTprjwzqVsbmC50qdjc2gn3AvtzmSM+YCdmG/i5Oc0AfSFFZXhvVW1jThcvAIWDFDskEsb4/iRx95T7gEdCBirWq3gsNOnuSNzIvyL/AH3PCr9SSB+NAFXSlabVdUvGKlS620RA/hQZP/j7OPwqne6bC2tXNzNH5dpFZuWYIMO8nDtk8EhY1HOeDWrpFmbDTYLd2DyKuZHAxvcnLt+LEn8ag8RIZNNZFABZghcrkRoeHY/RC3XigD55v7u40S3sbHUYWCabfw6raZ+Vi6mQuq44x8nKcYOcEDCjV8YoJPhNeWWHL6ffX2mxOxALJlpkYn02KnT/AOvUviW/EVvaW2vWEUqahcxrDPuCbfMlhJkXOTlfOlUqOR7jkZwWe/8ABnitJiVe2On3gGehmsliZvQnLNnntQB6J+z/AGy2XhHVrVI2jWDW76MKRjAEpxj2xiuu8d+IE8K+D9W1t081rOBnji/56SHiNP8AgTlR+Ncv8GWVT42t14WLxJdMo/2JEjkU/TD0vj24TVvF+jaOqNNb6SRrV4q9DKCUtIT2y8pZwD/zxH1oAwPA+h3Wk+H7aKWWW91sM00ryjcDO3765kwBwFndMjG4tCFx6W4LG61F7izUqls5gjMsL58uHadsJ3AZf5zIeM7iuevHTaJqVnp1vqV/cs0gjRDvRQdys7BdoHJaVy0gH/TVB6VuvNGkktxNKIrW1RjMOqmQ4JJ9duPzPsKAPDvEvwzsbma6m0pRY3N1811aMWZftMh3xwxqmfmVD838IGDwCxrBsP7d8L2Ys0XS7jS/LL2k1uSiXCMwxLKeCBnYQ5ZB9xlbJy3pU6zXETosWY52eMRTuFLruzMJG4xGvLzMPvsREDgAG3cQxvp9zaW1sILOZDDeT3BJafHGJMf6tSpDFRhvnRBtP3QDgtXeKfw7H/bHiSxfVrq3a3mktPma0IVsgPG5U5RgHU5BAAJ+6K5Pwb4m8Upr2naXNDpninQNPhW1NzbRrHJBER5UP+kvtaJjIQcE7hgkZ61rf8Krhu9atLbwxfz6d4fubk2FxcyQxytJOFd5BE2CML5bR7+7nHzbcn1mz8JfD3StFs/A3nQENcCaOBr1hcPcL84curBg/wApIHHQ4HFAFD4Dfbbz+3NX1fy7zUbkwRXGpLbeUJZY0Mbxxt/HGmxMP0ZmcjgjHqV7d21hayXN9cQ21tGMvLM4RFHuTwK858fay+g2Fl4W8FNPHqMcG4QWEBuJYIFGADlHCbuzOOSuO+RLo3gf+25IdZ8fCa8uIlZYNPupA0NqgPVlDFWYhVJY5685oAg8VfFaKCwvG8I6Xd63JACGuwnl2iN0C+Y2A7Fiqqi5LEgCs/wF4bv1nfW9fuE1HxvqkRV3Lh49KgBIaMEY+bIIbbjLAhcKpNQ6lqa+INUtbyL91pVsf+JVAq7EReU+1kDnc43CPHKx7mA3ugrovDoOo3N7o1hM8Mds6DUriJQjRnaNtqrL0fbgtg/u1KqOTuABqwaZHPbJo+hyNb6XC5W+uVUbrhhwUVvXjDMBgD5RzwunpNzAbGWPS7BP7HtY/KgEQAEu3IKxr02jGAe5zjjBNUxLqkv9k6btttEssQ3LRDb5hH/LBMdAONx/4COdxG7PHILXybFo4WACqduRGOnA6cdh0oAghvHlv1tobcqkaBp2bgISPlQY4J7nB4GPUUzWZZJYEs7SXZc3XyhweUT+NxjuAeD/AHitUtWvodMhisbeQQqq+bcTM+fs8Ocs7E5O5sEAnqcnnBqrbXs+pWzXEUUtteXpC2olwDHCMHzB36HcVP8AEQp45oAu2lvFdanH5KBbDSh5MCjODLt2sQPRV+UH1ZvSvOviRrN1e6RDpOiI02t63esAUXY0VvDJtVs8kYfYA3qWYAgEH0q+lh0fTrazt9xllYQQgt8xJ5ZycHoNzEn096xPBOiQ/a7rXGaaRZtkOnpKwKw2salEKgD+PLvk5OJO3IoA0vBPhi08LaLFaW6I104D3d1t+e5lx8zsep9s9BxXQUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXOeOdEuNW02G40pkj1vTpRdWEjHA8wAgo3+y6kqfrntXR0UAebxsfFXhye50hpLO6jkNytvI/77TNRTJ2so6ozEhl7hm7Nxv6T4it9R0hP7Ykj07UolTzl3bRHISFJUntuO3B6ZwevNfxR4Uu5dXXxB4Tvk03xAiCOVZQWtb6MdI50Hcc4kX5lyeo4rAe/tvEd99hv4H8LeNdrBLa6w8V2AuCUb7s6YJHHzAZ3LjggHW2JXTdYlW4f7GJQHlBXFvcOxA8xG6I5PBTvnOD942dUkjiez1i1lLorJDJ5bApLE7Bee3ykhs9cAjua57Trq+slg0q7Wz+2zIQNKvHYRvs6mCYhty4wdhBI/2QMDorqzl1nRJLSaB9ODOg2Eo52Kykj5SQMgEe1AGV4j0uazSPUtOSPztLk+02sMY+d4z/AMfEOO4ZeV9GC9lFeRfFzTB4W8UWvxG8PzbtE1cQreyQfNGkhx5c5XoUcbQSMEMFOTuIPu1zaXcmrafO0sDW0EkjEbMONyYXnPbJHvkenPA+C7WDRhr/AIL1gwXfh9LuSC3ikGRbwzgPHA47xkOVVj0Klf7tAHXeCfFdt4lsyNjW99EP3tu7Bjjj5wR1U564HPYVvXVpFdNAZtxEMglUBiAWAOM+uM5x6gHtXzvqGk6t8HtWiLXt1J4SeUm21UgzGyJ4SG4Tun8IcEDoDjivW/CvjaPUtPt7i+Nu0U5yl5aNut9pHyksTwSeMc8/nQB2lZviAvJYfZIcebdsIBkZwp++fwTd+OB3rSrN1dobFZdUkV5JoYjFGgyeWI4AHdjtGfYe9AHifxUkh/4STSdJuS4kbU7BLeVmDRyTG63v7rjzGxnqF9jTfAOjTeKvCfxHjTYDqFna2lqEzhXSyVkP/fTr+X41z3xlu7201Pw66zRQz22oQ6jLJeP5Sx722RyEnlE35c9xlh/DUvw70m4j0vUdWe4a1cS7hZaZqipHctsWGKxEynYGZ4kyUOTuC7sqRQB0/gzxxZeGNP1vWNUE8p1Gx0vUYYbaNpGmuJLVIjCMA4kLxrwcffBPWtzw2qWnhe+udXeMeJdel+36jNGAwgXnbsPpHEqBOvzMh/jrnvAehvdLZ6ZetC2haGs00955mIpLxpHNzIoOPlBMsUbHGFErddhrsAxe8kuIIsSSzrLDby5G6R+YIm7jhRK46qqRjotAFyws7likFjboj2brPPEMbBcsoWKMnGCsMe0nH92PHOavR3jXUkui6M4igLbPtEXEigMfPlz05Y7FPXfvPIWrU0EmnQW+k2NyzahdgjzQvKDOZp2GcbiTx/tMo6ZrDhmSKwnsrVmt1lY/aruEnFvaqSiJE3UsSCinqW8xx2yAXLL7N9kzaLCbq6LW8GY8paW0LYJyQQQuM56M5HOMEcvBpz+KtbisbTzobW0BW5u/M3nZuz8rA8SPjgg5Xls7ghOv4vE9hpi6VpFvGdXvljit4Q/yW6LxEnAHyDazH2WQ8hcV1/hPQo/D2ixWSytcXB/eXN04w1xMcbpG9M44HQAADgCgDnfiB4esU8Pi4S2d4tNtGt7GziZkihkfEaS7VYAFAeGA3KC2OeKr33hLRF0CTwnpmhR3UQeG5uWdVKPIsivmZ2bczsFPqcHnAIrs9esBqmi3tiQn+kRNGN4yASOD+B5q8FAzgcnqfWgDE8OeFNE8NRJHoenQ2YVWTMYwzAnOGPVsdi2SB0rmfiVq/wBsu4vC1owImQT6mQ+zbbndtiLfw+bsfcf4Y0lbrtz2+r6hb6Tpd3qF65S2tYmmkIGTtUZOB3PtXiVxczaksrSRhNS1Z/Muw/ybF2qZImPVQiKkbHn5Ys/8tDQBq6Ukuo3iyWLOZ5CqwEJtABA+cAfdOF4H8Cr6rFnt7ayXTbK38M+H28qRV33dygwYVYks/f8AeOc7QenXoADQ063m0LTFntbRp9a1A+XaW7AAxJxlnGQF4Ad8Y6Kg+6lbujBbENaxAytI2TdMQXuZMDfIQOgHA/IDAAoA17K1gsbWK1tYxHDEu1EHYf1+tZniDWl0qNLe1ha6v5FJjhUjCKOskjEgKgx1JGTwMk1atbR7CwlH2iW6uTukM0y7izH2UDgdAB2rM0rT4dKj1S41W/jvJp2BubiSMJx0Efpt5wF689yckAyLCwtdY0tLq4luI7IkXNxfS5glupAfmBHVYxtAGD0AA4GTvW0kVhb32s6s0dtEqsQXUL5MCk4Hrz94g85OOwAh1S7iVbGZUuXnZCLXSuIzM4wQWHYLxyeFzkgnFc3N/a2rXcdnfxrcXcExlhgkXEWSeJpQOkSchFbDuVB45IAJYFufFWpyC4jEccq7ZlwVa3syQRC3P+smxk/3U44JGfQAAoAAAA4AFUdE0uLSbBbeJnlkJLzTyY3zyH7zse5P5AYAwABV+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArM8RaDpniPTWsNas47u1LBwrZBRh0ZGGGVh2ZSCOxrTooA5EeH9Usbc2qXsevaX1FprHzSpjptnAO7nH31Zv9qse5u5dNaPytQ1jw6wIBg1KH7ZaPxgATZbZ2x8491NejUUAcFe69p1vo8V9d+KtOnS3lDtO1zE6oDx8qxoN7dQo9WzyQBXKW8N74mv8AW9cheWx/tB45LWyuMjzLWNCivKvTY+5/mU5UMob/AGfR/EHg7RdckjuLm0WDUYSWg1C2AjuIG/vK4GfTg5BxyDXMX0+r+EZRda1BHqWnRsZW1a1gbzIuDkz26ZxkHBliH+8gWgDV8P62mxNJ1sFopkWOKW5IcPuHELt0ckHCuOJBn+IMK5zUPg9babqB1P4f6lL4dvMHdaHdNZS5OcGLcCnPdCMdhV66l0y8tv3Nt5AmT92iGKWMF2+YLzhkc4IGdrn7pWTirOla9qujMiXtpc6norN8t7BmV7YEnAb+J1GCCT86kYIbgkAzINX+IHhSxmbVfDEWuWkCF86VqPmOAOflSZVkY+25j6HtVjwL8Rr7xxdWr6NpVtHp2N11MbxZmj7bCFHyNznBySAeO9egabqFpqdotzp9zFcwNwHjYMM+h9D7HkV454u0Xw14f8Va9d6dZ2dtrFx/ZkkLW0SCWKeSebc46dVQEjodvIOaAIPjbZ6dLrsNlPHEp1hfIa7Yr+7XcgnOeTlLdZzk4A3JjkViavHbPNpGhaIDbazYMoeGG3SGIXbwjDjnarWsL4yBjzJo2PIIGfrmom58Z2Ooa9AL2PRoY40hWRI/tF3cylwpycHMYiJOAAjOSPlrsPCWhWc9/F9iJe+1BXuw98fMdbV2Zh5oGAXlLNI/Q4dY+ByADb0XT7K00yGK1hV9LsERYoUAxcSMFCRqx5y+E69IwgP3nra0IrHrUst48WyxV5bi4B2pJcOdsj4PYY8tCeyOPSktJbMTRs/2n7LBFNJaFADLIxyr3Tf7Ts5VOOckjhsCWZf+Ec0PyjDbQXN1tMZlYOsLKCeePuQom4njJB7tQBQvNcl8nU32Si+unEO6EgvFGCFMUf8AthnWPdn/AF0h/hSqV1cR6Lps95cShorGTfIkQ3LPeZWMIgPVIhsiQdDIRu+ZSaSKUW7NNJNJAsR2QmVA7RuFJaRx/E0SuSRg7ppivULWdJoEfirWYdGe3ik0+3ZHvkJJWFUPEJYfec5dSc/eeduoSgDa+FGjz3Mk/ibUw+643JYxtN5oWEn/AFgPfICqp5yq7s5kavSqRFWNFRFCoowFAwAPSloAKKKKAPN/i74gt7RbTS2k+cYvpowM5VGxEpGO8mHHr5LDvWD8PLP7Zql5LeiIW9sq/aZ5JSx2p8zJz91d4VTk8+TIO9YWvXcWt/EbxDNLLPbw2khSWQPyYrcKixKACcvNK2OOAXPpXXeHbLT/APhFLWNJFOjSObi62EyPcojBUXHX95ICSvO7Lr3NAHZ6XHNdM+rzxyQT3YURq+N0FuDlUx2Zup9yB/CKuTXv2a+hs4IkuL2T5nCnYsEOfvN1IHYD+I56AEiK41uHTbeOXUiwX94Z50QiKEIPmZiegBwo6k9QMAkc1EGu766e9mW20uYC5jsSxSe5Xp5lyeWEecAIOuMHj5AAbra3JrCTLoJcWaZD6ns3IcEgiEf8tG4642j/AGulVHjniWzlXT8uJXdLflv3nP7x3+6G5yXIIHRQxOawvEHjO00aGGE29zqesklLbQ9Oxu6Ar5q9Ih0+9zg9D0XV0XRfEOuRrc+PZrRIidyaNYg+SvOR50hJMpHHAwnXIbggAdYT3mr3Qm0dk3lQtxqxjPksAT8kCn76jJO4YXIBJbla6nTNOt9OhdLdTukbzJZWOXlc9WY9z/IAAYAAq0qhVCqAFAwABgAUtABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFY8viPTbbU00/ULhbG8llEVulyQguSRkeUTw59hyD1HTOxVTVNNsdWsns9Us7e8tX+9DPGHU46cGgC3RXIDw7rGhKP+ET1RXtQRjTdVLSxKOBiOUfvI/od4HQAVam8WwaWFHia2m0cEhftEp8y1J/67Lwo/3wh9qAOloqGzure9to7izniuLeQZSWJw6sPUEcGpqACiiigAooooA4TXfDseiiS80zS1v9LdibrTFGSitkO8K5wQc5aLo2BjBAzc02O21KNZtIuN9vMMSu53x3MeAPm5zuxnEn3srhskYrr65W4sF8N6u2q2wC6PMWN3bpEv7mVyubgEcgHHzjkdG4w2QCC78NWunT3OovqB0+OKLd9uifypVCj/AJan/VyqAON6kjHfrXnVi9xrUN1qWqXLzR586ZpYkz+5QsrgKBhlUYIGPmmU4Ga6z48eJn0LwnHZWrMt3qcohBUZKxAgyEDqcghBju4riNe1iDwroNgrWkV5M5ijjtxwJpN+5yxGSA0iO/H8FrGP4hQBhafawarqE9veWMlzqdtdSm4dJQYpt6iP7MigdFINuZMk7I7jHbHo2mxyww373UyX8moEGd7fjzUyU2IQeDLJmNTx8kZORWR4G0XT9M0FfOto7MebLLNggrHbDarRpliWOcQBs5bMjdSSessIbu7+xXjqlvPel5YQvJjZht80g4wsUXyr2JcZHzUAOg3RSGaR4WunmMayFMRmdAdzjOP3EC7guerAn7xBNW5v5tTvpbpZVkWJFjhE6YGGAaNX4GN23z5AMYjWIY5ObuvSWMi29vpC/aTLbxQBC52yRtlkhHXHmFQznBPloSf4az9de0sIILRZ4ribbLPczuPlck7pZHC8gMVYf9c0dR95cgHO63fXsLadpugZn1y/ZYLHz04jOPMM83HRVY3Djr5kkS/wV6t4P8O2vhfQYNNtGaQr8007j555SBukb3OPwGB2rmfhfpDTNceKLxZQ9/GI7COYfvIrTO7c/wD00lcmV/qo/hr0CgAooooAKKKKAPnK31Bx8Pb15Yo2nk1jUYpBLlcytct8r8jOJJIj1yTGBxxju4Li30vS4HtYfPhsTEIYgi/vZCMW6nngnLS7QAd0yV53pkcuoeM9T0GSYPFJ4nuCsPLeV/pRnkJXHBMYBVgcckn7tdt4ev7Xxdph1fVvMsdFspbrUbmXfsWf966Rqx7oscfPTlV5x1AJb+e10y0h1HWFjuy84Nha5x9suOAZ3PaBOq54CLv5O2k0a6utdvLiWJZzLJIu2RFMb3wXgyhjnyoQSwXqVHTLsax2uZfGmr/ZkjlcyMFlwm1Y4j8yW4bGNvCu5A4QDnMoU+y6Ppkem25VW8yd8GWYqAXI6DHZR0A7D8SQDO8K+F7LQYldIYjemMRtKqn5VHRFySce5JJ4yTxjoKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoIBBBAIPBBoooA429+Hei/aXvNBNz4e1B23GfSZPJVz/txf6t899yk8dalspPFujR7NUW18RW6nAuLRBa3IXnlomJRz05Vl9lrraKAMHSPF2i6pdiziu/s+okZ+w3iNb3Hv8Au3AYj3AI961dTuJbXTrm4gge4lijZ1hT70hAztHuai1jSNO1m1Ntq1jbXtv18u4iDgH1Geh9xWI+l6xos6nQJUvdLZdr6fe3Dh4sDAMMx3H0+Rsj0K9CAamia3Zaw919guoLhIivEb5ZQyg4ZeqnOeD6fWtWvOPENj4k8SXMUun6JHoOpWpzBqV5dRybDkZKpCSXyAV2syrhjkHpWhc6r4qskjiXw/eSMr5Z7aW3uoyv91S8sLj6lSfWgDt6bIiSxtHIqujgqysMgg9QRXFXGteK72AraeFLy2SQrl7jULaGWMcZ2qvmqe/U9D2rJ8Q2XxB1zSru1sYdPsRNG6J9vvAWRjwGPkxEMAMkLxyBncMggHm129t4k8T2d9PdSSaZaXMltYNFhQllbPJ++J3HJ3pKQRyRDGTgkiqi6jda/Kml6dElrYXN1E9rapCkgjKSeWjhtuVXcojXBAItJWP360/BPwy8cWhtbBorDRI7KBLVr6WVb2O4QFWby4VKnDsgB3lflLDnJy69XXPDvxAuIfFb2Ud1qLhtNlsIZIra5AhZEhUHOxkbLFSxJ80kZoA7AxWs2paRoNodlhceVJIuw5NnC+yBflA4lcSSZ9yTwpronmj1e7BeWNLS/UgMx2LHYJk4B4OZSpP+4D/drmr1beHXr2W3s2JugLOIbtoMUZMGEP8ADwsqqc8faN3RWNS3Wpy6zcrJcwo+jWSJAUijKrdSHB8pRg4jOFLZ52hEwS7qADduJJrmUavZ20iLcK32UxRfNHbKF8yYDH+tkARUB6DZ6MK5nQrKfxZrk8c+37HJIJrvyzhfKU4SJSMHaSijPAIT1Q5u/EDXGu7600zTHZ727i8qeKA/M2Rkxg5wzYfHoocs3YjuvB+gReHtIS3UIbl/mnkUk7m7AE87QOB9M9SaANwAAAAYA7UUUUAFFFFABRRRQB4jrVrLonxv1RmjD2ep2dvrEQxkrJbMiTeWOzlFTOOqseaW2t4L7TtK8FpF5tnNaRX1zamYCOOGAqJI33HOHmyrccBW75rqfjXp0k/h2PVtPbydY0MS6jazFAVKKhE0RJ4+eMtgdyoPavP/AIPz/wDCQwXdwNPltLTUraw0yLJZUZcT3N1tGM4PmP8AN3Lj8QD13wPpkcFi2otG4mvC0itKMSeWzFssOAGYncQAMZC9EGOnoAwMDpRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUNc0fT9e02XT9XtIru0k+9G46HswI5Vh1DAgg8gir9FAHlV/8JLqKJ18PeNNasywCql/HFqCRoM4RS6hwvLZG/kEg5BIqC38B+L7e8t2N14Xube3HyrJBdAO2T8zp5zAnknkkZZj1JJ9cooA8b+HOkv4M8Q3lx40kH9tXQaH+05ixtnQyFkWCVjiMEMA0b4dnBbL5zXslR3EEVzbyQXMUc0EqlHjkUMrqeCCDwR7VxvhCzn8MeJb7w557y6LLAL3SUkYs1uoYLNACeSiloyvoH29FFAHbUUUUAFFFFABRRRQBzfj21gutD23ETTfOY0RQCWaRGix+Uh6denevO/2dr4ar4e0mQwFZLewj8xtwZciGGFNp/wB2Bsg8gkivVtdks1gt1vrgwAzrIhXqzR5lx9MRkn2Bryj9nO3axsJIZjCZZoPN/drtG3zGZeMekoGfagD2miiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmPGRns77QdTtLcTvBdGCUGTYBFKjDr/viL8cV09VNW0+DVdNuLG7UmCdCjbTgj0IPYg4IPYigC0rBlDDoRmlrmtB1W4gvIdF1t449QjjIVyu1b0DGJIj0HAO6Pqp/2cE9GkisWAPKnacjHNADqKZHLHIzrHIjMhwwU52n0NPBBJAIyOtABSMyqpZyFUDJJ4AFZl/4h0mwD/atQt1dcjylbfISDjAQZZjnjABNYd5ZX/ia5jlNvLYWCnAN5ks4B4It87cnn5pMkf3KAMXxr4hjnsL2X7QsVk9qwhDFctC3ytPg/wB8kRR9M7mbkcjirHUYPD91bal4ei+3LosK22oW8Mw3pCp2tJsB+7tCsD/tk9Bx6db/AA28LpfS3t5p7andSuZHfUpnuwzldpbbISoO0Y4AAHAwKvTeBvC0ixgeH9LiMYIR4LZYXQHqFZACAe+DzQBtabf2up2FvfafOlxaToJIpUOQynvVmuU07wLpOiAjww1zoYJJMVlJ+5YkDkxPuTPA5AB96sgeKrPaA2kaqg6lt9m+Pw8xSf8AvkfSgDoqK55tc1WFf3/hbU3bIH+jT2zj6/NIp/SqcvjG6jUn/hD/ABO2OywwH/2tQB1tFchD4zvJ2Cw+C/FBc/34reMD6lpgK0ZZfEV7Eotbex0vevMly5uJEP8A1zTCk/8AA/zoA25pY4YzJNIsca9Wc4A/Gs64mu9QhePTmksxnabqaHnGWDbEbnIwMFht5BG7pVKw8LW8d8l/q11c6vqCHKS3hBSE4wTFEoCJ9QN3qTXQ0AQWVstpaxwLJNKEH35pC7tznJJ/z6VPRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBS1jSbDWrI2mq2kN3blg4SVc7WHRgeoYdiORWOfCSIAlrrWu28I6Ri9MoH4yBm/WulooA5e08JzWjP5HiPWVR2LMoS1G4nJ5YQ7jyeuc1M3hK0nQLf3+s3gHaTUJUU/VYyoP4iuiooAoaVo2m6SrDTLC2td33jFGFZ/8AePUn3NX6KKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The distal ureters and bladder are retracted while the proximal vagina is stretched up to facilitate further dissection prior to vaginectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10594=[""].join("\n");
var outline_f10_22_10594=null;
var title_f10_22_10595="Patient information: Food poisoning (The Basics)";
var content_f10_22_10595=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15737\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"UTD.htm?0/34/557\">",
"         Tips for safe food handling",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/42/2723\">",
"         Patient information: Campylobacter infection (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/29/28114\">",
"         Patient information: Listeria (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/57/28562\">",
"         Patient information: Nausea and vomiting in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/13/27858\">",
"         Patient information: Rotavirus infection (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/26/38305\">",
"         Patient information: Typhoid fever (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/3/9267\">",
"         Patient information: Viral gastroenteritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/29/36308\">",
"         Patient information: Acute diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/1/27\">",
"         Patient information: Acute diarrhea in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/14/7395\">",
"         Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Food poisoning (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/food-poisoning-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1481515303\">",
"      <span class=\"h1\">",
"       What is food poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Food poisoning is an illness that can cause nausea, vomiting, or diarrhea. Food poisoning is caused by eating food that contains germs, such as bacteria, viruses, or parasites. Two examples of bacteria that are common causes of food poisoning are salmonella and E. coli. Parasites include tiny worms that people can catch in some countries.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481515310\">",
"      <span class=\"h1\">",
"       How can germs get in food?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Germs can get in food in different ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        People who are sick can spread their germs to the food they cook if they do not wash their hands before they touch the food.",
"       </li>",
"       <li>",
"        Germs can live in or on food. If food is not washed or cooked enough, the germs in it or on it can infect people.",
"       </li>",
"       <li>",
"        Germs from one food can get on another food. This can happen when a person uses the same cutting board or knife to prepare different foods.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481515317\">",
"      <span class=\"h1\">",
"       What are the symptoms of food poisoning?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can happen right after a person eats the food, or not until days or weeks later. Common symptoms of food poisoning include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Diarrhea that can be watery or bloody",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other symptoms can include problems with the nervous system, such as blurry vision or feeling dizzy. But these problems are not as common.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481515324\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Drink enough liquids so that your body does not get &ldquo;dehydrated.&rdquo; Dehydration is when the body loses too much water.",
"       </li>",
"       <li>",
"        Eat small meals that do not have a lot of fat in them",
"       </li>",
"       <li>",
"        Rest, if you feel tired",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481515331\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have severe belly pain",
"       </li>",
"       <li>",
"        Cannot eat or drink",
"       </li>",
"       <li>",
"        Vomit blood or have blood in your bowel movements",
"       </li>",
"       <li>",
"        Have a fever higher than 100.4&deg;F (38&deg;C)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Young children and older adults with symptoms should make sure to see their doctor or nurse. That&rsquo;s because these groups can get dehydrated more easily.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481515338\">",
"      <span class=\"h1\">",
"       Do I need to have tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people do not need to have tests. But it&rsquo;s possible that your doctor will do tests to check if you are dehydrated or to figure out which germ caused your food poisoning. Your doctor might do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Tests on a sample of your bowel movement",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481515345\">",
"      <span class=\"h1\">",
"       How is food poisoning treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people do not need any treatment, because their symptoms will get better on their own. But some people need:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics &ndash; These medicines treat infections.",
"       </li>",
"       <li>",
"        Fluids through an &ldquo;IV&rdquo; &ndash; An IV is a thin tube that goes into your vein. People with a lot of diarrhea or vomiting might need IV fluids to treat or prevent dehydration.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors do not usually recommend that people take anti-diarrhea medicines. That&rsquo;s because these medicines can make the symptoms last longer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481515352\">",
"      <span class=\"h1\">",
"       Can food poisoning be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chance of getting food poisoning or spreading germs that can cause food poisoning by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Washing your hands after changing diapers, going to the bathroom, blowing your nose, touching animals, or taking out the trash",
"       </li>",
"       <li>",
"        Staying home from work or school until you feel better (if you are sick)",
"       </li>",
"       <li>",
"        Paying attention to food safety. Tips include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Not drinking unpasteurized milk or foods made with it",
"       </li>",
"       <li>",
"        Washing fruits and vegetables well before eating them",
"       </li>",
"       <li>",
"        Keeping the refrigerator colder than 40&deg;F (4.4&deg;C) and the freezer below 0&deg;F (-18&deg;C)",
"       </li>",
"       <li>",
"        Cooking meat and seafood until well done",
"       </li>",
"       <li>",
"        Cooking eggs until the yolk is firm",
"       </li>",
"       <li>",
"        Washing hands, knives, and cutting boards after they touch raw food",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For more food safety tips to prevent food poisoning, see the table (",
"      <a class=\"graphic graphic_table graphicRef60529 \" href=\"UTD.htm?0/34/557\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Pregnant women and people whose bodies have trouble fighting off infections can do more things to prevent getting food poisoning. If you are pregnant or have trouble fighting off infections, talk to your doctor or nurse about other ways to prevent getting food poisoning.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1481515359\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=see_link\">",
"       Patient information: Nausea and vomiting in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=see_link\">",
"       Patient information: Viral gastroenteritis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/13/27858?source=see_link\">",
"       Patient information: Rotavirus infection (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/26/38305?source=see_link\">",
"       Patient information: Typhoid fever (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=see_link\">",
"       Patient information: Campylobacter infection (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28114?source=see_link\">",
"       Patient information: Listeria (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"       Patient information: Acute diarrhea in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"       Patient information: Acute diarrhea in children (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"       Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/22/10595?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15737 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10595=[""].join("\n");
var outline_f10_22_10595=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481515303\">",
"      What is food poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481515310\">",
"      How can germs get in food?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481515317\">",
"      What are the symptoms of food poisoning?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481515324\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481515331\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481515338\">",
"      Do I need to have tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481515345\">",
"      How is food poisoning treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481515352\">",
"      Can food poisoning be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1481515359\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15737\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/34/557\">",
"      Tips for safe food handling",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=related_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=related_link\">",
"      Patient information: Campylobacter infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=related_link\">",
"      Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28114?source=related_link\">",
"      Patient information: Listeria (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/57/28562?source=related_link\">",
"      Patient information: Nausea and vomiting in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/13/27858?source=related_link\">",
"      Patient information: Rotavirus infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/26/38305?source=related_link\">",
"      Patient information: Typhoid fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=related_link\">",
"      Patient information: Viral gastroenteritis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_22_10596="Elbow joint external landmarks";
var content_f10_22_10596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elbow joint external landmarks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The elbow joint is best palpated as the soft spot in the middle of a triangle formed by the lateral epicondyle, olecranon, and radial head.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neeru Jayanthi, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10596=[""].join("\n");
var outline_f10_22_10596=null;
var title_f10_22_10597="Acral lentiginous melanoma in situ";
var content_f10_22_10597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51165%7EDERM%2F64134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51165%7EDERM%2F64134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acral lentiginous melanoma in situ",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acral lentiginous melanoma in situ on the left index finger of a 74-year-old man, presenting as a linear pigmented streak (melanonychia striata) with Hutchinson sign (pigmentation of the proximal and lateral nail folds).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subungual acral lentiginous melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Melanoma originating from the nail matrix. An area of hyperpigmentation of the proximal nail fold (Hutchinson sign) is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10597=[""].join("\n");
var outline_f10_22_10597=null;
var title_f10_22_10598="Carotid sinus hypersensitivity";
var content_f10_22_10598=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Carotid sinus hypersensitivity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10598/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10598/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10598/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10598/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10598/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10598/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/22/10598/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity of the afferent or efferent limbs of the carotid sinus reflex arc results in vagal activation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sympathetic inhibition, which leads to bradycardia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasodilation; this is also called the carotid sinus syndrome or carotid sinus syncope.",
"   </p>",
"   <p>",
"    Carotid sinus syncope is similar to vasovagal (neurocardiogenic) syncope since both are forms of reflex syncope reflecting alterations in autonomic tone with similar clinical manifestations. However, precipitating factors for these two types of syncope differ and carotid sinus hypersensitivity tends to occur in older patients. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prevalence and clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Carotid sinus hypersensitivity will be reviewed here. Other types of reflex syncope including vasovagal syncope and general discussions of the pathogenesis, etiology, and evaluation of syncope are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"     \"Pathogenesis and etiology of syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of craniofacial pain\", section on 'Glossopharyngeal neuralgia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of carotid sinus hypersensitivity in patients with syncope depends upon how it is defined [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Spontaneous carotid sinus syndrome\" is diagnosed when by history spontaneous syncope occurs after accidental mechanical manipulation (eg, pressure from shaving or tight collars) of the carotid sinuses. Syncope can often be reproduced by carotid sinus massage. This clinical syndrome is rare, accounting for about 1 percent of syncope cases [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      \"Induced carotid sinus syndrome\" is diagnosed in patients with an abnormal response to carotid sinus massage and an otherwise negative work-up for syncope. The diagnosis is made despite lack of history linking carotid sinus manipulation and spontaneous syncope. This clinical syndrome appears common, occurring in 14 percent in one prospective series of unselected syncope patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/3\">",
"       3",
"      </a>",
"      ] and in up to 50 percent of patients with syncope unexplained by initial screening [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/4-6\">",
"       4-6",
"      </a>",
"      ]. However, older people are more likely to have this response even if they do not clearly have symptoms due to carotid hypersensitivity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, carotid sinus syndrome may be responsible for many unexplained \"falls\" in older adults, as suggested by the observation that treatment of this condition reduced the frequency of falls. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The prevalence of carotid sinus syndrome appears to increase with age and is rare in patients &lt;40 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/10\">",
"     10",
"    </a>",
"    ]. However, false positive diagnoses also appear to be common in older adults (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Elderly patients'",
"    </a>",
"    below). Thus, the diagnosis should not be based solely on an abnormal hemodynamic response to carotid sinus massage (CSM). To establish the diagnosis, alternative causes of syncope should be excluded, and reproduction of symptoms should accompany the hemodynamic response to CSM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF CAROTID SINUS SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carotid sinus reflex arc is composed of an afferent limb arising from mechanoreceptors in the internal carotid artery and terminating in midbrain centers in the vagal nucleus and the vasomotor center. The efferent limb innervates the sinus and atrioventricular nodes via the vagus nerve and the parasympathetic ganglia and also inhibits sympathetic nervous tone to the heart and blood vessels. The site of the abnormality that causes the hypersensitive response has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of syncope should include history, physical examination, and an electrocardiogram (ECG). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A history of syncope following accidental manipulation of the carotid sinuses should be sought although it is rarely present. Absence of such a history does not exclude carotid sinus syndrome. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prevalence and clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Carotid sinus massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus hypersensitivity can be demonstrated by careful carotid sinus massage (CSM). The 2009 European Society of Cardiology (ESC) syncope guidelines recommend CSM in patients over age 40 with syncope of unknown etiology after the initial evaluation (",
"    <a class=\"graphic graphic_table graphicRef69426 \" href=\"UTD.htm?34/25/35227\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ESC guidelines recommend that CSM be performed for 10 seconds on each side and with the patient both supine and erect with continuous HR monitoring and periodic BP measurement.",
"   </p>",
"   <p>",
"    CSM should be avoided in patients with prior TIA or stroke within the past three months and in patients with carotid bruits (unless carotid Doppler studies have excluded significant stenosis). Contraindications, complications, and procedure for CSM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=see_link\">",
"     \"Vagal maneuvers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The test is considered positive for carotid sinus hypersensitivity if CSM provokes asystole longer than three seconds",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a fall in systolic blood pressure &gt;50 mmHg. Carotid sinus syncope is diagnosed if spontaneous symptoms are reproduced along with signs of carotid sinus hypersensitivity. The response to carotid sinus massage is generally classified as cardioinhibitory (asystole), vasodepressor (drop in BP), or mixed. A positive response is diagnostic of the cause of syncope in the absence of any other competing diagnosis.",
"   </p>",
"   <p>",
"    An asymptomatic pause is less sensitive and less specific than reproduction of symptoms, particularly if a full evaluation for other causes of syncope has not yet been performed. As an example, an \"abnormal\" response can be seen in asymptomatic elderly patients, which is considered nonspecific.",
"   </p>",
"   <p>",
"    The finding of cardioinhibitory (asystole &gt;3 seconds) carotid sinus hypersensitivity predicts an asystolic mechanism of spontaneous syncope and thus may be useful for guiding use of pacing therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. For example, in a study of 18 patients with recurrent syncope and cardioinhibitory response to CSM and 36 patients with recurrent syncope and negative response to CSM, implantable loop recordings identified asystole syncope in 16 of 18 (89 percent) of patients with a cardioinhibitory response to CSM and in 18 of 36 (50 percent) of patients with negative response to CSM [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Combination with tilt table testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 ESC syncope guidelines recommend performance of carotid sinus massage in the supine and erect positions. The diagnostic yield of carotid sinus massage may be increased by performing massage during head-up tilt testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This was illustrated in a report of 1149 patients over 55 years of age presenting with unexplained syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/14\">",
"     14",
"    </a>",
"    ]. Carotid hypersensitivity provoked by carotid sinus massage was seen in 223 patients (19 percent); in one-third of these patients, a response to carotid sinus massage was elicited during tilt table testing after a negative response to supine massage. No control had a response to carotid sinus massage in either the supine or upright position. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27399?source=see_link\">",
"     \"Upright tilt table testing in the evaluation of syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;False positive results with carotid sinus massage may be relatively common in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/7\">",
"     7",
"    </a>",
"    ]. This was illustrated in a study that evaluated the response to CSM in an unselected sample of 272 elderly patients (mean age 71) from a community practice [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/15\">",
"     15",
"    </a>",
"    ]. CSM was performed in both the supine and upright positions according to recommended protocols. Carotid sinus hypersensitivity was present in 39 percent overall and in 35 percent of 80 individuals with no prior history of falls, syncope, or dizziness. Thus, alternative causes should be explored before attributing syncope to carotid sinus hypersensitivity in elderly patients. Some have advocated using stricter criteria for identification of carotid sinus hypersensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DRIVING RESTRICTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the guidelines in the 1996 statement from the American Heart Association (AHA) and North American Society of Pacing and Electrophysiology (NASPE, now Heart Rhythm Society, HRS) on personal and public safety issues related to arrhythmias provided recommendations for driving (that were unchanged by the 2007 addendum) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Driving recommendations in both the 1996",
"    <span class=\"nowrap\">",
"     AHA/NASPE",
"    </span>",
"    statement and the 2009 ESC syncope update are stratified according to whether syncope is categorized as \"mild\" or \"severe\": Mild neurally mediated syncope is characterized by infrequent mild symptoms (usually without syncope), occurring with warning and usually only with standing, with clear precipitating causes, and infrequent occurrence. Severe neurally mediated syncope is characterized by severe symptoms (usually syncope), occurring without warning and in any position, with no clear precipitating causes,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent occurrence. In the ESC guidelines, syncope during \"high-risk\" activity (eg, driving, machine operator, flying, competitive athletics) is also considered severe.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with mild carotid sinus hypersensitivity, no driving restrictions are recommended for private or commercial drivers. [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      For untreated patients with severe carotid hypersensitivity, all driving is prohibited.",
"     </li>",
"     <li>",
"      For patients with severe carotid sinus hypersensitivity who are treated with control, both private and commercial driving is permitted after controlled arrhythmia is documented for one month.",
"     </li>",
"     <li>",
"      For patients with severe carotid sinus hypersensitivity who are treated with uncertain control, private driving is permitted after controlled arrhythmia is documented for three months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In such patients, commercial driving is permitted after controlled arrhythmia is documented for six months.",
"   </p>",
"   <p>",
"    The 2009 ESC syncope guidelines included more limited driving restriction recommendations (",
"    <a class=\"graphic graphic_table graphicRef79808 \" href=\"UTD.htm?26/59/27580\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus hypersensitivity is often considered a variant of vasovagal syncope, and some of the same therapies have been used although the data are more limited.",
"   </p>",
"   <p>",
"    General treatment measures include reassurance and education regarding the nature, risks, and prognosis of the condition (",
"    <a class=\"graphic graphic_table graphicRef67864 \" href=\"UTD.htm?19/62/20460\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/1\">",
"     1",
"    </a>",
"    ]. The patient should be advised to avoid accidental mechanical manipulation of the carotid sinuses. Medications that may induce hypotension (such as vasodilator therapy) should be discontinued or reduced when feasible.",
"   </p>",
"   <p>",
"    Two small randomized trials found that pacing reduced the rate of syncope recurrence in patients with carotid sinus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Dual-chamber pacing is beneficial in patients with carotid sinus hypersensitivity who have a cardioinhibitory response, but not in those with a vasodepressor response.",
"   </p>",
"   <p>",
"    Pacing may prevent nonaccidental falls as well as syncope. This was illustrated in the SAFE PACE trial in which 175 patients seen in an emergency facility because of a nonaccidental fall without loss of consciousness were randomly assigned to a dual-chamber pacemaker or no therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/20\">",
"     20",
"    </a>",
"    ]. Pacing significantly reduced the mean frequency of falls by 66 percent (4.1 versus 9.3 per year for controls) with a nonsignificant trend toward fewer syncopal events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=see_link\">",
"     \"Falls in older persons: Risk factors and patient evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2008",
"    <span class=\"nowrap\">",
"     ACC/AHA/HRS",
"    </span>",
"    device guidelines recommend permanent pacing for patients with recurrent syncope caused by spontaneously occurring carotid sinus stimulation in whom carotid sinus pressure induces ventricular asystole of more than three seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/21\">",
"     21",
"    </a>",
"    ]. Permanent pacing may be considered in patients with recurrent syncope of unexplained origin and a hypersensitive cardioinhibitory response of three seconds or longer. Permanent pacing is NOT indicated for a hypersensitive cardioinhibitory response to carotid sinus stimulation without symptoms or with vague symptoms.",
"   </p>",
"   <p>",
"    The 2009 ESC syncope guidelines suggest cardiac pacing (single or dual chamber, depending on the frequency and severity of the pauses and the symptoms) in patients with cardioinhibitory carotid sinus syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data are available on treatment of patients with a vasodepressor response to carotid sinus massage. Drugs, such as vasodilators, that may exacerbate the condition should be reduced or discontinued, if feasible. Although some therapies for vasovagal syncope (such as salt loading and vasoconstrictors) may be expected to be helpful, such treatments may cause supine hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/1\">",
"     1",
"    </a>",
"    ]. A few reports suggest that serotonin reuptake inhibitors may be helpful in patients with a vasodepressor response to carotid sinus massage [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10598/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=see_link\">",
"       \"Patient information: Vagal maneuvers and their responses (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carotid sinus hypersensitivity is a cause of syncope. Its incidence increases with age.",
"     </li>",
"     <li>",
"      Carotid sinus massage is recommended as part of the diagnostic work-up for patients over age 40 with syncope of unknown etiology without contraindication to carotid sinus pressure. However, false positive results are common in older adults, so other potential causes of syncope should be excluded. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      General treatment measures include reassurance and education.",
"     </li>",
"     <li>",
"      Dual chamber pacing can be helpful in patients with a cardioinhibitory response but not in those with a vasodepressor response:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with recurrent syncope in the setting of a history of spontaneous carotid sinus stimulation, who also have ventricular asystole of more than three seconds in response to carotid sinus pressure are considered to have been definitively diagnosed with carotid sinus syncope. We recommend that such patients be treated with a permanent pacemaker (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with recurrent syncope of unexplained origin and a hypersensitive cardioinhibitory response of longer than three seconds may also have carotid sinus syndrome. We suggest placement of a pacemaker in such patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Legal requirements for physicians to report patients with conditions that could impair safe motor vehicle operation vary by state.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/1\">",
"      Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/2\">",
"      Thomas JE. Hyperactive carotid sinus reflex and carotid sinus syncope. Mayo Clin Proc 1969; 44:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/3\">",
"      Alboni P, Brignole M, Menozzi C, et al. Diagnostic value of history in patients with syncope with or without heart disease. J Am Coll Cardiol 2001; 37:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/4\">",
"      Volkmann H, Schnerch B, K&uuml;hnert H. Diagnostic value of carotid sinus hypersensitivity. Pacing Clin Electrophysiol 1990; 13:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/5\">",
"      McIntosh SJ, Lawson J, Kenny RA. Clinical characteristics of vasodepressor, cardioinhibitory, and mixed carotid sinus syndrome in the elderly. Am J Med 1993; 95:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/6\">",
"      Brignole M, Menozzi C, Gianfranchi L, et al. Carotid sinus massage, eyeball compression, and head-up tilt test in patients with syncope of uncertain origin and in healthy control subjects. Am Heart J 1991; 122:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/7\">",
"      Sullivan RM, Olshansky B. Carotid sinus hypersensitivity: disease state or clinical sign of ageing? The need for hard endpoints. Europace 2010; 12:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/8\">",
"      Tan MP, Kenny RA, Chadwick TJ, et al. Carotid sinus hypersensitivity: disease state or clinical sign of ageing? Insights from a controlled study of autonomic function in symptomatic and asymptomatic subjects. Europace 2010; 12:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/9\">",
"      Krediet CT, Parry SW, Jardine DL, et al. The history of diagnosing carotid sinus hypersensitivity: why are the current criteria too sensitive? Europace 2011; 13:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/10\">",
"      Humm AM, Mathias CJ. Unexplained syncope--is screening for carotid sinus hypersensitivity indicated in all patients aged &gt;40 years? J Neurol Neurosurg Psychiatry 2006; 77:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/11\">",
"      Menozzi C, Brignole M, Lolli G, et al. Follow-up of asystolic episodes in patients with cardioinhibitory, neurally mediated syncope and VVI pacemaker. Am J Cardiol 1993; 72:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/12\">",
"      Maggi R, Menozzi C, Brignole M, et al. Cardioinhibitory carotid sinus hypersensitivity predicts an asystolic mechanism of spontaneous neurally mediated syncope. Europace 2007; 9:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/13\">",
"      Morillo CA, Camacho ME, Wood MA, et al. Diagnostic utility of mechanical, pharmacological and orthostatic stimulation of the carotid sinus in patients with unexplained syncope. J Am Coll Cardiol 1999; 34:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/14\">",
"      Parry SW, Richardson DA, O'Shea D, et al. Diagnosis of carotid sinus hypersensitivity in older adults: carotid sinus massage in the upright position is essential. Heart 2000; 83:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/15\">",
"      Kerr SR, Pearce MS, Brayne C, et al. Carotid sinus hypersensitivity in asymptomatic older persons: implications for diagnosis of syncope and falls. Arch Intern Med 2006; 166:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/16\">",
"      Epstein AE, Baessler CA, Curtis AB, et al. Addendum to \"Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology\": public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and the Heart Rhythm Society. Circulation 2007; 115:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/17\">",
"      Epstein AE, Miles WM, Benditt DG, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996; 94:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/18\">",
"      Brignole M, Menozzi C, Lolli G, et al. Long-term outcome of paced and nonpaced patients with severe carotid sinus syndrome. Am J Cardiol 1992; 69:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/19\">",
"      Claesson JE, Kristensson BE, Edvardsson N, W&auml;hrborg P. Less syncope and milder symptoms in patients treated with pacing for induced cardioinhibitory carotid sinus syndrome: a randomized study. Europace 2007; 9:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/20\">",
"      Kenny RA, Richardson DA, Steen N, et al. Carotid sinus syndrome: a modifiable risk factor for nonaccidental falls in older adults (SAFE PACE). J Am Coll Cardiol 2001; 38:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/21\">",
"      Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117:e350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/22\">",
"      Grubb BP, Samoil D, Kosinski D, et al. The use of serotonin reuptake inhibitors for the treatment of recurrent syncope due to carotid sinus hypersensitivity unresponsive to dual chamber cardiac pacing. Pacing Clin Electrophysiol 1994; 17:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10598/abstract/23\">",
"      Dan D, Grubb BP, Mouhaffel AH, Kosinski DJ. Use of serotonin re-uptake inhibitors as primary therapy for carotid sinus hypersensitivity. Pacing Clin Electrophysiol 1997; 20:1633.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1071 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-FFF4911520-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10598=[""].join("\n");
var outline_f10_22_10598=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS OF CAROTID SINUS SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Carotid sinus massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Combination with tilt table testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DRIVING RESTRICTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1071\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1071|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/25/35227\" title=\"table 1\">",
"      ESC recommendations carotid sinus massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/59/27580\" title=\"table 2\">",
"      Recommendations for driving in patients with syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/62/20460\" title=\"table 3\">",
"      Treatment of reflex syncope",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/4/22602?source=related_link\">",
"      Falls in older persons: Risk factors and patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11431?source=related_link\">",
"      Overview of craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/17/33042?source=related_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27399?source=related_link\">",
"      Upright tilt table testing in the evaluation of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_22_10599="Emergent literacy including language development";
var content_f10_22_10599=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergent literacy including language development",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10599/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10599/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10599/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10599/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10599/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10599/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10599/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/22/10599/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Literacy acquisition begins long before children encounter formal school instruction. During their early years, children acquire knowledge and skills that are literate behaviors in informal settings. The term emergent literacy&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/1-3\">",
"     1-3",
"    </a>",
"    ] emphasizes that:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Literacy development is an ongoing process",
"     </li>",
"     <li>",
"      All aspects of literacy develop simultaneously",
"     </li>",
"     <li>",
"      There is a natural hierarchy to the stages of development",
"     </li>",
"     <li>",
"      Language and literacy acquisition share important features",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Domains of communications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Communication has nonverbal and verbal domains. Nonverbal communication includes body language, gestures, and signing. Verbal communication occurs in oral or written modes and has three components [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Receptive language &ndash; reception of sensory information",
"     </li>",
"     <li>",
"      Expressive language &ndash; motoric expression; involves articulation, voice, fluency",
"     </li>",
"     <li>",
"      Linguistics &ndash; CNS processing of sensory and motor functions and formulating language",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Language parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Language has four components [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phonologic &ndash; speech sounds, phonemes",
"     </li>",
"     <li>",
"      Semantics &ndash; vocabulary, word meaning",
"     </li>",
"     <li>",
"      Syntax &ndash; grammar, combining words into sentences",
"     </li>",
"     <li>",
"      Pragmatics &ndash; use in context to communicate effectively",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LITERATURE REVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of language and the attainment of literacy skills in children occur along a continuum that has a hierarchy of stages of development, including the acquisition of oral language, reading, writing, and spelling skills [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/2,3,6,7\">",
"     2,3,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most children progress toward language competence through a series of similar stages despite differences in cultural and linguistic backgrounds [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children pass through these stages at different ages and in a variety of ways [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/1\">",
"       1",
"      </a>",
"      ]. A child may be at a different level of competency for each domain of literacy.",
"     </li>",
"     <li>",
"      Literacy acquisition begins when children learn to recognize letters as unique patterns and comprehend that print, not pictures, carries the message. Next, children become aware that letters provide clues for reading, and they may recognize some words. During the third stage of literacy development, children realize sounds are determined by letters and words are created by putting sounds together. In the most advanced phase of development, children begin to immediately recognize morphemic parts of words [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/2,3,6,7\">",
"       2,3,6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The acquisition of literacy requires not only competent oral language skills, but an understanding of the relationship between oral and written language [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/8\">",
"       8",
"      </a>",
"      ]. Literacy and language are related in important ways. Both occur in a social context for the purpose of communication. Characteristics of parent-child interactions that support language acquisition also facilitate early reading and writing development. Oral language competence is highly correlated with success in learning to read [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/2,9\">",
"       2,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Environment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child's early literacy environment plays a critical role in the emergence of literacy. Young children learn many important concepts about reading before going to school [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/6,10-12\">",
"     6,10-12",
"    </a>",
"    ]. Their early experience with books and reading contributes to their later success or failure in learning to read [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children enter school with different knowledge levels and learn to read at different rates. Those who enter school with the least knowledge of beginning reading skills are at academic risk [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/12\">",
"     12",
"    </a>",
"    ]. The US Department of Education's February 2000 report states that America's kindergartners who are living in poverty, from single-parent homes and non-English-speaking families, and have parents who did not finish high school have fewer early reading and math skills, exhibit more problem behaviors, and are less healthy than their peers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/13\">",
"     13",
"    </a>",
"    ]. Reading ability predicts change in problem behaviors during the primary school years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of early literacy experiences, including listening to stories, in preschoolers is directly associated with [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Teacher ratings of oral language skills at five years of age and reading comprehension at seven years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Success on reading achievement tests in second grade [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vocabulary, syntax, letter recognition, and print awareness [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of parent-child reading increases when parents receive books and encouragement to read at health supervision visits [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Parents in families who are involved in clinic-based literacy promotion projects (eg, Beginning with Books or Reach Out and Read) are more likely to read regularly to their children and to describe reading as a favorite parent-child activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. The frequency of parent-child book sharing in first-generation Hispanic immigrant families also is related directly to parental reports that they read frequently to themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reports of the effects of clinic-based literacy programs on language and literacy development vary slightly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. However, most studies demonstrate an increase in the expressive and receptive language scores of children who received books and whose parents received modeling and encouragement to read aloud during health maintenance visits. Children in prekindergarten classes who were given books and encouraged to share them with their parents had greater word knowledge, spelling, and story-reading ability at the end of kindergarten than did those who did not receive books [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, fewer of the children who were given books were in low reading groups at the end of first grade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Quality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the frequency of early literacy experiences, the quality of the parent-child interaction and the child's environment affect literacy development. Children need access to a variety of reading materials and need to observe diverse, developmentally appropriate literate behaviors to achieve their literacy potential. As Marilyn Jager Adams states, \"it is not just reading to children that makes the difference, it is enjoying the books with them and reflecting on their form and content\" [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considerable interaction exists between adult reading style and the child's skill level. Various reading styles benefit different literacy skills depending upon the child's level of development. A lower-demand reading style (describing and labeling) may be most appropriate for advancing vocabulary development with younger or less skilled learners, whereas a higher-demand, uninterrupted style (discussion before and after the story) may be most beneficial for older or more advanced children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In observational studies, parents do alter the interactional style of reading depending upon the child's level of communicative competence [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children whose parents were instructed to increase open-ended questions, expand on replies, and encourage discussions of function and attributes had higher expressive language scores and longer mean utterance than did children whose parents did not receive this intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The type of book that is read affects the teaching strategy of parents; greater participation from mothers and children is elicited when expository books (collections of pictures or labels), rather than narrative books (stories), are read [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Demographics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Researchers have reported variable effects of socioeconomic status, ethnicity, and parental education on emergent literacy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some report that low socioeconomic, minority, and less educated parents may be adequate teachers for their child's present level of development but less sensitive to the changing needs and capabilities of their children [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/36\">",
"       36",
"      </a>",
"      ] and less able to foster the acquisition of prereading skills [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others associate greater child-centered literacy orientation with two-parent families, higher adult-to-child ratios, households speaking only English, ownership of more than 10 children's books, and parents who read a few times per week themselves [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Still others have found a wide range in the quantity and nature of literacy materials present in the homes and a large variation in the utilization of these materials, rather than a distinct difference in literacy practice by ethnicity or educational level of low-income families [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NORMAL LANGUAGE DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Language and literacy skills develop along several parameters simultaneously, over an extended period of time, in a predictable order, and at a predictable rate. The achievement of isolated milestones may be misleading. As an example, a child may have a large vocabulary because of a great ability to imitate or memorize, yet be incapable of using these words appropriately in conversation. The normal milestones in language and literacy development are shown in the graphics (",
"    <a class=\"graphic graphic_figure graphicRef78646 \" href=\"UTD.htm?15/46/16110\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef72624 \" href=\"UTD.htm?35/25/36253\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/39-45\">",
"     39-45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DELAYED LANGUAGE AND LITERACY DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental language delays or disorders occur in 5 to 10 percent of preschool children. They can involve aspects of expressive, comprehensive, or total language development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21399?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology of speech and language disorders in children\", section on 'Language disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delays in language and literacy development do not occur because the child is lazy, his older siblings speak for",
"    <span class=\"nowrap\">",
"     him/her,",
"    </span>",
"    the child lives in a bilingual environment, or the child is a twin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/42\">",
"     42",
"    </a>",
"    ]. Children do not \"outgrow\" these problems and should be referred as soon as possible for evaluation and intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26343?source=see_link\">",
"     \"Evaluation and treatment of speech and language disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Red flags",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red flags for language or literacy problems are numerous and include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/5,45,46\">",
"     5,45,46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Parental concern regarding hearing, abnormal speech production, or comprehension",
"     </li>",
"     <li>",
"      No babbling by nine months",
"     </li>",
"     <li>",
"      No first words by 15 months",
"     </li>",
"     <li>",
"      No consistent words by 18 months",
"     </li>",
"     <li>",
"      No word combinations by 24 months",
"     </li>",
"     <li>",
"      Speech is difficult for parents to understand at 24 months",
"     </li>",
"     <li>",
"      Speech is difficult for strangers to understand at 36 months",
"     </li>",
"     <li>",
"      Deficient lexicon &mdash; slow growth of vocabulary",
"     </li>",
"     <li>",
"      Dysfluencies (stutters) consist of more than tension-free whole word repetitions",
"     </li>",
"     <li>",
"      Child is frustrated by communication difficulty",
"     </li>",
"     <li>",
"      Child is teased by peers for \"talking funny\"",
"     </li>",
"     <li>",
"      Child avoids talking situations",
"     </li>",
"     <li>",
"      Child acquires vocabulary and sentence structure but does not use language appropriately for communicative purposes",
"     </li>",
"     <li>",
"      Language is unusual or confused, or ideas are not expressed clearly",
"     </li>",
"     <li>",
"      Child cannot follow instructions without supplemental visual cues",
"     </li>",
"     <li>",
"      Loss of milestones",
"     </li>",
"     <li>",
"      Poor memory skills at five to six years of age: inability to learn colors, numbers, shapes, alphabet",
"     </li>",
"     <li>",
"      Decreased linguistic awareness at five to six years of age: phonemic awareness, segmentation, syntax, concepts of print",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1081709\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of delayed language development are numerous and include issues like social deprivation, anatomic structural defects, oral motor or neuromotor dysfunction, hearing impairment, and neurocognitive delays. The evaluation and management of children with delayed expressive language development are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5098?source=see_link&amp;anchor=H19048066#H19048066\">",
"     \"Overview of expressive language delay (&ldquo;late talking&rdquo;) in young children\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early identification and intervention for children with abnormal language or literacy development are critical. Children whose speech and language impairment persists beyond five years of age may continue to have difficulty into adulthood. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with a history of phonologic disorders perform more poorly than do controls on writing tasks; those with a language disorder in addition to the phonologic disorder have the greatest difficulty [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seventy-one children with speech-language impairment at age four years were followed into adolescence [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/48\">",
"       48",
"      </a>",
"      ]. Those whose speech and language impairment persisted at age five (56 percent) were at high risk for language, literacy, and educational difficulties throughout childhood and adolescence. By comparison, when the early speech and language impairment resolved by age five (44 percent), the outlook for spoken language development was better, but literacy skills were weak because of residual phonologic processing deficits.",
"     </li>",
"     <li>",
"      Another prospective longitudinal trial compared children with speech and language impairment at age five with age-matched controls; high rates of communication difficulty remained at 12 and 19 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/49\">",
"       49",
"      </a>",
"      ]. However, only approximately 50 percent of the subjects in this study received treatment, usually during early years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     BILINGUAL LANGUAGE DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Questions often arise about the language development of children reared in bilingual environments. Bilingualism is the ability to speak two languages [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/50\">",
"     50",
"    </a>",
"    ]. Early research that suggested bilingual children were less intelligent than were monolingual children is incorrect. Learning two languages at once does not harm a child's cognitive abilities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]; rather, it enhances them [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. An initial stage of confusion, code-mixing, and comprehension-building for young bilinguals may occur but resolves [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/58\">",
"     58",
"    </a>",
"    ]. At 24 to 30 months of age, bilingual children may intermix vocabulary and syntax from both languages, but vocabulary size, intelligibility, and length of utterance are normal. By 36 months of age, they become fluent bilingual speakers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10599/abstract/42\">",
"     42",
"    </a>",
"    ]. One should note that single-language scores in one language may not accurately reflect the child's abilities, and direct comparisons across languages and different writing systems are precarious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUGGESTIONS FOR PARENTS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Speak slowly and succinctly",
"     </li>",
"     <li>",
"      Label objects",
"     </li>",
"     <li>",
"      Repeat, repeat, repeat",
"     </li>",
"     <li>",
"      Ask open-ended questions",
"     </li>",
"     <li>",
"      Expand on the child's conversation",
"     </li>",
"     <li>",
"      Correct positively &mdash; rephrase, repeat, relabel",
"     </li>",
"     <li>",
"      Use interactive games and humor",
"     </li>",
"     <li>",
"      Encourage your child",
"     </li>",
"     <li>",
"      Tell stories to each other",
"     </li>",
"     <li>",
"      Limit television viewing time",
"     </li>",
"     <li>",
"      Visit the library regularly",
"     </li>",
"     <li>",
"      Dialogue your activities: tell your child about what you are doing, even if it is baking a cake",
"     </li>",
"     <li>",
"      Read every day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics has developed a tool kit for the promotion of literacy (",
"    <a class=\"external\" href=\"file://www.aap.org/literacy\">",
"     www.aap.org/literacy",
"    </a>",
"    ) that includes information for parents about selecting books and sharing books with children of various ages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184273897\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Communication has verbal and nonverbal domains. Verbal communication includes receptive language, expressive language, and linguistics. Nonverbal communication includes body language, gestures, and signing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Domains of communications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The development of language and literacy occurs along a continuum that has a hierarchy of stages, including the acquisition of oral language, reading, writing, and spelling skills (",
"      <a class=\"graphic graphic_figure graphicRef78646 \" href=\"UTD.htm?15/46/16110\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72624 \" href=\"UTD.htm?35/25/36253\">",
"       table 1",
"      </a>",
"      ). The development of literacy requires competent oral language skills and an understanding of the relationship between oral and written language. Oral language competence is highly correlated with success in learning to read. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Literature review'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Normal language development'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A child's early literacy environment plays a critical role in the emergence of literacy. Early experience with books and reading contributes to subsequent success or failure in learning to read. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Environment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency of early literacy experiences, including listening to stories, in preschoolers is directly associated with oral language skills, reading comprehension, and reading achievement. The frequency of parent-child reading increases when parents receive books and encouragement to read at health supervision visits. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Frequency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a number of things that parents can do to promote their child&rsquo;s early language and literacy development. These include speaking slowly and succinctly, asking open-ended questions, expanding on the child&rsquo;s conversation, telling stories to each other, limiting television time, visiting the library, telling the child what they are doing, and reading every day. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Suggestions for parents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Teale W, Sulzby E. Emergent literacy as a perspective for examining how young children become writers and readers. In: Emergent Literacy: Writing and Reading, Teale W, Sulzby E (Eds), Ablex Publishing Corp, Norwood, NJ 1986.",
"    </li>",
"    <li>",
"     Lipson MY, Wixson KK. The foundations of literacy. In: Assessment and Introduction of Reading Disability &mdash; An Interactive Approach, Lipson MY, Wixson KK (Eds), Harper Collins Publishers Inc, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/3\">",
"      Whitehurst GJ, Lonigan CJ. Child development and emergent literacy. Child Dev 1998; 69:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/4\">",
"      Ruben RJ. Communicative disorders. The first year of life. Pediatr Clin North Am 1994; 41:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/5\">",
"      Flax JF, Rapin I. Evaluating children with delayed speech and language. Contemp Pediatr 1998; 15:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/6\">",
"      Mason JM. When do children begin to read: An exploration of four year old children's letter and word reading competencies. Reading Research Quarterly 1980; 2:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/7\">",
"      Frith U. A developmental framework dyslexia. Ann Dyslexia 1986; 36:69.",
"     </a>",
"    </li>",
"    <li>",
"     Sulzby E. Writing and reading: Signs of oral and written language organization in the young child. In: Emergent Literacy: Writing and Reading, Teale W, Sulzby E (Eds), Ablex Publishing Corp, Norwood, NJ 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/9\">",
"      Snow CE. Literacy and language: Relationships during the preschool years. Harvard Ed R 1983; 53:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/10\">",
"      Clay MM. The reading behavior of five-year old children: A research report. New Zealand Journal of Educational Studies 1967; 2:11.",
"     </a>",
"    </li>",
"    <li>",
"     Goodman KS, Goodman YM. Learning to read is natural. In: Theory and Practice of Early Reading, Resnick LB, Weaver P (Eds), Hilldale, Erlbaum, NJ 1979.",
"    </li>",
"    <li>",
"     McCormick CE, Mason JM. Intervention procedures for increasing preschool children's interest in and knowledge about reading. In: Literacy: Writing and Reading, Teale W, Sulzby E (Eds), Ablex Publishing Corp, Norwood, NJ 1986.",
"    </li>",
"    <li>",
"     US Department of Education. America's Kindergartners. Available at: file://nces.ed.gov/pubsearch/pubsinfo.asp?pubid=2000070 (Accessed on May 27, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/14\">",
"      Stanton WR, Feehan M, McGee R, Silva PA. The relative value of reading ability and IQ as predictors of teacher-reported behavior problems. J Learn Disabil 1990; 23:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/15\">",
"      Duursma E, Augustyn M, Zuckerman B. Reading aloud to children: the evidence. Arch Dis Child 2008; 93:554.",
"     </a>",
"    </li>",
"    <li>",
"     Wells G. Preschool literacy-related activities and success in school. In: Literacy, Language, and Learning: The Nature and Consequences of Reading and Writing, Olson DR, Torrance N, Hildyard A (Eds), Cambridge University Press, New York 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/17\">",
"      Scarborough HS, Dobrich W, Hager M. Preschool literacy experience and later reading achievement. J Learn Disabil 1991; 24:508.",
"     </a>",
"    </li>",
"    <li>",
"     Snow CE, Ninio A. The contracts of literacy: What children learn from learning to read books. In: Emergent Literacy: Writing and Reading, Teale W, Sulzby E (Eds), Ablex Publishing Corp, Norwood, NJ 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/19\">",
"      Locke J. Pittsburgh's beginning with books project. Sch Lib J 1988; :22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/20\">",
"      Needlman R, Fried LE, Morley DS, et al. Clinic-based intervention to promote literacy. A pilot study. Am J Dis Child 1991; 145:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/21\">",
"      Silverstein M, Iverson L, Lozano P. An English-language clinic-based literacy program is effective for a multilingual population. Pediatrics 2002; 109:E76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/22\">",
"      High P, Hopmann M, LaGasse L, Linn H. Evaluation of a clinic-based program to promote book sharing and bedtime routines among low-income urban families with young children. Arch Pediatr Adolesc Med 1998; 152:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/23\">",
"      Golova N, Alario AJ, Vivier PM, et al. Literacy promotion for Hispanic families in a primary care setting: a randomized, controlled trial. Pediatrics 1999; 103:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/24\">",
"      Needlman R, Toker KH, Dreyer BP, et al. Effectiveness of a primary care intervention to support reading aloud: a multicenter evaluation. Ambul Pediatr 2005; 5:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/25\">",
"      Weitzman CC, Roy L, Walls T, Tomlin R. More evidence for reach out and read: a home-based study. Pediatrics 2004; 113:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/26\">",
"      Sanders LM, Gershon TD, Huffman LC, Mendoza FS. Prescribing books for immigrant children: a pilot study to promote emergent literacy among the children of Hispanic immigrants. Arch Pediatr Adolesc Med 2000; 154:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/27\">",
"      Mendelsohn AL, Mogilner LN, Dreyer BP, et al. The impact of a clinic-based literacy intervention on language development in inner-city preschool children. Pediatrics 2001; 107:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/28\">",
"      High PC, LaGasse L, Becker S, et al. Literacy promotion in primary care pediatrics: can we make a difference? Pediatrics 2000; 105:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/29\">",
"      Theriot JA, Franco SM, Sisson BA, et al. The impact of early literacy guidance on language skills of 3-year-olds. Clin Pediatr (Phila) 2003; 42:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/30\">",
"      Sharif I, Rieber S, Ozuah PO, Reiber S. Exposure to Reach Out and Read and vocabulary outcomes in inner city preschoolers. J Natl Med Assoc 2002; 94:171.",
"     </a>",
"    </li>",
"    <li>",
"     Adams MJ. Beginning to Read: Thinking and learning about print, The MIT Press, Cambridge,MA 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/32\">",
"      Reese E, Cox A. Quality of adult book reading affects children's emergent literacy. Dev Psychol 1999; 35:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/33\">",
"      Pellegrini AD, Brody G. Parents' book-reading habits with their children. J Educ Psychol 1985; 77:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/34\">",
"      Pellegrini AD, Perlmutter JC, Galda L, Brody GH. Joint reading between black Head Start children and their mothers. Child Dev 1990; 61:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/35\">",
"      Whitehurst GJ, Falco CJ, Lonigan CJ, et al. Accelerating language development through picture book reading. Dev Psychol 1988; 24:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/36\">",
"      Ninio A. Picture-book reading in mother-infant dyads belonging to two subgroups in Israel. Child Dev 1980; 51:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/37\">",
"      High P, Hopmann M, LaGasse L, et al. Child centered literacy orientation: a form of social capital? Pediatrics 1999; 103:e55.",
"     </a>",
"    </li>",
"    <li>",
"     Teale WH. Home background and young children's literacy development. In: Emergent Literacy: Writing and Reading, Teale W, Sulzby E (Eds), Ablex Publishing Corp, Norwood, NJ 1986.",
"    </li>",
"    <li>",
"     Frankenburg, WK, Dodds, JB, et al. Denver developmental screening text II. Denver Developmental Materials, Inc, Denver, CO 1990.",
"    </li>",
"    <li>",
"     Zimmerman IL, Steiner VG, Pond RE. Preschool Language Scale-3. The Psychological Corp, San Antonio, TX 1992.",
"    </li>",
"    <li>",
"     Coplan J. Early Language Milestone Scale. PRO-ED, Austin, TX 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/42\">",
"      Coplan J. Normal speech and language development: an overview. Pediatr Rev 1995; 16:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/43\">",
"      Capute AJ, Palmer FB, Shapiro BK, et al. Clinical linguistic and auditory milestone scale: prediction of cognition in infancy. Dev Med Child Neurol 1986; 28:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/44\">",
"      Capute AJ, Shapiro BK, Palmer FB. Marking the milestones of language development. Contemp Pediatr 1987; 4:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/45\">",
"      Sturner RA, Howard BJ. Preschool development. 1: Communicative and motor aspects. Pediatr Rev 1997; 18:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/46\">",
"      Johnson CP, Blasco PA. Infant growth and development. Pediatr Rev 1997; 18:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/47\">",
"      Lewis BA, O'Donnell B, Freebairn LA, Taylor HG. Spoken language and written expression&mdash;interplay of delays. Am J Speech Lang Pathol 1998; 7:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/48\">",
"      Stothard SE, Snowling MJ, Bishop DV, et al. Language-impaired preschoolers: a follow-up into adolescence. J Speech Lang Hear Res 1998; 41:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/49\">",
"      Johnson CJ, Beitchman JH, Young A, et al. Fourteen-year follow-up of children with and without speech/language impairments: speech/language stability and outcomes. J Speech Lang Hear Res 1999; 42:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/50\">",
"      Chiocca EM. Language development in bilingual children. Pediatr Nurs 1998; 24:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/51\">",
"      Bosch L, Sebasti&aacute;n-Gall&eacute;s N. Native-language recognition abilities in 4-month-old infants from monolingual and bilingual environments. Cognition 1997; 65:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/52\">",
"      Oller DK, Eilers RE, Urbano R, Cobo-Lewis AB. Development of precursors to speech in infants exposed to two languages. J Child Lang 1997; 24:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/53\">",
"      Bialystok E. Effects of bilingualism and biliteracy on children's emerging concepts of print. Dev Psychol 1997; 33:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/54\">",
"      Umbel VM, Pearson BZ, Fern&aacute;ndez MC, Oller DK. Measuring bilingual children's receptive vocabularies. Child Dev 1992; 63:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/55\">",
"      Bruck M, Genesee F. Phonological awareness in young second language learners. J Child Lang 1995; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/56\">",
"      Galambos SJ, Goldin-Meadow S. The effects of learning two languages on levels of metalinguistic awareness. Cognition 1990; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/57\">",
"      Bialystok E. Levels of bilingualism and levels of linguistic awareness. Dev Psychol 1988; 24:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10599/abstract/58\">",
"      Genesee F, Nicoladis E, Paradis J. Language differentiation in early bilingual development. J Child Lang 1995; 22:611.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 617 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-FD0A04FE88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10599=[""].join("\n");
var outline_f10_22_10599=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H184273897\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Domains of communications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Language parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LITERATURE REVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Environment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Frequency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Quality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Demographics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NORMAL LANGUAGE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DELAYED LANGUAGE AND LITERACY DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Red flags",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1081709\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      BILINGUAL LANGUAGE DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUGGESTIONS FOR PARENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H184273897\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/617\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/617|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/46/16110\" title=\"figure 1\">",
"      Speech sound development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/617|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/25/36253\" title=\"table 1\">",
"      Language literacy milestones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21399?source=related_link\">",
"      Etiology of speech and language disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26343?source=related_link\">",
"      Evaluation and treatment of speech and language disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/62/5098?source=related_link\">",
"      Overview of expressive language delay (&ldquo;late talking&rdquo;) in young children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_22_10600="Histology case 7 with answer";
var content_f10_22_10600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 569px\">",
"   <div class=\"ttl\">",
"    Histology case 7 with answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 549px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The correct answer is",
"    <strong>",
"     atheroembolic renal disease",
"    </strong>",
"    in panel B. The photomicrograph shows an atheroembolus in a muscular renal artery (arrow) with cleft-like spaces due to washout of the cholesterol crystals during histologic processing. Panel shows diffuse and nodular (N) glomerulosclerosis in diabetic nephropathy. Although this patient is diabetic, the rapid decline in renal function and lack of proteinuria suggest a diagnosis other than diabetic nephropathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10600=[""].join("\n");
var outline_f10_22_10600=null;
var title_f10_22_10601="Heart rate variability: Use after myocardial infarction";
var content_f10_22_10601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heart rate variability: Use after myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10601/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10601/contributors\">",
"     Phyllis K Stein, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10601/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10601/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10601/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10601/contributors\">",
"     Hugh Calkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10601/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/22/10601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart rate (RR interval) variability (HRV) measurements provide a low-cost, widely available, noninvasive method for assessing cardiac autonomic function in humans and for predicting cardiovascular events, especially cardiac death and sustained ventricular arrhythmias in coronary heart disease patients.",
"   </p>",
"   <p>",
"    This topic will review the predictive value of HRV in patients who have had a myocardial infarction. The uses of HRV in other cardiopulmonary settings and technical issues related to HRV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link\">",
"     \"Heart rate variability: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METHODOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variation in RR intervals derived from intervals between normal heart beats can be measured by many methods, which can be categorized as time domain measures, frequency domain measures, and",
"    <span class=\"nowrap\">",
"     nonlinear/complexity-based",
"    </span>",
"    measures (",
"    <a class=\"graphic graphic_table graphicRef79145 \" href=\"UTD.htm?15/22/15725\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various commercial Holter and signal averaged electrocardiogram (SAECG) software provide estimates of HRV. The measures most often available from commercial software include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SDNN &mdash; Standard deviation of NN (normal to normal RR) intervals over a 24-hour period or over a brief (usually five minutes) measuring period",
"     </li>",
"     <li>",
"      SDANN &mdash; Standard deviation of the average NN intervals for the 288 five-minute intervals in a 24-hour continuous ECG recording",
"     </li>",
"     <li>",
"      pNN50 &mdash; Percent NN intervals &gt;50 ms different from the prior interval",
"     </li>",
"     <li>",
"      rMSSD &mdash; Root mean square of differences between successive NN intervals",
"     </li>",
"     <li>",
"      Total power, (ULF) ultra-low frequency power, (VLF) very low frequency power, (LF) low-frequency power, (HF) high-frequency power and the ratio of",
"      <span class=\"nowrap\">",
"       LF/HF",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Detailed definitions for these HRV indices are found in the following table (",
"    <a class=\"graphic graphic_table graphicRef79145 \" href=\"UTD.htm?15/22/15725\">",
"     table 1",
"    </a>",
"    ) and a more extensive discussion of them and of others that are primarily used in research are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link\">",
"     \"Heart rate variability: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Open source software for HRV analysis and open access databases are freely available at the website of the",
"    <span class=\"nowrap\">",
"     NIH/NCRR",
"    </span>",
"    Research Resource for Complex Physiologic Signals (",
"    <a class=\"external\" href=\"file://www.physionet.org/\">",
"     www.physionet.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REPRODUCIBILITY OF RR VARIABILITY MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of RR variability for prediction of outcome or detection of changes in clinical status depends on their stability over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     RR variability in normal subjects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The day-to-day stability of frequency domain measures of RR variability was studied in 14 normal subjects, 20 to 55 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/8\">",
"     8",
"    </a>",
"    ]. Two 24-hour recordings were made three to 65 days apart (median 18 days). The measures of RR variability calculated were 24-hr averaged LF and HF power; their mean values were virtually identical in the two 24-hour ECG recordings, and the standard errors of measurement between the two recordings was very small. Furthermore, the intraclass correlation coefficients (a measure of within-subject agreement) for LF and HF power were 0.91 and 0.84, respectively. When analyzed for the median time between recordings, the intraclass correlation coefficients were 0.93 and 0.90 for recordings obtained less than 18 days apart and 0.88 and 0.75 for those obtained more than 18 days apart.",
"   </p>",
"   <p>",
"    Thus, power spectral measures of RR variability appear to be highly consistent from day-to-day during the range of times studied; this day-to-day stability exists for the 24-hour average values for power spectral measures of RR variability, despite marked differences among the five minute intervals during a day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     RR variability in patients with cardiac arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reproducibility of RR variability measurements in patients with previous myocardial infarction and ventricular arrhythmias is comparable to the high stability observed in normal subjects. The stability of measures of heart period variability makes it possible to distinguish real changes due to progression or regression of cardiac disease or drug effects from apparent changes due to random variation. As an example, one study evaluated the day to day stability of RR variability in two groups of arrhythmia patients: a random sample of 40 patients in the Electrophysiological Study Versus Electrocardiographic Monitoring (ESVEM) study who had sustained ventricular arrhythmias and a random sample of 40 patients in the placebo group of the Cardiac Arrhythmia Pilot Study (CAPS) who had nonsustained ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/9\">",
"     9",
"    </a>",
"    ]. The ESVEM group was much sicker than the CAPS group, having more abnormal left ventricular function and more baseline arrhythmias.",
"   </p>",
"   <p>",
"    Although HRV was markedly lower in the ESVEM group, there were no significant differences in measures of RR variability between the two 24-hour recording sessions in either the ESVEM or the CAPS group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     RR variability in patients with stable angina",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stability of RR variability measured over three years was verified in 261 patients with chronic stable angina. Most HRV measures remained largely unchanged over time, although pNN50 and",
"    <span class=\"nowrap\">",
"     LF/HF",
"    </span>",
"    were less stable. Declines in most HRV measures, although not HF power, were seen in those who suffered a myocardial infarction during that period [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     RR variability in patients with heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even among 17 patients with stable heart failure, HRV measured on two occasions, two weeks apart, was highly reproducible with no significant test-retest differences, and intraclass correlations &ge;0.86 for time and frequency domain HRV indices [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effect of myocardial infarction on RR variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;RR variability is significantly decreased, compared to normal values, among postmyocardial infarction (MI) patients. This decreased HRV is a marker for autonomic imbalance and likely reflects both decreased cardiac vagal activity and increased sympathetic nerve traffic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/12\">",
"     12",
"    </a>",
"    ]. Moreover, as will be described in detail later, this autonomic imbalance is believed to be both a marker for worse cardiac function and a mechanism underlying malignant arrhythmic events. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Autonomic nervous system and cardiac arrhythmias'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a direct comparison of data from a large post-MI study and data from healthy age- and gender-matched normal controls, six frequency domain (power spectral) measures of RR period variability (ULF, VLF, LF, HF, total power, and",
"    <span class=\"nowrap\">",
"     LF/HF",
"    </span>",
"    ratio) were found to be substantially reduced 10 days after a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/13\">",
"     13",
"    </a>",
"    ]. It is not known to what extent RR variability is reduced prior to myocardial infarction in patients with coronary heart disease; however, no relationship between HRV and degree of stenosis was reported among patients with uncomplicated coronary artery disease undergoing cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/14\">",
"     14",
"    </a>",
"    ]. In a canine model of myocardial infarction, coronary artery ligation is followed by an abrupt decrease in RR variability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recovery of RR variability after myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small studies have investigated the recovery of RR variability after myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Early phase of recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time course of recovery of vagal modulation of RR intervals after a first myocardial infarction was evaluated in 20 highly selected patients under the age of 70 upon admission to the coronary care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients had no previous infarction, no history of diabetes, renal failure, alcohol abuse, hypertension, or prior treatment with or contraindication to beta blockers or antihypertensive drugs, and had no arrhythmias or heart failure. All patients received streptokinase and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    at presentation and were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    and aspirin over the three-month follow-up period. Continuous 24-hour ECG recordings were obtained at 1.5 days after the infarction and at days 7, 42, and 140. Cardiac parasympathetic activity was estimated using counts of the number of times that successive RR intervals differed by &gt;50 ms in a 24-hour period (NN50). For the 20 patients overall, NN50 doubled between 1.5 days and 42 days after infarction and tripled between 1.5 days and 140 days.",
"   </p>",
"   <p>",
"    The pattern of recovery of NN50, however, varied with the site of infarction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with an inferior infarct, NN50 was initially within the normal limits for age and did not change significantly over the 140 day follow-up. It was postulated that stimulation of vagal afferent nerves by ischemia and prostaglandins preserved the efferent vagal activity in this setting.",
"     </li>",
"     <li>",
"      Among patients with an anterior infarct, NN50 was 20 percent of normal at 1.5 days and recovered progressively to 67 percent of normal by 140 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another study RR variability was measured during the acute phase of MI (within 24 hours), the subacute phase (10 days later) and the chronic phase (12 months later) among 100 patients with a first ST-segment elevation MI who underwent successful PTCA and received optimal medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/17\">",
"     17",
"    </a>",
"    ]. Mean RR was unchanged between the subacute and chronic phases, but RR variability increased significantly over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Late phase of recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recovery of RR variability was studied in the 68 placebo-treated patients entered into the Cardiac Arrhythmia Pilot Study (CAPS) who had 24-hour ECG recordings at baseline and at 3, 6, and 12 months after a myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/18\">",
"     18",
"    </a>",
"    ]. The 24-hour power spectral density was computed using fast Fourier transforms and total ULF, VLF, LF, and HF powers were analyzed. Mean baseline values were generally representative of postinfarction patients.",
"   </p>",
"   <p>",
"    There was a substantial increase in all measures of RR variability between three weeks and three months (p&lt;0.001). On average, recovery of RR variability was completed by three months after the infarct; between three and twelve months, the values were stable for the group as a whole and for individual patients. However, even at 12 months after infarction, the average full recovery values for the five measures of RR variability were only one-half to two-thirds the values found in a sample of 274 normal age and sex matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/19\">",
"     19",
"    </a>",
"    ]. There was substantial interpatient variability: some patients recovered to normal values of RR variability while others had little recovery or even a further reduction, possibly associated with disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect of coronary artery bypass graft surgery on HRV recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;RR variability is significantly depressed after coronary artery bypass graft (CABG) surgery and remains depressed for at least six months or more afterwards [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, HRV is not meaningful for risk stratification of post-CABG patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     USE OF RR VARIABILITY FOR RISK ASSESSMENT AFTER MYOCARDIAL INFARCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As stated by the Task Force on Heart Rate Variability, there are two proven clinical uses of RR variability [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prediction of risk cardiac death or arrhythmic events after acute myocardial infarction",
"     </li>",
"     <li>",
"      Detection and quantification of autonomic neuropathy in patients with diabetes mellitus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most frequent use of RR variability, for risk stratification for all cause, cardiac, and arrhythmic death after a myocardial infarction, will be discussed in the following sections. However, since the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on ST elevation myocardial infarction concluded that efficacy was less well established for the use of HRV for noninvasive assessment of the risk of ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/21\">",
"     21",
"    </a>",
"    ], the precise role for HRV testing in clinical practice remains undefined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Autonomic nervous system and cardiac arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autonomic nervous system, which includes both the sympathetic and parasympathetic nervous systems, has an important role in the triggering or sustaining of malignant ventricular arrhythmias, particularly after myocardial infarction. This relationship partly explains the predictive value of RR variability as it reflects autonomic balance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sympathetic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased sympathetic nerve traffic and elevated plasma catecholamines can be found in the setting of myocardial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These alter the electrophysiologic properties of the myocardium and promote arrhythmogenesis, regardless of the mechanism involved (enhanced automaticity, triggered activity, or reentry) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/6,24\">",
"     6,24",
"    </a>",
"    ]. Some of the arrhythmogenic effects are related to the adverse effects of tachycardia, such as ischemia, while others result from heterogeneity of ventricular repolarization.",
"   </p>",
"   <p>",
"    There are a number of observations from animal models implicating the sympathetic nervous system in arrhythmogenesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a normal animal, stimulation of the hypothalamus and other areas of the brain that are associated with increased sympathetic nervous system activity cause cardiac arrhythmias, including ventricular fibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhibition of sympathetic nervous system activity by interruption of central pathways prevents cardiac arrhythmias [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Experimental situations that evoke anger or fear can provoke ventricular arrhythmias in intact animals [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When the myocardium is \"sensitized\" to cardiac arrhythmias as a result of acute myocardial ischemia or drug toxicity (eg, digitalis, cocaine, certain anesthetics), the probability of ventricular fibrillation is increased when there is activation of the sympathetic nervous system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interaction between myocardial ischemia or infarction and the sympathetic nervous system is complex. Myocardial ischemia increases the neural activity of afferent cardiac sympathetic fibers, triggering reflexes that increase efferent cardiac sympathetic neural activity while decreasing efferent vagal activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. There is also release of norepinephrine from epicardial sympathetic nerves and an increase in its local myocardial concentrations due to the high extracellular potassium concentrations in the ischemic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/31\">",
"     31",
"    </a>",
"    ]. The increased levels of potassium and norepinephrine plus the heterogeneous response between normal and ischemic tissue to them result in regional heterogeneity of depolarization and repolarization, which is an important precondition for the development of reentrant activity and the precipitation of ventricular fibrillation.",
"   </p>",
"   <p>",
"    Infarction can also involve the epicardial sympathetic nerves, producing regional sympathetic denervation of the myocardium distal to the infarct [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This can further enhance heterogeneity of repolarization and increase the potential for reentry during times of enhanced sympathetic activity. The noninfarcted tissue responds normally to sympathetic stimulation with a shortening of the ventricular refractory period while denervated tissue fails to respond. In addition, denervated tissue displays denervation hypersensitivity (ie, is hypersensitive to circulating catecholamines).",
"   </p>",
"   <p>",
"    Preliminary studies in humans have shown that the extent of damage to cardiac sympathetic nerves two to four weeks after infarction, quantified by scanning with radiolabeled metaiodobenzylguanidine, is related to the magnitude of reduction of two time-domain measures of HRV: SDNN and r-MSSD (",
"    <a class=\"graphic graphic_table graphicRef79145 \" href=\"UTD.htm?15/22/15725\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link&amp;anchor=H30#H30\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'Heart rate variability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Parasympathetic nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parasympathetic nervous system exerts pronounced antiarrhythmic effects by reducing the heart rate and counteracting the proarrhythmic effects of sympathetic nervous system activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. The antiarrhythmic effect of increased vagal tone is particularly evident when there is activation of the sympathetic nervous system as has been shown during the early period after a myocardial infarction in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In this setting, the reduction in the ventricular fibrillation threshold induced by enhanced sympathetic tone can be reversed with vagal stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/38\">",
"     38",
"    </a>",
"    ]. Furthermore, the parasympathetic nervous system plays a large role in regulating the inflammatory response and RR variability is inversely related to the production of many inflammatory markers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prediction of in-hospital mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first large study to show the usefulness of HRV for predicting long-term outcome after a myocardial infarction, the Multi-Center Post-Infarction Program, or MPIP, involved 808 patients who underwent ambulatory monitoring within 11 days of an acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/40\">",
"     40",
"    </a>",
"    ]. After a mean 31-month follow-up, the mortality rate of patients with SDNN &lt;50 ms was 34 percent compared to 12 percent in those with an SDNN &gt;100 ms (relative risk of 2.8). SDNN predicted mortality independently of other risk predictors such as left ventricular ejection fraction or ventricular arrhythmias.",
"   </p>",
"   <p>",
"    A reanalysis of the MPIP data comparing the predictive value of all time domain HRV indices, dichotomized at an arbitrary cutpoint, found that SDANN &lt;40 ms had the strongest univariate association with all-cause and both cardiac and arrhythmic mortality. This association persisted after adjustment for covariates. Measures of high frequency fluctuations in NN intervals, such as rMSSD or pNN50, were not significantly associated with outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MPIP was performed in the pre-fibrinolytic era. The effect of fibrinolysis on HRV and its consequent predictive value were addressed in a report from the GUSTO-I trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/42\">",
"     42",
"    </a>",
"    ]. Findings were similar to those in earlier studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal HRV, measured as early as 48 hours after a myocardial infarction, was noted to be prognostically useful with respect to 30 day and one year mortality in patients receiving fibrinolytic agents.",
"     </li>",
"     <li>",
"      There was an association between the degree of HRV abnormality and the patency of the infarct related artery. HRV was greatest in those with patent arteries (TIMI grade 3) while it was reduced (and equivalent) in those with partially (TIMI grade 2) or totally (TIMI grade 0 or 1) occluded vessels.",
"     </li>",
"     <li>",
"      Those patients with an anterior myocardial infarction had more abnormal HRV measurements than those with a non-anterior wall myocardial infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The continuing validity of time domain HRV for prediction of outcome post-MI was confirmed in the GISSI-2 study of fibrinolytic therapy in acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/43\">",
"     43",
"    </a>",
"    ]. A subset of 567 patients had a valid 24-hour ambulatory ECG recording and 52 of them died during 1000 days of follow-up. Decreased values for SDNN, NN50, and rMSSD identified high risk groups comprising 16 to 18 percent of the cohort, with mortalities ranging from 20.8 to 24.2 percent in the high-risk group versus 6.0 to 6.8 percent in the low-risk group. Thus, the relative risk of mortality was approximately 3.0 for the low HRV groups.",
"   </p>",
"   <p>",
"    The largest recent study of the predictive value of HRV post-MI was ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients (N = 1284) had Holter recordings 28 days post-MI and were followed for 21&plusmn;8 months. SDNN &lt;70 was associated with a relative risk of mortality of 3.2. In this study, baroreceptor sensitivity (BRS), another measure of cardiac autonomic function, was obtained. Abnormal BRS was also associated with increased risk of mortality. An especially high-risk group of patients with an elevated risk of mortality had LVEF &lt;35 percent and either low SDNN (relative risk 6.7) or low BRS (relative risk 8.7) compared to those with a higher left ventricular ejection fraction and less abnormal measures of autonomic function.",
"   </p>",
"   <p>",
"    A meta-analysis of 21 studies with 3489 patients confirmed the ATRAMI findings, showing that patients with SDNN&lt;70 ms (8.1 percent of patients) were almost four times as likely to die over the following three years. The authors caution however, that this finding applies to the population and not necessarily to the individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Prediction of long-term mortality by geometric time domain measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The group at St. George's Hospital has performed a large number of studies on the predictive value of HRV postmyocardial infarction (MI). Many of their studies use so-called geometric measures of HRV, which have the advantage of not being dependent, as are most other HRV measures, on a time-consuming, detailed annotation of the morphology and interbeat interval of each heart beat.",
"   </p>",
"   <p>",
"    One study was performed in 416 patients with an acute MI, 48 percent of whom were treated with a fibrinolytic agent. Twenty-four-hour ECG recording was performed six or seven days after myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/46\">",
"     46",
"    </a>",
"    ]. RR variability was quantified by triangular interpolation of the frequency distribution of normal RR intervals (TINN). TINN, a geometric measure of RR variability, is strongly correlated with SDNN, SDANN, total power, and ULF power. During an average follow-up of 20 months, the risk of experiencing a cardiac death was about seven times higher in those with a TINN &lt;20 ms compared to those with a TINN &ge;20 ms. TINN did not predict recurrent myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prediction of mortality by frequency domain measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequency domain measures of RR variability have also been used for predicting death after a myocardial infarction (",
"    <a class=\"graphic graphic_table graphicRef79145 \" href=\"UTD.htm?15/22/15725\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef79238 \" href=\"UTD.htm?29/49/30491\">",
"     table 2",
"    </a>",
"    ). In a reanalysis of the MPIP data, after a four-year follow-up, all frequency domain measures of RR variability were associated with all cause, cardiac, and arrhythmic death; the strongest univariate association was for total power and ULF power. After adjustment for five established risk predictors (age, NYHA functional class, rales detected on chest auscultation in the coronary care unit, left ventricular ejection fraction, and ventricular arrhythmias), the association between mortality and total power, ULF power, and VLF power remained significant and strong, whereas LF power and HF power were only moderately strongly associated with mortality. Cutpoints for frequency domain HRV obtained in MPIP are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef79238 \" href=\"UTD.htm?29/49/30491\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Power spectral measures over a 5-minute interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term power spectral measures of RR variability (ie, calculated from five minutes of normal RR interval data) are also predictive of mortality. Using data from MPIP, two randomly selected five-minute segments of RR intervals from 24-hour ambulatory monitoring (one between 8 AM and 4 PM and the other between 12 AM and 5 AM) were analyzed and VLF, LF, HF, and the",
"    <span class=\"nowrap\">",
"     LF/HF",
"    </span>",
"    ratio were calculated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mean power spectral values obtained from these brief periods during the day and night were similar to 24-hour values and the correlations between short segment values and 24-hour values were strong. The power spectral measures of RR variability, obtained from the five-minute ECG recordings, were excellent predictors of all cause, cardiac, and arrhythmic mortality; after an average follow up of 31 months, patients with low values were two to four times as likely to die compared to those with high values.",
"   </p>",
"   <p>",
"    The St. George's group performed a similar investigation. They compared the predictive value for one year survival of SDNN from a five minute segment of HRV on a Holter recording to the predictive value of the 24-hour geometric measure (HRV index) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/48\">",
"     48",
"    </a>",
"    ]. There was a significant but relatively poor correlation between SDNN over five minutes and HRV index (r = 0.51, p&lt;0.001) and the positive predictive accuracy of SDNN over five minutes for one year was lower than for HRV index. However, when the 24-hour recordings for the 35 percent of the population with the lowest five minute SDNN were selected, prediction of one year mortality was similar to that obtained by performing recordings on all of the patients. Their results suggested that a short-term HRV recording clearly identified patients with the lowest HRV in whom further testing can be recommended. Thus, a short-term ECG recording can be clinically useful in identifying patients at higher risk of postinfarction mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prediction of mortality using short-term fractal scaling exponent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short-term fractal scaling exponent, alpha, is a non-linear HRV index that provides information about the degree of randomness or correlations in heart rate fluctuations (see",
"    <a class=\"external\" href=\"file://www.physionet.org/\">",
"     www.physionet.org",
"    </a>",
"    for open-source software). Lower values for this index reflect increased randomness. This measure has been shown to be a powerful risk stratifier. In one study, for example, 24 hour recordings were obtained in 446 survivors of acute myocardial infarction with LVEF &le;35 percent in the DIAMOND study. Follow up was about two years. Although traditional HRV measures and power law slope were associated with mortality, the strongest predictor was reduced short-term fractal scaling exponent (relative risk 3.0). Even after adjustment for clinical and demographic risk factors, decreased short-term fractal scaling exponent was a significant predictor of both arrhythmic and nonarrhythmic mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prediction of mortality by power law regression parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Power law slope was calculated for the patients in the MPIP study. Those classified as high risk based upon altered power law scaling behavior had a 10-fold increased risk of dying during 2.5 years of follow-up compared with patients classified as low risk (79 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/50\">",
"     50",
"    </a>",
"    ]. The power law regression parameters predicted all-cause mortality or arrhythmic death better than any single power spectral band or any combination of power spectral variables.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Use of HRV with other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;By itself, HRV lacks the sensitivity and specificity to sufficiently identify high-risk patients. At the same time, correlations between time or frequency domain measures of RR variability and previously identified postinfarction risk factors such as left ventricular ejection fraction and ventricular arrhythmias are remarkably weak [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/40\">",
"     40",
"    </a>",
"    ]. This lack of correlation and the fact that measures of RR variability are independent predictors of patients at high risk after myocardial infarction suggest the potential utility of combining abnormal HRV with other risk stratifiers. An example of this was described above where, in ATRAMI, decreased left ventricular ejection fraction, combined with abnormal HRV, identified an especially high-risk subgroup.",
"   </p>",
"   <p>",
"    The first study in which HRV was combined with other risk factors was MPIP [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/13\">",
"     13",
"    </a>",
"    ]. The addition of power spectral measures of RR variability, particularly total power and ULF power, to left ventricular ejection fraction and frequent ventricular arrhythmias quantified over a 24-hour interval identified small subgroups with 50 percent mortality over a 2.5 year follow up.",
"   </p>",
"   <p>",
"    HRV measures were also combined with other risk factors in the analysis of the placebo arm of 610 patients entered into the EMIAT (European Myocardial Infarction",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     Amiodarone",
"    </a>",
"    Trial) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/51\">",
"     51",
"    </a>",
"    ]. This analysis showed that the predictive value of depressed RR variability, defined as the geometric measure HRV index &lt;20 U, is maintained when patients with depressed left ventricular ejection fraction (&lt;40 percent) were considered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/51\">",
"     51",
"    </a>",
"    ]. RR variability values were significantly lower in nonsurvivors compared to survivors. The all-cause mortality at two years was significantly higher in patients with depressed RR variability (23 versus 10 percent for preserved variability), primarily due to an increase in arrhythmic mortality. The higher mortality associated with depressed RR variability was also seen in patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      On beta blockers (15 versus 9 percent)",
"     </li>",
"     <li>",
"      With an ejection fraction &le;30 percent (28 versus 13 percent)",
"     </li>",
"     <li>",
"      With ventricular arrhythmias (34 versus 14 percent)",
"     </li>",
"     <li>",
"      With a heart rate &ge;75",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      (29 versus 12 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The high predictive accuracy of RR variability measured over 24 hours combined with other risk predictors can be extended to brief office screening procedures. For example, power spectral measures of RR variability calculated on the same five minutes of data used to record the signal averaged ECG has been proposed as an efficient and low cost screening tool [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Arrhythmic events after myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately half of all post-infarct deaths can be classified as arrhythmic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/52\">",
"     52",
"    </a>",
"    ]. Decreased HRV is associated with both arrhythmic and non-arrhythmic cardiac death, but HRV in combination with other risk factors for arrhythmic death can help identify high-risk patients. For example, the ability of the TINN in combination with other risk factors to predict arrhythmic events (sustained ventricular arrhythmias or arrhythmic death) was evaluated in 416 patients with acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/46\">",
"     46",
"    </a>",
"    ]. The best multivariate predictor for arrhythmic events, with a positive predictive accuracy of 58 percent, was the triad of TINN &lt;20 ms, a positive signal averaged ECG, and repetitive ventricular premature complexes present in the same 24-hour ECG recording that was used to calculate TINN.",
"   </p>",
"   <p>",
"    Combinations of noninvasive variables can achieve positive predictive accuracies of approximately 50 percent for mortality and arrhythmia events. Such high values for predictive accuracy have important implications for postinfarction assessment and management strategies, including ICD implantation, since they identify patients at high risk for an arrhythmic event who may be suitable candidates for prophylactic treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Predictive value of power spectral measures late after myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The substantial recovery of RR variability within the three months after myocardial infarction, particularly with inferior infarcts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/13,16\">",
"     13,16",
"    </a>",
"    ], raises a question as to whether recovery values for RR variability predict death. In one study of 331 patients entered into CAPS who survived for one year post-infarction, 24-hour ECG recordings were obtained after previous antiarrhythmic therapy was discontinued and power spectral measures of RR variability were calculated (ULF, VLF, LF, HF, and total power and the",
"    <span class=\"nowrap\">",
"     LF/HF",
"    </span>",
"    ratio) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since there is a large increase in RR variability during the first three months after myocardial infarction, the optimum cutpoints for measures of RR variability in the one year recordings were substantially higher than those previously determined for 24-hour ECG recordings made about two weeks after infarction. The following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each power spectral measure of RR variability had a strong and significant univariate association with all-cause mortality after a 2.5 year follow up; the relative risks for these variables ranged from 2.5 to 5.6.",
"     </li>",
"     <li>",
"      The predictive value of the measures of RR variability made one year after infarction was not improved when measures of RR variability made within one month of the infarct were added to the survival model.",
"     </li>",
"     <li>",
"      Measures of RR variability still had a strong and significant independent association with all-cause mortality after adjustment for age, NYHA functional class, the presence of rales on chest auscultation in the coronary care unit, left ventricular ejection fraction, and ventricular arrhythmias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, RR variability measured after full recovery from myocardial infarction predicts death independent of other important post infarction risk predictors. The final recovery values for RR variability are the best predictors of subsequent events and knowledge of the recovery pattern does not significantly improve prediction.",
"   </p>",
"   <p>",
"    In general clinical practice, Holter recordings might be obtained at any point after myocardial infarction and it is unclear whether HRV would risk stratify patients with such a broad range of times post-MI. The Cardiac Arrhythmia Suppression Trial (CAST) represented an opportunity to test this question. Results suggested that decreased time and frequency domain HRV continued to risk stratify such patients, but only in patients who had not had CABG surgery or were not diabetic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/20\">",
"     20",
"    </a>",
"    ]. Consistent with the results of many other studies, decreased ULF power was the strongest predictor of mortality. In contrast, in a reanalysis of the MPIP data, HRV determined shortly after MI retained its predictive value among diabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/54\">",
"     54",
"    </a>",
"    ]. Although it is unclear over what period this remains true, it is clear that HRV among patients with CABG surgery does not carry prognostic information.",
"   </p>",
"   <p>",
"    In healthy persons, RR variability is influenced significantly by age, sex, physical fitness, and drug treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. This raises a question as to whether these factors confound the use of RR variability to predict death and arrhythmic events in patients with coronary heart disease. In the CAST study described above, pretreatment HRV was significantly associated with mortality despite the fact that subjects were subsequently randomized to three different anti-arrhythmic treatments. While results of ATRAMI, in which the association of HRV and mortality was different for patients older than and younger than 65 years, suggested the risk stratification could be fine-tuned by considering other factors, the effect of coronary disease per se on RR variability is much greater than the possible effect of factors such as age, sex, physical fitness, or drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CONCLUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HRV analyses provide useful predictors of death and arrhythmic events after acute myocardial infarction and in chronic coronary heart disease. RR variability complements other risk stratifiers such as left ventricular ejection fraction and ventricular arrhythmias. However, RR variability, measured soon after acute myocardial infarction, does not predict recurrent infarction. Little is known about the predictive value of changes in HRV over time. Refinements in HRV analysis, further comparison of the utility of traditional versus newer",
"    <span class=\"nowrap\">",
"     nonlinear/complexity-based",
"    </span>",
"    measures, and resolution of conflicting results from studies should be facilitated by the availability of open access to previously collected Holter databases and open source software [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10601/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/1\">",
"      Malik M, Camm AJ. Components of heart rate variability--what they really mean and what we really measure. Am J Cardiol 1993; 72:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/2\">",
"      Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93:1043.",
"     </a>",
"    </li>",
"    <li>",
"     Heart Rate Variability, Malik, M, Camm, AJ (Eds), Futura Publishing Company, Armonk 1995.",
"    </li>",
"    <li>",
"     Dynamic Electrocardiography, Malik M, Camm AJ (Eds), Blackwell Futura, Elmsford 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/5\">",
"      Strauss, HM. Heart Rate Variability. Am J Physiol 2003; 285:R927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/6\">",
"      Seely AJ, Macklem PT. Complex systems and the technology of variability analysis. Crit Care 2004; 8:R367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/7\">",
"      Voss A, Schulz S, Schroeder R, et al. Methods derived from nonlinear dynamics for analysing heart rate variability. Philos Transact A Math Phys Eng Sci 2009; 367:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/8\">",
"      Kleiger RE, Bigger JT, Bosner MS, et al. Stability over time of variables measuring heart rate variability in normal subjects. Am J Cardiol 1991; 68:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/9\">",
"      Bigger JT Jr, Fleiss JL, Rolnitzky LM, Steinman RC. Stability over time of heart period variability in patients with previous myocardial infarction and ventricular arrhythmias. The CAPS and ESVEM investigators. Am J Cardiol 1992; 69:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/10\">",
"      Bj&ouml;rkander I, Forslund L, Ericson M, et al. Long-term stability of heart rate variability in chronic stable angina pectoris, and the impact of an acute myocardial infarction. Clin Physiol Funct Imaging 2009; 29:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/11\">",
"      Stein PK, Rich MW, Rottman JN, Kleiger RE. Stability of index of heart rate variability in patients with congestive heart failure. Am Heart J 1995; 129:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/12\">",
"      Bigger JT Jr, La Rovere MT, Steinman RC, et al. Comparison of baroreflex sensitivity and heart period variability after myocardial infarction. J Am Coll Cardiol 1989; 14:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/13\">",
"      Bigger JT Jr, Fleiss JL, Steinman RC, et al. RR variability in healthy, middle-aged persons compared with patients with chronic coronary heart disease or recent acute myocardial infarction. Circulation 1995; 91:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/14\">",
"      Nolan J, Flapan AD, Reid J, et al. Cardiac parasympathetic activity in severe uncomplicated coronary artery disease. Br Heart J 1994; 71:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/15\">",
"      Hull SS Jr, Evans AR, Vanoli E, et al. Heart rate variability before and after myocardial infarction in conscious dogs at high and low risk of sudden death. J Am Coll Cardiol 1990; 16:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/16\">",
"      Flapan AD, Wright RA, Nolan J, et al. Differing patterns of cardiac parasympathetic activity and their evolution in selected patients with a first myocardial infarction. J Am Coll Cardiol 1993; 21:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/17\">",
"      Ortak J, Weitz G, Wiegand UK, et al. Changes in heart rate, heart rate variability, and heart rate turbulence during evolving reperfused myocardial infarction. Pacing Clin Electrophysiol 2005; 28 Suppl 1:S227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/18\">",
"      Bigger JT Jr, Fleiss JL, Rolnitzky LM, et al. Time course of recovery of heart period variability after myocardial infarction. J Am Coll Cardiol 1991; 18:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/19\">",
"      Wiggers H, B&oslash;tker HE, Egeblad H, et al. Coronary artery bypass surgery in heart failure patients with chronic reversible and irreversible myocardial dysfunction: effect on heart rate variability. Cardiology 2002; 98:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/20\">",
"      Stein PK, Domitrovich PP, Kleiger RE, CAST Investigators. Including patients with diabetes mellitus or coronary artery bypass grafting decreases the association between heart rate variability and mortality after myocardial infarction. Am Heart J 2004; 147:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/21\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/22\">",
"      Metra M, Nodari S, D'Aloia A, et al. A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J 2000; 139:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/23\">",
"      Floras JS. Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. Acta Physiol Scand 2003; 177:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/24\">",
"      Zipes DP, Barber MJ, Takahashi N, Gilmour RF Jr. Influence of the autonomic nervous system on the genesis of cardiac arrhythmias. Pacing Clin Electrophysiol 1983; 6:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/25\">",
"      Hockman CH, Mauck HP Jr, Hoff EC. ECG changes resulting from cerebral stimulation. II. A spectrum of ventricular arrhythmias of sympathetic origin. Am Heart J 1966; 71:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/26\">",
"      Skinner JE, Reed JC. Blockade of frontocortical-brain stem pathway prevents ventricular fibrillation of ischemic heart. Am J Physiol 1981; 240:H156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/27\">",
"      Carpeggiani C, Landisman C, Montaron MF, Skinner JE. Cryoblockade in limbic brain (amygdala) prevents or delays ventricular fibrillation after coronary artery occlusion in psychologically stressed pigs. Circ Res 1992; 70:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/28\">",
"      Verrier RL, Lown B. Behavioral stress and cardiac arrhythmias. Annu Rev Physiol 1984; 46:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/29\">",
"      Malliani, A, Recordati, G, Schwartz, PJ. Nervous activity of afferent cardiac sympathetic fibers with atrial and ventricular endings. Am J Physiol 1973; 339:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/30\">",
"      Schwartz PJ, Pagani M, Lombardi F, et al. A cardiocardiac sympathovagal reflex in the cat. Circ Res 1973; 32:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/31\">",
"      Cascio WE, Johnson TA, Gettes LS. Electrophysiologic changes in ischemic ventricular myocardium: I. Influence of ionic, metabolic, and energetic changes. J Cardiovasc Electrophysiol 1995; 6:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/32\">",
"      Barber MJ, Mueller TM, Henry DP, et al. Transmural myocardial infarction in the dog produces sympathectomy in noninfarcted myocardium. Circulation 1983; 67:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/33\">",
"      Barber MJ, Mueller TM, Davies BG, et al. Interruption of sympathetic and vagal-mediated afferent responses by transmural myocardial infarction. Circulation 1985; 72:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/34\">",
"      Esperer, HD, Bentrup, A, Geller, JC, et al. Decreased heart rate variability in the early postinfarction period correlates with the extent of myocardial sympathetic denervation (abstract). Pacing Clin Electrophysiol 1997; 20:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/35\">",
"      Takahashi N, Barber MJ, Zipes DP. Efferent vagal innervation of canine ventricle. Am J Physiol 1985; 248:H89.",
"     </a>",
"    </li>",
"    <li>",
"     De, Ferrari, GM, Vanoli, E, Schwartz, PJ. Vagal activity and ventricular fibrillation. In: Vagal Control of the Heart, Levy, MN, Schwartz, PJ (Eds), Futura Publishing, Armonk 1994. p.613.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/37\">",
"      Bailey JC, Watanabe AM, Besch HR Jr, Lathrop DA. Acetylcholine antagonism of the electrophysiological effects of isoproterenol on canine cardiac Purkinje fibers. Circ Res 1979; 44:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/38\">",
"      Kolman BS, Verrier RL, Lown B. Effect of vagus nerve stimulation upon excitability of the canine ventricle. Role of sympathetic-parasympathetic interactions. Am J Cardiol 1976; 37:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/39\">",
"      Haensel A, Mills PJ, Nelesen RA, et al. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology 2008; 33:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/40\">",
"      Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/41\">",
"      Bigger JT Jr, Fleiss JL, Steinman RC, et al. Correlations among time and frequency domain measures of heart period variability two weeks after acute myocardial infarction. Am J Cardiol 1992; 69:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/42\">",
"      Singh N, Mironov D, Armstrong PW, et al. Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. Circulation 1996; 93:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/43\">",
"      Zuanetti G, Neilson JM, Latini R, et al. Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Circulation 1996; 94:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/44\">",
"      La Rovere MT, Bigger JT Jr, Marcus FI, et al. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 1998; 351:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/45\">",
"      Buccelletti E, Gilardi E, Scaini E, et al. Heart rate variability and myocardial infarction: systematic literature review and metanalysis. Eur Rev Med Pharmacol Sci 2009; 13:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/46\">",
"      Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/47\">",
"      Bigger JT, Fleiss JL, Rolnitzky LM, Steinman RC. The ability of several short-term measures of RR variability to predict mortality after myocardial infarction. Circulation 1993; 88:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/48\">",
"      Fei L, Copie X, Malik M, Camm AJ. Short- and long-term assessment of heart rate variability for risk stratification after acute myocardial infarction. Am J Cardiol 1996; 77:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/49\">",
"      Huikuri HV, M&auml;kikallio TH, Peng CK, et al. Fractal correlation properties of R-R interval dynamics and mortality in patients with depressed left ventricular function after an acute myocardial infarction. Circulation 2000; 101:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/50\">",
"      Bigger JT Jr, Steinman RC, Rolnitzky LM, et al. Power law behavior of RR-interval variability in healthy middle-aged persons, patients with recent acute myocardial infarction, and patients with heart transplants. Circulation 1996; 93:2142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/51\">",
"      Malik M, Camm AJ, Janse MJ, et al. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: a substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial). J Am Coll Cardiol 2000; 35:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/52\">",
"      Greene HL, Richardson DW, Barker AH, et al. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989; 63:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/53\">",
"      Bigger JT Jr, Fleiss JL, Rolnitzky LM, Steinman RC. Frequency domain measures of heart period variability to assess risk late after myocardial infarction. J Am Coll Cardiol 1993; 21:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/54\">",
"      Whang W, Bigger JT Jr. Comparison of the prognostic value of RR-interval variability after acute myocardial infarction in patients with versus those without diabetes mellitus. Am J Cardiol 2003; 92:247.",
"     </a>",
"    </li>",
"    <li>",
"     Bigger, JT. RR variability to evaluate autonomic physiology and pharmacology and to predict cardiovascular outcomes in human. In: Cardiac Arrhythmias: From Cell to Bedside, Zipes DP (Ed), Saunders, Philadelphia 1995. p.1151.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/56\">",
"      Liao D, Barnes RW, Chambless LE, et al. Age, race, and sex differences in autonomic cardiac function measured by spectral analysis of heart rate variability--the ARIC study. Atherosclerosis Risk in Communities. Am J Cardiol 1995; 76:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10601/abstract/57\">",
"      Goldberger AL, Amaral LA, Glass L, et al. PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals. Circulation 2000; 101:E215.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1003 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-FDE34C00CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10601=[""].join("\n");
var outline_f10_22_10601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METHODOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REPRODUCIBILITY OF RR VARIABILITY MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RR variability in normal subjects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RR variability in patients with cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RR variability in patients with stable angina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RR variability in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effect of myocardial infarction on RR variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recovery of RR variability after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Early phase of recovery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Late phase of recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect of coronary artery bypass graft surgery on HRV recovery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      USE OF RR VARIABILITY FOR RISK ASSESSMENT AFTER MYOCARDIAL INFARCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Autonomic nervous system and cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sympathetic nervous system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Parasympathetic nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prediction of in-hospital mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Prediction of long-term mortality by geometric time domain measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prediction of mortality by frequency domain measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Power spectral measures over a 5-minute interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prediction of mortality using short-term fractal scaling exponent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prediction of mortality by power law regression parameters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Use of HRV with other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Arrhythmic events after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Predictive value of power spectral measures late after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CONCLUSIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1003\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1003|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/22/15725\" title=\"table 1\">",
"      Measures RR variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/49/30491\" title=\"table 2\">",
"      HRV parameter values MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=related_link\">",
"      Heart rate variability: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=related_link\">",
"      Heart rate variability: Uses other than after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_22_10602="Treatment of Paget disease of bone";
var content_f10_22_10602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of Paget disease of bone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10602/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10602/contributors\">",
"     Margaret Seton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10602/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10602/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/22/10602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/22/10602/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/22/10602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paget disease of bone, also known as osteitis deformans, is a focal disorder of bone metabolism that is characterized by an accelerated rate of bone remodeling, resulting in overgrowth of bone at selected sites and impaired integrity of affected bone.",
"   </p>",
"   <p>",
"    Many patients with Paget disease of bone are asymptomatic. The diagnosis in such patients is usually made incidentally following a routine chemistry screen showing an elevated serum concentration of alkaline phosphatase of bone origin, or by an imaging study obtained for some other reason that shows pagetic changes in bone.",
"   </p>",
"   <p>",
"    The two main clinical manifestations of Paget disease are pain and deformities in affected areas. However, fractures, bone tumors, neurologic disease, cardiac disease, and abnormalities in calcium and phosphate balance can also occur. In addition, because of the vascularity of pagetic bone, excessive bleeding may occur during orthopaedic surgery.",
"   </p>",
"   <p>",
"    The goals of treatment are to ease pain and to reduce the rate of bone remodeling toward normal, which will enhance the deposition of normal lamellar bone, decrease the vascularity of bone, and slow disease progression.",
"   </p>",
"   <p>",
"    The newer generations of nitrogen-containing bisphosphonates are potent inhibitors of osteoclastic bone resorption. As described below, clinical trials with these medications in Paget disease have demonstrated easing of pain, deposition of normal lamellar bone, and normalization of serum alkaline phosphatase and other markers of bone resorption. Effective therapy may also lead to radiographic healing of lytic lesions and reversal of increased isotope uptake on bone scan [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Analgesic, rehabilitative, surgical, and other measures may also be of benefit.",
"   </p>",
"   <p>",
"    The treatment of Paget disease of bone will be reviewed here. The pathogenesis, clinical manifestations, and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment decisions in Paget disease depend upon the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The presence or absence of symptoms from active disease",
"     </li>",
"     <li>",
"      The distribution of pagetic lesions in the skeleton",
"     </li>",
"     <li>",
"      The metabolic activity of pagetic lesions, as determined by bone turnover markers or bone scintigraphy",
"     </li>",
"     <li>",
"      The potential consequences of bony overgrowth at affected sites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Life expectancy, which may be difficult to predict, should only be a limited consideration in decisions to treat. Age alone is generally not a factor, as the newer bisphosphonates are usually well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Symptomatic Paget disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose symptoms are caused by metabolically active Paget disease (usually associated with an elevated serum alkaline phosphatase of bone origin) should be treated. The most common symptom is bone pain at a pagetic site (eg, headache, limb, joint, or back pain, or radicular pain or neural impingement by pagetic bone).",
"   </p>",
"   <p>",
"    Patients with back or joint pain often have coexistent neuromuscular or joint disease, such as osteoarthritis, associated with nearby pagetic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The precise cause of pain in these patients may be difficult to determine, and a trial of bisphosphonate therapy is generally indicated, particularly if the serum alkaline phosphatase is elevated.",
"   </p>",
"   <p>",
"    When given, antipagetic treatment in such patients should be accompanied by supportive measures, and the possible limitations of antipagetic therapy in this setting should be reviewed with the patient. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Response to therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Asymptomatic Paget disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic Paget disease is detected on imaging studies performed for some other reason (eg, suspected kidney stones) or by the finding of an elevated serum alkaline phosphatase of bone origin, which is associated with metabolically active disease. Decisions regarding therapy in asymptomatic patients should take into account the location of the disease and the presence of comorbidities.",
"   </p>",
"   <p>",
"    The main indication for treatment of asymptomatic Paget disease is biochemically active disease at sites where complications could occur (eg, skull, spine, weight-bearing bones, and bone abutting a joint), as described in the preceding section on symptomatic disease. In asymptomatic patients with pagetic changes at other sites, it is reasonable to initiate therapy if the serum alkaline phosphatase is more than two to four times the upper limit of normal.",
"   </p>",
"   <p>",
"    In patients with a normal serum alkaline phosphatase in whom a pagetic lesion has been detected incidentally, we suggest performance of bone scintigraphy. The bone scan can detect active disease and determine its extent. Antipagetic therapy should be initiated if involvement is at a site where complications could occur. If not, the patient should be monitored yearly for signs of progressive disease or functional impairment.",
"   </p>",
"   <p>",
"    Other indications for treatment of patients with asymptomatic active Paget disease include planned surgery at an active pagetic site and the rare development of hypercalcemia in association with immobilization in patients with polyostotic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/7\">",
"     7",
"    </a>",
"    ]. Hypercalcemia in an ambulatory patient suggests the presence of a second disorder such as primary hyperparathyroidism. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Preoperative antipagetic therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Preoperative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For planned surgery at an active pagetic site, preoperative medical treatment to reduce abnormal bone turnover may be beneficial by reducing hypervascularity and possibly perioperative blood loss. In patients presenting with fracture through pagetic bone, formal recommendations to guide therapy are lacking. Treatment may be initiated once the patient is stable. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Preoperative antipagetic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drugs used for the treatment of Paget disease are antiresorptive agents that target the osteoclast, which is considered the primary cell responsible for Paget disease. These drugs suppress bone resorption within days to weeks, as shown by decreased urine hydroxyproline, pyridinolines, or N-telopeptides, followed by suppression of bone formation in weeks to months, with a reduction in the serum fraction of alkaline phosphatase that comes from bone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=see_link\">",
"     \"Bone physiology and biochemical markers of bone turnover\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newer nitrogen-containing bisphosphonates (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    , and neridronate) are the primary agents used for the initial treatment of Paget disease (",
"    <a class=\"graphic graphic_table graphicRef50479 \" href=\"UTD.htm?6/1/6171\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. These medications have different mechanisms of action than the simple bisphosphonates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    ), resulting in sustained suppression of bone turnover at doses that do not impair mineralization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms of action and pharmacokinetics of the bisphosphonates are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=see_link\">",
"     \"Pharmacology of bisphosphonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcitonin is another antiresorptive agent that is now used infrequently. It is less potent than the newer bisphosphonates and unlikely to result in a sustained clinical remission. However, it is relatively safe and can be used in patients intolerant of bisphosphonates. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Preoperative antipagetic therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Calcitonin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    More toxic agents, such as mithramycin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/60/22467?source=see_link\">",
"     gallium nitrate",
"    </a>",
"    , are NOT recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nitrogen-containing bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newer generation of nitrogen-containing bisphosphonates that are currently used and best studied for the treatment of Paget disease include two oral agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , and two administered by intravenous infusion,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several general principles for the use of the bisphosphonates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All bisphosphonates are poorly absorbed when taken orally. As a result, they must be taken with plain water, not other beverages, first thing in the morning and at least 30 minutes before the first food, beverage, or other oral medications. Patients should not lie down during this period to prevent gastroesophageal reflux and possible esophageal irritation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Risedronate'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H13\">",
"       'Alendronate'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Normal serum levels of calcium, phosphorus, and 25-hydroxyvitamin D (calcidiol) should be present when initiating bisphosphonate therapy and throughout the ensuing year. All patients should be given supplemental vitamin D (800 international units daily) and calcium (1200 mg of elemental",
"      <span class=\"nowrap\">",
"       calcium/day",
"      </span>",
"      in divided doses) to avoid hypocalcemia. Additional vitamin D supplementation (50,000 international units weekly) should be given for eight weeks prior to initiating therapy in patients whose 25-hydroxyvitamin D level is 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (50",
"      <span class=\"nowrap\">",
"       nmol/L)",
"      </span>",
"      or less. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of vitamin D deficiency in adults\", section on 'Vitamin D repletion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measurement of serum parathyroid hormone (PTH) is warranted in patients who are hypercalcemic. As examples, the serum PTH concentration is low with hypercalcemia associated with immobilization and increased in coexistent primary hyperparathyroidism, which can occur in patients with Paget disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Major comparative trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to the nitrogen-containing bisphosphonates, several major trials have been performed. These include one comparing intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , one comparing intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    , and one comparing zoledronic acid with pamidronate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Normalization or substantial reduction in levels of serum alkaline phosphatase have been the primary end points in clinical trials of antipagetic therapies, as surrogate markers for reduction in increased bone turnover. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       Zoledronic acid",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      &mdash; Zoledronic acid (a single 5 mg infusion) was compared with oral risedronate (30",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 60 days) in a combination of two identical, randomized, six-month trials involving a total of 357 patients with Paget disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/14\">",
"       14",
"      </a>",
"      ]. Both groups had improvement in bone pain and quality of life. Zoledronic acid had the following benefits compared with risedronate:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      More frequent attainment of the primary end point, normalization of the serum alkaline phosphatase, or a 75 percent reduction in total alkaline phosphatase excess (the difference from the midpoint of the reference range) (96 versus 74 percent). This difference between drugs was mostly due to normalization of alkaline phosphatase.",
"     </li>",
"     <li>",
"      A shorter median time to therapeutic response (64 versus 89 days)",
"     </li>",
"     <li>",
"      A much lower frequency of loss of response in post-trial follow-up for a median of 190 days (1 versus 27 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suppression of bone turnover markers was sustained in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    during an 18-month extension of the original 6-month trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/15\">",
"     15",
"    </a>",
"    ]. The 296 patients who responded in the original trial were followed for a total of two years. In patients who received zoledronic acid, the serum alkaline phosphatase concentration remained in the middle of the reference range throughout the extension, while the patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    showed a linear increase in serum alkaline phosphatase beginning six months after the cessation of therapy.",
"   </p>",
"   <p>",
"    Adverse effects occurred more frequently in the first three days in those who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    (54 versus 25 percent), most commonly transient mild to moderate influenza-like symptoms (eg, fever and rigors) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/14\">",
"     14",
"    </a>",
"    ]. Aside from this acute reaction, both drugs were relatively well tolerated, and side effects occurred over the course of the study with equal frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Side effects of bisphosphonates'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       Pamidronate",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      &mdash; The second trial was a two-year randomized, open label trial of 72 patients that compared pamidronate (60 mg IV once every three months) with alendronate (40 mg daily by mouth in three-month blocks); therapy was continued until biochemical remission was attained [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/16\">",
"       16",
"      </a>",
"      ]. Randomization was stratified according to baseline serum alkaline phosphatase and according to whether or not the patient had received previous bisphosphonate therapy. Pamidronate nonresponders were crossed over to alendronate after one year.",
"      <br/>",
"      <br/>",
"      Biochemical remission was defined as both the serum alkaline phosphatase and urine",
"      <span class=\"nowrap\">",
"       deoxypyridinoline/creatinine",
"      </span>",
"      ratio being in the normal range. The following findings were noted at one year:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Biochemical remission occurred significantly more often in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      group (86 versus 56 percent). However, the results were affected by whether or not the patients had previously been treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      . In the 44 previously untreated patients, the rate of biochemical remission was similar in the two groups (91 versus 86 percent). In contrast, in the 28 patients previously treated with pamidronate, the rate of biochemical remission was higher with alendronate (79 versus 14 percent). These data suggested a high rate of acquired resistance to pamidronate and were consistent with prior observations of pamidronate resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The medications were both relatively well tolerated, with few major adverse effects. Four patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      experienced adverse effects sufficient to withdraw from the study, three because of gastrointestinal symptoms. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Side effects of bisphosphonates'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       Zoledronic acid",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      &mdash; A third trial included 120 patients with active Paget disease who were randomly assigned to zoledronic acid (a single 4 mg infusion) or pamidronate (30 mg IV for two consecutive days every three months) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/17\">",
"       17",
"      </a>",
"      ]. The primary efficacy end point was a biochemical response at six months, which was defined as normalization of serum alkaline phosphatase or at least a 75 percent reduction in alkaline phosphatase excess.",
"      <br/>",
"      <br/>",
"      At six months, zoledronic acid was associated with higher rates of both the biochemical response (97 versus 45 percent) and normalization of serum alkaline phosphatase (93 versus 35 percent). The 33 nonresponders to pamidronate were crossed over to zoledronic acid or neridronate (100 mg IV for two consecutive days). Both drugs produced a similar response rate (94 and 93 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Zoledronic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    is well tolerated, is easy to administer intravenously in hospital or outpatient settings, and is the most potent bisphosphonate approved for Paget disease in the United States. It is given in a dose of 5 mg IV over not &lt;15 minutes in 100 mL of saline or 5 percent dextrose in water or as a premixed solution. It should be infused in a line separate from other medications. Zoledronic acid is NOT recommended by the United States Food and Drug Administration for use in patients with a creatinine clearance &lt;30 to 35",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    Sustained",
"    biochemical remissions are achieved in most patients and can last up to one or two years. There are no data available from clinical trials regarding retreatment. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Retreatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pamidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    is well tolerated and easy to administer in hospital or outpatient settings. It can be given in a dose of 30 mg IV in 500 mL of one-half isotonic saline, isotonic saline, or 5 percent dextrose in water over four hours, daily for three consecutive days, according to the dosing regimen approved by the United States Food and Drug Administration.",
"   </p>",
"   <p>",
"    Other regimens have been used that may be more convenient than the FDA regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the randomized trial cited above comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      , the pamidronate regimen was 60 mg IV every three months until biochemical remission [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review, a general regimen consisted of a 60 to 90 mg infusion in 250 to 300 mL over two to four hours on two or more nonconsecutive days [",
"      <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A disadvantage to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    is the development of drug resistance in some patients, which affects the efficacy of retreatment. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Retreatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    has not been established in patients with a serum creatinine &gt;5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (442",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    The manufacturer recommends that clinical judgment be used in patients with renal insufficiency to determine if benefits outweigh potential risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Risedronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    is taken orally and is usually well tolerated. The comparative efficacy of risedronate to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    is presented above [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], and risedronate is substantially more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Major comparative trials'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    is given in a dose of 30 mg, once daily for two months. The goal of therapy is normalization of the serum alkaline phosphatase, which results in a more sustained remission than in patients whose values do not decrease to this level. Thus, patients whose alkaline phosphatase levels do not reach normal levels within two months of therapy should be retreated. Retreatment is discussed below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Retreatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    is NOT recommended by the United States Food and Drug Administration for use in patients with a creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Alendronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    is used in Paget disease at a dose of 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/2,11,16\">",
"     2,11,16",
"    </a>",
"    ]. The tablet form is given once daily for six months. It is usually well tolerated and, like the other newer bisphosphonates, is effective in normalizing the serum alkaline phosphatase.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    in patients previously treated with a bisphosphonate and is more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/11,16\">",
"     11,16",
"    </a>",
"    ]. However, alendronate and pamidronate are comparably effective in patients who are naive to bisphosphonates. Retreatment is discussed below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Major comparative trials'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H28\">",
"     'Retreatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    is NOT recommended by the United States Food and Drug Administration for use in patients with a creatinine clearance &lt;35",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109819800\">",
"    <span class=\"h3\">",
"     Neridronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neridronate is a nitrogen-containing bisphosphonate that is efficacious in Paget disease but is only available in a small number of countries; it is not available in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ]. It can be administered by either the intravenous or the intramuscular route [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/21\">",
"     21",
"    </a>",
"    ]. Neridronate has exhibited comparable efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    in a small randomized trial in patients who had had an inadequate response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Major comparative trials'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Simple bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The simple bisphosphonates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    , are no longer employed as first-line therapy but may have a role in selected patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Etidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     Etidronate",
"    </a>",
"    was the first bisphosphonate approved for the treatment of Paget disease in the United States. The usual dose is 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (200 to 400 mg daily) taken orally for six months.",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    is a relatively weak bisphosphonate that normalizes the serum alkaline phosphatase in less than 20 percent of patients. In addition, etidronate worsens bone pain in many patients and can impair bone mineralization, resulting in osteomalacia and fractures. As a result, etidronate is contraindicated in patients with lytic lesions in weight-bearing bones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and is generally used only in patients with an allergic reaction to the nitrogen-containing bisphosphonates.",
"   </p>",
"   <p>",
"    When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    is given, care should be taken to administer only the prescribed dosages, not exceeding six months per course. Patients can be retreated after at least a six-month interval off the drug, but this is not often done because of limited efficacy, the risk of impaired bone mineralization, and the possible development of drug resistance. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Retreatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specific guidelines are not available for use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    in patients with decreased renal function. The United States Food and Drug Administration recommends that etidronate be used cautiously, and dose reduction is advised in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Tiludronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     Tiludronate",
"    </a>",
"    is slightly more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    and does not result in the impaired mineralization associated with etidronate. Evidence of efficacy is provided by both randomized trials and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/24-28\">",
"     24-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized, placebo-controlled trial of 149 patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    at doses of 400 and 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three months significantly reduced serum and urine bone biomarkers and pain, although a significant frequency of complete resolution of pain was only seen at a dose of 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/25\">",
"     25",
"    </a>",
"    ]. Similar benefits were noted in another randomized trial of 112 patients, which noted that a 400 mg dose once daily appeared to offer the best balance of efficacy and tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition to reductions in bone biomarkers and pain, improvements are also seen on bone scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    is 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally for three months. Tiludronate is NOT recommended by the United States Food and Drug Administration for use in patients with a creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Clodronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     Clodronate",
"    </a>",
"    can be given both by mouth and intravenously for the treatment of Paget disease but is not approved for use in the United States, and evidence of efficacy comes from observational studies, not randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In addition, acquired resistance has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Side effects of bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bisphosphonates in current use are generally well tolerated. However, several side effects occur more commonly or are of particular concern even though they are seen infrequently.",
"   </p>",
"   <p>",
"    Bisphosphonate dosing in Paget disease is different from that in other disorders in which these drugs are used, such as osteoporosis and malignancy. Adverse effects with these treatment regimens are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a brief review of adverse effects that can occur with the dosing regimens used in Paget disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Influenza-like symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any of the nitrogen-containing bisphosphonates, particularly the intravenous agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ), can cause transient fever and an influenza-like syndrome in patients naive to these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/14\">",
"     14",
"    </a>",
"    ]. The syndrome is typical of an acute phase response and is characterized by fever, chills, bone pain, myalgias, and arthralgias. These symptoms are usually self-limited, resolving after several days, and may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or NSAIDs. They usually do not recur upon retreatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Musculoskeletal pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a syndrome distinct from the acute phase response, severe and sometimes incapacitating bone, joint, or muscle pain can occur within days, months, or years after starting a bisphosphonate and does not always resolve completely with discontinuation of therapy. This syndrome has been the subject of an alert by the United States Food and Drug Administration, as it may be overlooked by clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/33\">",
"     33",
"    </a>",
"    ]. The alert advises that clinicians prescribing bisphosphonates should discuss this syndrome with their patients and advise them to promptly contact their doctor if they develop severe bone, joint, or muscle pain while taking a bisphosphonate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Osteonecrosis of the jaw",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis of the jaw (ONJ) is a potentially serious complication of bisphosphonate use. It has primarily been described in patients with malignancy, particularly those treated with monthly intravenous therapy using high-potency bisphosphonates. In comparison, the risk is very low with chronic oral bisphosphonate therapy in postmenopausal women with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H48#H48\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of ONJ in Paget disease is unknown. There were no cases in the randomized trials described above that compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    in 357 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. An observational study from Australia primarily using a postal survey of Australian Oral and Maxillofacial Surgeons identified 158 patients with bisphosphonate-associated ONJ, eight of whom had Paget disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/34\">",
"     34",
"    </a>",
"    ]. State and national prescription databases were used to calculate frequency estimates (minimum to maximum) in Paget disease of 0.26 to 1.8 percent; the frequency estimate was higher if tooth extractions were carried out (2.1 to 13.5 percent).",
"   </p>",
"   <p>",
"    We suggest that extensive dental work be performed prior to treatment with bisphosphonates whenever possible, based upon evolving data that dental extractions constitute a significant risk for ONJ in patients on bisphosphonates. There is a lack of sufficient data to guide decisions regarding the risk from dental implants, although cases of successful implants have been reported in patients with Paget disease receiving bisphosphonate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Evidence of benefit from suspending treatment with bisphosphonates for several months prior to dental care is also lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical trials comparing intravenous with oral bisphosphonates, gastrointestinal side effects were more common with oral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Symptomatic hypocalcemia was rarely noted, but patients who did not take supplemental calcium and vitamin D may have been at higher risk.",
"   </p>",
"   <p>",
"    A possible link between bisphosphonate therapy and atrial fibrillation has been proposed. However, this association has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H49#H49\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Calcitonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salmon calcitonin, given subcutaneously, is the only preparation approved in the United States for the treatment of patients with Paget disease who cannot tolerate bisphosphonates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. The usual initial dose is 50 to 100 units daily, as tolerated; the usual maintenance regimen is 50 units daily or 50 to 100 units every one to three days. Therapy is often continued indefinitely, since cessation typically results in recurrent disease activity.",
"   </p>",
"   <p>",
"    The efficacy of parenteral salmon calcitonin was evaluated in a report of 85 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/39\">",
"     39",
"    </a>",
"    ]. Markers of bone turnover, such as serum alkaline phosphatase or urine hydroxyproline excretions, were initially reduced by about 50 percent. However, these parameters returned to pretreatment levels in 22 (26 percent) despite continuous therapy. Almost all of these patients developed high titer anti-calcitonin antibodies.",
"   </p>",
"   <p>",
"    In addition to the reduction in markers of bone turnover, other clinical benefits that have been described with parenteral calcitonin therapy include relief of bone pain, improvement or stabilization of hearing loss and other neurologic deficits, and decreased bone vascularity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/38,40\">",
"     38,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nausea, vomiting, or flushing are not uncommon but can be avoided or minimized in some patients by giving the drug at bedtime and slowly increasing the dose. The side effects of calcitonin are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=see_link\">",
"     \"Calcitonin in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intranasal formulation of calcitonin may be as effective as parenteral therapy in Paget disease, and the ease of administration makes it preferable to patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. This formulation is not approved in the United States for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CHOICE OF MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The drug selected for a given patient will be influenced by several factors, including the properties of the given drug, the burden of pagetic bone in the skeleton, and the particular circumstances of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/5,7,44\">",
"     5,7,44",
"    </a>",
"    ]. The nitrogen-containing bisphosphonates are effective, are relatively safe, and have advantages compared with the simple bisphosphonates or calcitonin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    is highly potent, has the advantage of being infused over 15 to 20 minutes, and produces the most sustained response among the available bisphosphonates. Biochemical remissions lasting up to one to two years are achieved in most patients after a single dose. In addition, zoledronic acid is effective in patients previously treated with other bisphosphonates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Zoledronic acid'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    is generally preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and oral agents because of its greater efficacy and ease of administration, especially in patients with more extensive disease and in those who are already on complex medication regimens for other conditions. The main limitations to zoledronic acid therapy are higher cost up front and unknown risks of long-term treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     Pamidronate",
"    </a>",
"    is an alternative intravenous agent, but it is less potent than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    and takes longer to infuse. Also, some patients develop drug resistance. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Pamidronate'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H28\">",
"     'Retreatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Oral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    may be preferred in younger patients with more limited disease. Overtreatment with oral medications should be avoided. In a managed care plan claims-based observational study of 433 patients with Paget disease, over 40 percent of those treated with an oral bisphosphonate received prescriptions for a duration beyond the recommended treatment regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients allergic to nitrogen-containing bisphosphonates, a simple bisphosphonate such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"     tiludronate",
"    </a>",
"    may be considered. Calcitonin is an option in patients who are unable to take bisphosphonates and in whom easing of pain and disease activity, rather than achieving disease remission, is the goal of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Preoperative antipagetic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For planned surgery at an active pagetic site, preoperative medical treatment with a nitrogen-containing bisphosphonate, beginning three months prior to surgery, may be beneficial by reducing hypervascularity and possibly perioperative blood loss. However, there are no clinical trials to guide the timing of such therapy, and significantly reduced blood loss in treated patients has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcitonin is an alternative in untreated patients unable to take a bisphosphonate or who require surgery prior to the time needed for a bisphosphonate to have sufficient benefit. Calcitonin can decrease vascularity of pagetic bone and has a rapid onset of action, with decreased skeletal blood flow observed within weeks to months of starting treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Calcitonin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients presenting with fracture through pagetic bone, formal recommendations to guide therapy are lacking. Bisphosphonates may be used once the patient is stable, and after calcium, phosphorus, and vitamin D have been measured and appropriate treatment begun to prevent hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'General principles'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the nitrogen-containing bisphosphonates, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , antipagetic interventions will usually be brief, will be well tolerated, and will offer pain relief and sustained clinical remission. In contrast, progression of disease can occur in untreated patients, with extension of osteolytic lesions and progressive bony deformity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized clinical trials of the bisphosphonates in patients with Paget disease, outcome measures have included reduction in pain, reduction in serum alkaline phosphatase, normalization of other bone turnover markers, the replacement of abnormal bone with normal lamellar bone, radiographic healing, and some improvement in measures of quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/1,2,5,7,11,12,14-16,51-53\">",
"     1,2,5,7,11,12,14-16,51-53",
"    </a>",
"    ]. Pain arising from pagetic bone usually responds rapidly to therapy, followed in weeks to months by gradual normalization of the serum alkaline phosphatase. Most studies have not been performed to confirm the expectation that bisphosphonate therapy will prevent long-term complications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/5,7,44\">",
"     5,7,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of bisphosphonate treatment on long-term complications were examined in a randomized, unblinded study involving 1324 patients followed for three years that found no evidence of reduction in the combined total of pagetic and nonpagetic fractures in patients treated based upon laboratory findings compared with those treated only for symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients treated with bisphosphonates to achieve normalization of the serum alkaline phosphatase had a similar number of fractures compared with patients treated only for pagetic bone pain. The latter group was treated initially with analgesics or nonsteroidal antiinflammatory drugs, then with bisphosphonates if symptoms were persistent. There were a number of limitations to the trial. These included the large proportion (70 percent) of patients previously treated with bisphosphonates, the absence of a treatment-na&iuml;ve patient population with more severe disease and at risk for a greater number of fractures, follow-up limited to a median of three years, lack of sufficient power to evaluate outcomes other than total fractures, and the performance of the study prior to the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Thus, it is uncertain whether these results can be generalized to patients receiving initial or currently preferred therapy for PDB and whether they apply to the patients at the most risk.",
"   </p>",
"   <p>",
"    In addition, the structural integrity of pagetic bone is abnormal, and restoration of normal bone or disappearance of pagetic bone from radiographs following treatment with bisphosphonates or calcitonin has not been reported. This has implications for treatment outcomes, in that risk of fracture or arthritis is unlikely to be mitigated in all patients once deformation or incongruity of bone is present. Thus, in patients with established disease, aggressive treatment aimed at normalization of the serum alkaline phosphatase, rather than treatment for symptoms only, would not be expected to result in substantial differences in fracture rates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/54\">",
"     54",
"    </a>",
"    ]. Early treatment of Paget disease may have different implications in terms of prevention of complications, but further study is needed to determine whether this will be the case.",
"   </p>",
"   <p>",
"    Some manifestations of Paget disease may also not be reversible. As examples, antipagetic therapy will rarely restore hearing, although it may stabilize hearing loss; it will not reverse deformity of bone or, as noted, all radiographic evidence of Paget disease on plain radiography; and it will not diminish the pain and dysfunction caused by secondary osteoarthritic changes. There are case reports of improvement in paraparesis or symptoms of spinal stenosis with bisphosphonate therapy, but there have been no comparative trials with other treatment modalities, such as surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Role of surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The secondary consequences of Paget disease need to be treated with modalities other than bisphosphonates or calcitonin. These include hearing aids, analgesics for arthritis pain, and, as adjuncts to antipagetic medications, physical therapy, bracing, and walking aids. In addition, attention must be paid to psychosocial issues [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/7,58-60\">",
"     7,58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normalization of serum alkaline phosphatase is associated with a sustained period of biochemical remission and histologic evidence of normal bone turnover; on the other hand, increases in serum alkaline phosphatase are consistent with increases in disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/1,2,11,14,51-53\">",
"     1,2,11,14,51-53",
"    </a>",
"    ]. Thus, as a marker of bone turnover, serum alkaline phosphatase can be used as an appropriate outcome measure when monitoring the biochemical response to bisphosphonate therapy.",
"   </p>",
"   <p>",
"    Serum alkaline phosphatase should be measured at three to six months to assess the initial response to therapy; once the value plateaus, it can be measured once or twice a year as a marker of bone activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/27\">",
"     27",
"    </a>",
"    ]. We do not routinely measure other markers of bone turnover, such as urinary pyridinium crosslink excretion, since there is no evidence that they are better measures of clinical response than serum alkaline phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computerized tomography or magnetic resonance imaging should be used to further characterize bone lesions if bone pain is refractory to medical therapy. Serial imaging studies, including bone scintigraphy, are not generally useful for routine monitoring of the response to treatment. However, bone scintigraphy may be helpful in monitoring the response to therapy after 6 to 12 months of treatment in the subset of patients with monostotic disease and normal bone turnover markers at baseline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RETREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for retreatment with bisphosphonates generally depend upon evidence of increased or recurrent abnormal bone turnover as determined by periodic serial measurements of serum alkaline phosphatase, radiographic progression of disease, or recurrent pain. New symptoms, which may respond to retreatment if due to Paget disease, should be distinguished from secondary or unrelated changes that are not caused by current disease activity.",
"   </p>",
"   <p>",
"    Some clinicians retreat patients only for symptoms related to Paget disease, while others retreat whenever the serum alkaline phosphatase becomes elevated above normal or rises to a significant degree above the previous nadir [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. As learned from the PRISM trial, an abnormal serum alkaline phosphatase is not by itself an indication for retreatment. Clinical judgement is required. Data from clinical trials do not address this issue adequately, but available guidelines have been summarized [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/7\">",
"     7",
"    </a>",
"    ]. For retreatment, the dose and duration of therapy are the same as for initial treatment.",
"   </p>",
"   <p>",
"    If retreatment seems advisable, in accordance with the available evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/7\">",
"     7",
"    </a>",
"    ], we suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no retreatment guidelines available for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      . A second dose can be administered once a nadir is reached if the serum alkaline phosphatase remains elevated at three to six months following the initial infusion or if there is subsequent escape from initial benefit.",
"     </li>",
"     <li>",
"      Retreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      is appropriate when serum alkaline phosphatase values rise above normal or increase more than 25 percent above nadir levels if normal values were not reached with the prior course of treatment. Pamidronate resistance has been reported in patients previously treated with pamidronate, but the mechanism is unclear. If resistance develops, a different nitrogen-containing bisphosphonate, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      , or neridronate, is usually effective. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Major comparative trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      is warranted in patients whose serum alkaline phosphatase levels do not reach normal within two months of initial therapy or subsequently rise above normal. We suggest switching to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      if two courses of risedronate do not result in normalization of the serum alkaline phosphatase.",
"     </li>",
"     <li>",
"      Retreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      can be given after a six-month post-treatment evaluation period if normal serum alkaline phosphatase values were attained and then rise above normal or if normal values were not attained during the initial course. An alternative to retreatment is switching to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      , which should be delayed until six months after the cessation of alendronate.",
"     </li>",
"     <li>",
"      Retreatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"       etidronate",
"      </a>",
"      should be limited in duration and considered with caution because of its marginal benefit relative to risk.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/51/38709?source=see_link\">",
"       Tiludronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"       clodronate",
"      </a>",
"      may be preferred alternatives for patients who require retreatment with a simple bisphosphonate. Calcitonin is also an option. These drugs have less potential for adverse effects on bone and, unlike etidronate, may be used in patients with lytic lesions in weight-bearing bones who are not candidates for a nitrogen-containing bisphosphonate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ROLE OF SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthopedic surgical options that may be considered in selected patients with Paget disease include corrective osteotomy for long bone deformity, fracture fixation, joint arthroplasty, spinal decompression, and resection of bone tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/22/10602/abstract/62\">",
"     62",
"    </a>",
"    ]. Factors that may pose additional challenges for the surgeon include the abnormal quality and hypervascularity of bone, bowing deformity of the limbs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distortion of the acetabulum. Patients with Paget disease are also at increased risk for postoperative heterotopic bone formation following joint replacement surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Paget disease of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with active disease in operative sites are at increased risk for blood loss, which may be decreased by preoperative antipagetic treatment. We suggest that treatment with bisphosphonates be initiated three months prior to elective surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=see_link\">",
"       \"Patient information: Paget disease of bone (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/59/14258?source=see_link\">",
"       \"Patient information: Paget disease of bone (osteitis deformans) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional patient and professional information is offered by:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;The Paget Foundation for Paget's Disease of Bone and Related Disorders",
"    <br/>",
"    &nbsp; &nbsp;120 Wall Street, Suite 1602",
"    <br/>",
"    &nbsp; &nbsp;New York, NY 10005-4035",
"    <br/>",
"    &nbsp;&nbsp;&nbsp;&nbsp;",
"    <a class=\"external\" href=\"file://www.paget.org/\">",
"     file://www.paget.org",
"    </a>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Tel: 1 800 23PAGET (1 800 237 2438) or 212 509 5335",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;FAX: 212 509 8492",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;E-mail:",
"    <a class=\"external\" href=\"mailto:PagetFdn@aol.com\">",
"     PagetFdn@aol.com",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goals of pharmacologic treatment for Paget disease are to ease pain and to reduce the rate of bone remodeling, which is pathologically increased in untreated patients, toward normal. Success of treatment is generally assessed by periodic monitoring of the alkaline phosphatase. The secondary consequences of Paget disease need to be treated with other modalities. These include hearing aids, analgesics for arthritis pain, and, as adjuncts to antipagetic medications, physical therapy and walking aids. In addition, attention must be paid to psychosocial issues. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms and findings that may respond to pharmacologic treatment in patients with active disease include bone pain, symptoms of nerve compression, and radiographic findings of osteolytic bone lesions. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although unproven, treatment with nitrogen-containing bisphosphonates is generally expected to prevent the long-term complications of disease, such as pathologic fractures, skeletal deformity, secondary osteoarthritis, and neurologic disorders including deafness.",
"     </li>",
"     <li>",
"      When treatment for Paget disease is indicated, we recommend a nitrogen-containing bisphosphonate as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nitrogen-containing bisphosphonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In symptomatic patients, we recommend treatment if the alkaline phosphatase level is elevated (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We also suggest treatment in symptomatic patients if the alkaline phosphatase level is normal but there is evidence of active disease on bone scintigraphy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In asymptomatic patients with active disease (as determined by bone scintigraphy or an increased alkaline phosphatase):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest treatment if disease is present at sites where complications could occur (eg, skull, spine, weight-bearing bones, abutting joint lines) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest treatment if bone surgery is planned on sites with active disease or if the alkaline phosphatase is greater than twice the upper limit of normal (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most other asymptomatic patients with active disease who do not meet the above criteria, we also suggest treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, in patients who are willing and able to undergo close follow-up, deferring treatment until there is evidence of disease progression is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications for therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Response to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential side effects of bisphosphonates include an acute phase response lasting several days, which occurs most commonly but not exclusively with the intravenous medications on initial administration and which can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      or nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nitrogen-containing bisphosphonates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Side effects of bisphosphonates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Choice of medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In older patients or in those with more extensive disease, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      rather than an oral bisphosphonate (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Choice of medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In younger patients or in those with less extensive disease, the choice of nitrogen-containing bisphosphonate can be based upon patient preference for intravenous or oral therapy, availability, and cost. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Choice of medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the rare patient intolerant of both parenteral and oral bisphosphonates, we suggest treatment with calcitonin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Choice of medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In all patients who will be treated with bisphosphonates, normal serum levels of calcium and 25-hydroxyvitamin D (calcidiol) should be documented, and supplemental vitamin D (800 international units daily) and calcium supplements (1200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of elemental calcium) should be given to avoid hypocalcemia. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nitrogen-containing bisphosphonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of a small but undetermined level of risk for osteonecrosis of the jaw in association with bisphosphonate use in Paget disease, planned invasive dental work, such as extractions or implants, should be performed prior to institution of bisphosphonate therapy whenever possible. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Side effects of bisphosphonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for retreatment with bisphosphonates generally depend upon evidence of increased or recurrent abnormal bone turnover as determined by periodic serial measurements of serum alkaline phosphatase, radiographic progression of disease, or recurrent pain. New symptoms, which may respond to retreatment if due to Paget disease, should be distinguished from secondary or unrelated changes that are not caused by current disease activity. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Monitoring'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Retreatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/1\">",
"      Brown JP, Chines AA, Myers WR, et al. Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone 2000; 26:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/2\">",
"      Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996; 101:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/3\">",
"      Ryan PJ, Gibson T, Fogelman I. Bone scintigraphy following intravenous pamidronate for Paget's disease of bone. J Nucl Med 1992; 33:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/4\">",
"      Vellenga CJ, Pauwels EK, Bijvoet OL, Hosking DJ. Evaluation of scintigraphic and roentgenologic studies in Paget's disease under treatment. Radiol Clin (Basel) 1976; 45:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/5\">",
"      Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 2008; 372:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/6\">",
"      Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 2001; 16:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/7\">",
"      Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J Bone Miner Res 2006; 21 Suppl 2:P94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/8\">",
"      Franck WA, Bress NM, Singer FR, Krane SM. Rheumatic manifestations of Paget's disease of bone. Am J Med 1974; 56:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/9\">",
"      Altman RD. Musculoskeletal manifestations of Paget's disease of bone. Arthritis Rheum 1980; 23:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/10\">",
"      Altman RD, Brown M, Gargano F. Low back pain in Paget's disease of bone. Clin Orthop Relat Res 1987; :152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/11\">",
"      Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996; 81:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/12\">",
"      Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med 1999; 106:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/13\">",
"      Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995; 38:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/14\">",
"      Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005; 353:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/15\">",
"      Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007; 22:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/16\">",
"      Walsh JP, Ward LC, Stewart GO, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 2004; 34:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/17\">",
"      Merlotti D, Gennari L, Martini G, et al. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. J Bone Miner Res 2007; 22:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/18\">",
"      Joshua F, Epstein M, Major G. Bisphosphonate resistance in Paget's disease of bone. Arthritis Rheum 2003; 48:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/19\">",
"      Filipponi P, Cristallini S, Policani G, et al. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate. Bone 1998; 23:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/20\">",
"      Adami S, Bevilacqua M, Broggini M, et al. Short-term intravenous therapy with Neridronate in Paget's disease. Clin Exp Rheumatol 2002; 20:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/21\">",
"      Merlotti D, Rendina D, Gennari L, et al. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone. J Bone Miner Res 2011; 26:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/22\">",
"      Eyres KS, Marshall P, McCloskey E, et al. Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate). Drug Saf 1992; 7:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/23\">",
"      Gibbs CJ, Aaron JE, Peacock M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br Med J (Clin Res Ed) 1986; 292:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/24\">",
"      Morales-Piga A. Tiludronate. A new treatment for an old ailment: Paget's disease of bone. Expert Opin Pharmacother 1999; 1:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/25\">",
"      Reginster JY, Colson F, Morlock G, et al. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study. Arthritis Rheum 1992; 35:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/26\">",
"      Fraser WD, Stamp TC, Creek RA, et al. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J 1997; 73:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/27\">",
"      Alvarez L, Peris P, Gua&ntilde;abens N, et al. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Rheumatology (Oxford) 2004; 43:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/28\">",
"      Peris P, Alvarez L, Vidal S, et al. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. Clin Exp Rheumatol 2007; 25:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/29\">",
"      Khan SA, McCloskey EV, Nakatsuka K, et al. Duration of response with oral clodronate in Paget's disease of bone. Bone 1996; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/30\">",
"      Yates AJ, Percival RC, Gray RE, et al. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1985; 1:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/31\">",
"      Khan SA, McCloskey EV, Eyres KS, et al. Comparison of three intravenous regimens of clodronate in Paget disease of bone. J Bone Miner Res 1996; 11:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/32\">",
"      Mossetti G, Gennari L, Rendina D, et al. Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget's disease of bone. Calcif Tissue Int 2008; 83:414.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/drug/InfoSheets/HCP/bisphosphonatesHCP.htm (Accessed on November 12, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/34\">",
"      Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/35\">",
"      Pirih FQ, Zablotsky M, Cordell K, McCauley LK. Case report of implant placement in a patient with Paget's disease on bisphosphonate therapy. J Mich Dent Assoc 2009; 91:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/36\">",
"      Torres J, Tamimi F, Garcia I, et al. Dental implants in a patient with Paget disease under bisphosphonate treatment: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/37\">",
"      DeRose J, Singer FR, Avramides A, et al. Response of Paget's disease to porcine and salmon calcitonins: effects of long-term treatment. Am J Med 1974; 56:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/38\">",
"      Singer FR. Clinical efficacy of salmon calcitonin in Paget's disease of bone. Calcif Tissue Int 1991; 49 Suppl 2:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/39\">",
"      Singer FR, Fredericks RS, Minkin C. Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum 1980; 23:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/40\">",
"      Wootton R, Reeve J, Spellacy E, Tellez-Yudilevich M. Skeletal blood flow in Paget's disease of bone and its response to calcitonin therapy. Clin Sci Mol Med 1978; 54:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/41\">",
"      Evans RA, Somers NM, Dunstan CR, et al. Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide. Calcif Tissue Int 1991; 49:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/42\">",
"      Reginster JY, Jeugmans-Huynen AM, Albert A, et al. One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Miner Res 1988; 3:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/43\">",
"      Gagel RF, Logan C, Mallette LE. Treatment of Paget's disease of bone with salmon calcitonin nasal spray. J Am Geriatr Soc 1988; 36:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/44\">",
"      Seton M, Krane SM. Use of zoledronic acid in the treatment of Paget's disease. Ther Clin Risk Manag 2007; 3:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/45\">",
"      Dolgitser M, Stern L, Katz LM, et al. Bisphosphonate use in the treatment of Paget's disease of the bone: analysis of claims in a large database. Manag Care Interface 2007; 20:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/46\">",
"      Calderoni P, Ferruzzi A, Andreoli I, Gualtieri G. Hip arthroplasty in coxarthrosis secondary to Paget's disease. Chir Organi Mov 2002; 87:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/47\">",
"      Barry HC. Orthopedic aspects of Paget's disease of bone. Arthritis Rheum 1980; 23:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/48\">",
"      Bidner S, Finnegan M. Femoral fractures in Paget's disease. J Orthop Trauma 1989; 3:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/49\">",
"      Whitson HE, Lobaugh B, Lyles KW. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone. Bone 2006; 39:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/50\">",
"      Siris ES, Feldman F. Natural history of untreated Paget's disease of the tibia. J Bone Miner Res 1997; 12:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/51\">",
"      Brown JP, Kylstra JW, Bekker PJ, et al. Risedronate in Paget's disease: preliminary results of a multicenter study. Semin Arthritis Rheum 1994; 23:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/52\">",
"      Singer FR, Clemens TL, Eusebio RA, Bekker PJ. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab 1998; 83:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/53\">",
"      Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 1998; 13:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/54\">",
"      Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone. J Bone Miner Res 2010; 25:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/55\">",
"      Reid IR, Cundy T, Bolland MJ, Grey A. Response to publication of PRISM trial. J Bone Miner Res 2010; 25:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/56\">",
"      Douglas DL, Duckworth T, Russell RG, et al. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1980; 1:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/57\">",
"      Wallace E, Wong J, Reid IR. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Intern Med 1995; 155:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/58\">",
"      Gold DT, Boisture J, Shipp KM, et al. Paget's disease of bone and quality of life. J Bone Miner Res 1996; 11:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/59\">",
"      Langston AL, Campbell MK, Fraser WD, et al. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int 2007; 80:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/60\">",
"      Seton M, Moses AM, Bode RK, Schwartz C. Paget's disease of bone: the skeletal distribution, complications and quality of life as perceived by patients. Bone 2011; 48:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/61\">",
"      Reid IR, Davidson JS, Wattie D, et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004; 35:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/22/10602/abstract/62\">",
"      Parvizi J, Klein GR, Sim FH. Surgical management of Paget's disease of bone. J Bone Miner Res 2006; 21 Suppl 2:P75.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5596 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-0869272E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10602=[""].join("\n");
var outline_f10_22_10602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS FOR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Symptomatic Paget disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Asymptomatic Paget disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Preoperative therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHARMACOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nitrogen-containing bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Major comparative trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Zoledronic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pamidronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Risedronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Alendronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H109819800\">",
"      - Neridronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Simple bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Etidronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Tiludronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Clodronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Side effects of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Influenza-like symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Musculoskeletal pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Osteonecrosis of the jaw",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Calcitonin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CHOICE OF MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Preoperative antipagetic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RETREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ROLE OF SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      ADDITIONAL INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5596\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5596|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/1/6171\" title=\"table 1\">",
"      Bisphosphonates in order of potency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42519?source=related_link\">",
"      Bone physiology and biochemical markers of bone turnover",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=related_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/50/7978?source=related_link\">",
"      Clinical manifestations and diagnosis of Paget disease of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=related_link\">",
"      Patient information: Paget disease of bone (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/59/14258?source=related_link\">",
"      Patient information: Paget disease of bone (osteitis deformans) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=related_link\">",
"      Pharmacology of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_22_10603="Burn nutr shriners";
var content_f10_22_10603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Caloric requirements for children based on the Galveston Shriners Burns Institute",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Calories (Kcal/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0 to 1",
"       </td>",
"       <td>",
"        2100 Kcal/m",
"        <sup>",
"         2",
"        </sup>",
"        plus 1000 Kcal/m",
"        <sup>",
"         2",
"        </sup>",
"        burn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 to 11",
"       </td>",
"       <td>",
"        1800 Kcal/m",
"        <sup>",
"         2",
"        </sup>",
"        plus 1300 Kcal/m",
"        <sup>",
"         2",
"        </sup>",
"        burn",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12 to 18",
"       </td>",
"       <td>",
"        1500 Kcal/m",
"        <sup>",
"         2",
"        </sup>",
"        plus 150 Kcal/m",
"        <sup>",
"         2",
"        </sup>",
"        burn",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Saffle JR, Graves C. Nutritional support of the burned patient. In: Total Burn Care: 3rd Edition, Herndon, DN (Ed), Saunders Elsevier, Philadelphia, PA 2007. p.398.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10603=[""].join("\n");
var outline_f10_22_10603=null;
var title_f10_22_10604="Survival postsurgery IPHC DPAM";
var content_f10_22_10604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcomes of radical surgery and intraperitoneal chemotherapy for disseminated peritoneal adenomucinosis (DPAM)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author, year",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Median&nbsp;follow-up, months",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Survival rate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        2 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        3 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        5 years",
"       </td>",
"       <td class=\"subtitle2\">",
"        10 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ronnett BM; 2001",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        96",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"        <br/>",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smith JW; 1992",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sugarbaker P; 1993",
"       </td>",
"       <td>",
"        38&nbsp;",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        86*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sugarbaker P; 2001",
"       </td>",
"       <td>",
"        224",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        86*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        van Ruth S; 2003",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        70&bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients with complete cytoreduction.",
"     <br>",
"      &bull; 44 percent without evidence of disease at three years of follow-up.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10604=[""].join("\n");
var outline_f10_22_10604=null;
var title_f10_22_10605="CytoredsurgIPchem app muc tum";
var content_f10_22_10605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contemporary series of cytoreductive surgery and perioperative intraperitoneal chemotherapy for mucinous appendiceal tumors with peritoneal dissemination",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author; year",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        IP chemo",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Perioperative morbidity, percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Perioperative mortality, percent",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Overall survival, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        3-yr",
"       </td>",
"       <td class=\"subtitle2\">",
"        5-yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sugarbaker P; 1999",
"       </td>",
"       <td>",
"        385",
"       </td>",
"       <td>",
"        MMC + 5 FU",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        2.7",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        63",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loungnarath R; 2005",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        MMC",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Guner Z; 2005",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        Cisplatin or MMC or 5-FU",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moran BJ; 2006",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        MMC + 5 FU",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stewart J; 2006",
"       </td>",
"       <td>",
"        110*",
"       </td>",
"       <td>",
"        MMC",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Baratti D; 2008",
"       </td>",
"       <td>",
"        104",
"       </td>",
"       <td>",
"        MMC and cisplatin",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chua T; 2009",
"       </td>",
"       <td>",
"        106",
"       </td>",
"       <td>",
"        MMC + 5-FU",
"       </td>",
"       <td>",
"        49",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elias D; 2010",
"       </td>",
"       <td>",
"        301",
"       </td>",
"       <td>",
"        Not reported (n = 255)",
"       </td>",
"       <td>",
"        40",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Youssef H; 2011",
"       </td>",
"       <td>",
"        456",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        MMC",
"       </td>",
"       <td>",
"        &loz;",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        69 (57 percent at 10-years)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IP chemo: intraperitoneal chemotherapy; NR: not reported; MMC: mitomycin C; 5-FU: 5-fluorouracil.",
"     <br>",
"      * Included 55 DPAM, 29 peritoneal mucinous carcinomatosis (PMCA), 18 PMCA with intermediate features and 8 high grade mucinous lesions.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Severe (grade 3/4) morbidity.",
"       <br>",
"        &Delta; 289 patients (out of 456) had complete surgical cytoreduction; five and ten-year predicted survival were 87 and 74 percent, respectively.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Grade 3 or 4 complications in 7 percent of patients undergoing cytoreductive surgery; among 441 patients undergoing cytoreductive surgery or major debulking, 3.6 percent reoperation rate for bleeding, 10 percent venous thromboembolism, including 2 percent pulmonary emboli.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10605=[""].join("\n");
var outline_f10_22_10605=null;
var title_f10_22_10606="ECT consent continuation rx";
var content_f10_22_10606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F64703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F64703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Electroconvulsive Therapy (ECT) Consent Form: Continuation/Maintenance Treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        <p>",
"         Name of Patient:",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        <p>",
"         My doctor, _________________________, has recommended that I receive continuation or maintenance treatment with electroconvulsive therapy (ECT). This treatment, including the risks and benefits that I may experience, has been fully described to me. I give my consent to be treated with this type of ECT.",
"        </p>",
"        <p>",
"         I will receive ECT to prevent return of my illness. Whether ECT or an alternative treatment, like medication or psychotherapy, is most appropriate for me at this time depends on my prior experience with these treatments in preventing the return of symptoms, the features of my illness, and other considerations. Why continuation/maintenance ECT has been recommended for me has been explained.",
"        </p>",
"        <p>",
"         Continuation/maintenance ECT involves a series of treatments with each usually separated in time by 1 or more weeks. Continuation/ maintenance ECT is usually given for a period of several months or longer. These treatments may be given on an inpatient or outpatient basis.",
"        </p>",
"        <p>",
"         To receive each continuation/maintenance treatment I will come to a specially equipped area in this facility. The treatments are usually given in the morning. Because the treatments involve general anesthesia, I will have had nothing to eat or drink for several hours before each treatment. Before the treatment, a small needle will be placed in my vein so that I can be given medications. An anesthetic medication will be injected that will quickly put me to sleep. I will then be given another medication that will relax my muscles. Because I will be asleep, I will not experience pain or discomfort or remember the procedure. Other medications may also be given depending on my needs.",
"        </p>",
"        <p>",
"         To prepare for the treatment, monitoring sensors will be placed on my head and body. Blood pressure cuffs will be placed on an arm and leg. This monitoring involves no pain or discomfort. After I am asleep, a carefully controlled amount of electricity will be passed between two electrodes that have been placed on my head.",
"        </p>",
"        <p>",
"         I may receive bilateral ECT or unilateral ECT. In bilateral ECT, one electrode is placed on the left side of the head, the other on the right side. In unilateral ECT, both electrodes are placed on the same side of the head, usually the right side. Right unilateral ECT (electrodes on the right side) is likely to produce less memory difficulty than bilateral ECT. However, for some patients bilateral ECT may be a more effective treatment. My doctor will carefully consider the choice of unilateral or bilateral ECT.",
"        </p>",
"        <p>",
"         The electrical current produces a seizure in the brain. The amount of electricity used to produce the seizure will be adjusted to my individual needs, based on the judgment of the ECT physician. The medication used to relax my muscles will greatly soften the contractions in my body that would ordinarily accompany the seizure. I will be given oxygen to breathe. The seizure will last for approximately 1 minute. During the procedure, my heart, blood pressure, and brain waves will be monitored. Within a few minutes, the anesthetic medications will wear off and I will awaken. I will then be observed until it is time to leave the ECT area.",
"        </p>",
"        <p>",
"         The number of continuation/maintenance treatments that I will receive will depend on my clinical course. Continuation ECT is usually given for at least 6 months. If it is felt that continuation ECT is helpful and should be used for a longer period (maintenance ECT), I will be asked to consent to the procedure again.",
"        </p>",
"        <p>",
"         ECT is expected to prevent the return of my psychiatric condition. Although for most patients ECT is effective in this way, I understand that this cannot be guaranteed. With continuation/maintenance ECT I may remain considerably improved or I may have a partial or complete return of psychiatric symptoms.",
"        </p>",
"        <p>",
"         Like other medical treatments, ECT has risks and side effects. To reduce the risk of complications, I will receive a medical evaluation before starting ECT. The medications I have been taking may be adjusted. However, in spite of precautions, it is possible that I will experience a medical complication. As with any procedure using general anesthesia, there is a remote possibility of death from ECT. The risk of death from ECT is very low, about one in 10,000 patients. This rate may be higher in patients with severe medical conditions.",
"        </p>",
"        <p>",
"         ECT very rarely results in serious medical complications, such as heart attack, stroke, respiratory difficulty, or continuous seizure. More often, ECT results in irregularities in heart rate and rhythm. These irregularities are usually mild and short lasting, but in rare instances can be life threatening. With modem ECT technique, dental complications are infrequent and bone fractures or dislocations are very rare.",
"        </p>",
"        <p>",
"         If serious side effects occur, I understand that medical care and treatment will be instituted immediately and that facilities to handle emergencies are available. I understand, however, that neither the institution nor the treating physicians are required to provide long-term medical treatment. I shall be responsible for the cost of such treatment whether personally or through medical insurance or other medical coverage. I understand that no compensation will be paid for lost wages or other consequential damages.",
"        </p>",
"        <p>",
"         The minor side effects that are frequent include headache, muscle soreness, and nausea. These side effects usually respond to simple treatment.",
"        </p>",
"        <p>",
"         When I awaken after each treatment, I may be confused. This confusion usually goes away within 1 hour.",
"        </p>",
"        <p>",
"         I understand that memory loss is a common side effect of ECT. The memory loss with ECT has a characteristic pattern, including problems remembering past events and new information. The degree of memory problems is often related to the number and type of treatments given. A smaller number of treatments is likely to produce less memory difficulty than a larger number. Shortly following a treatment, the problems with memory are greatest. As time from treatment increases, memory improves.",
"        </p>",
"        <p>",
"         I may experience difficulties remembering events that happened before and while I received ECT. The spottiness in my memory for past events may extend back to several months before I received ECT, and, less commonly, for longer periods of time, sometimes several years or more. Although many of these memories should return during the first few months following continuation/maintenance ECT, I may be left with some permanent gaps in memory.",
"        </p>",
"        <p>",
"         For a short period following each treatment, I may also experience difficulty in remembering new information. This difficulty in forming new memories should be temporary and will most likely disappear following completion of continuation/maintenance ECT.",
"        </p>",
"        <p>",
"         The effects of continuation/maintenance ECT on memory are likely to be less pronounced than those during an acute ECT course. By spreading treatments out in time, with an interval of a week or more between treatments, there should be substantial recovery of memory between each treatment.",
"        </p>",
"        <p>",
"         Because of the possible problems with confusion and memory, it is important that I not drive or make any important personal or business decisions the day that I receive a continuation/maintenance treatment. Limitations on my activities may be longer depending on the side effects I experience following each treatment and will be discussed with my doctor.",
"        </p>",
"        <p>",
"         The conduct of ECT at this facility is under the direction of Dr. ______________________. I may contact him/her at _______________________ if I have further questions.",
"        </p>",
"        <p>",
"         I am free to ask my doctor or members of the ECT treatment team questions about ECT at this time or at any time during or following the ECT course. My decision to agree to continuation/maintenance ECT is being made voluntarily, and I may withdraw my consent for future treatment at any time.",
"        </p>",
"        <p>",
"         I have been given a copy of this consent form to keep.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        <p>",
"         Signature:",
"        </p>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <p>",
"         Date:",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Person Obtaining Consent:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        <p>",
"         Name:",
"        </p>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <p>",
"         Signature:",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. Copyright &copy; 2001 American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_22_10606=[""].join("\n");
var outline_f10_22_10606=null;
var title_f10_22_10607="Contents: Pediatric signs and symptoms";
var content_f10_22_10607=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric signs and symptoms",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric signs and symptoms",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acute and emergent",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/34/31272\">",
"           Apparent life-threatening event in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/36/16970\">",
"           Approach to acute vision loss in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27241\">",
"           Approach to chest pain in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/53/17241\">",
"           Approach to hypertensive emergencies and urgencies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/4/42057\">",
"           Approach to the child with a limp",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32472\">",
"           Approach to the child with acute ataxia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/8/35977\">",
"           Approach to the child with headache",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/60/22474\">",
"           Approach to the child with occult toxic exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/34/22056\">",
"           Approach to the child with palpitations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/38/9832\">",
"           Approach to the child with tachycardia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/60/24521\">",
"           Approach to the infant or child with nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17018\">",
"           Approach to the septic-appearing infant",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/0/1033\">",
"           Approach to upper gastrointestinal bleeding in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/20/11593\">",
"           Causes of acute abdominal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/12/39113\">",
"           Causes of acute respiratory compromise in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/39/32376\">",
"           Causes of scrotal pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/10/36007\">",
"           Causes of syncope in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7367\">",
"           Classification of trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29513\">",
"           Diagnostic approach to lower gastrointestinal bleeding in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/35/4666\">",
"           Emergency department evaluation of acute onset psychosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/61/7130\">",
"           Emergent evaluation of acute respiratory compromise in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10201\">",
"           Emergent evaluation of acute upper airway obstruction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/52/14153\">",
"           Emergent evaluation of headache in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/10/11432\">",
"           Emergent evaluation of syncope in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/61/22490\">",
"           Emergent evaluation of the child with acute abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/16/27912\">",
"           Epidemiology and etiology of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/41/31385\">",
"           Etiology and evaluation of cyanosis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/54/24425\">",
"           Etiology and evaluation of the child with muscle weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/39/40569\">",
"           Evaluation of dysphagia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/47/13050\">",
"           Evaluation of earache in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/42/18086\">",
"           Evaluation of epistaxis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/42/22185\">",
"           Evaluation of inguinal swelling in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/25/18842\">",
"           Evaluation of neck stiffness in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26841\">",
"           Evaluation of purpura in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/38/2663\">",
"           Evaluation of scrotal pain or swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/40/12936\">",
"           Evaluation of the immobile arm in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/10/15529\">",
"           Evaluation of vaginal bleeding in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/39/30329\">",
"           Evaluation of weight loss in infants over six months of age, children, and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/33/23065\">",
"           Management of hypertensive emergencies and urgencies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/62/33768\">",
"           Overview of blunt abdominal trauma in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/32/40457\">",
"           Traumatic causes of acute shoulder pain and injury in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ambulatory",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/26/8616\">",
"           Acquired torticollis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/28/41417\">",
"           Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/34/12840\">",
"           Approach to the child with an enlarged spleen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43880\">",
"           Approach to the child with anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33128\">",
"           Approach to the child with peripheral lymphadenopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/13/34004\">",
"           Approach to the infant with hypotonia and weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/36/34376\">",
"           Approach to the pediatric patient with vision change",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30424\">",
"           Approach to wheezing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/47/43766\">",
"           Causes of painless scrotal swelling in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30744\">",
"           Causes of peripheral lymphadenopathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/63/25591\">",
"           Causes of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/27/10680\">",
"           Clinical features and etiology of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24295\">",
"           Clinical manifestations and evaluation of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/23/25975\">",
"           Definition and evaluation of abnormal uterine bleeding in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11160\">",
"           Differential diagnosis and approach to the adolescent with abnormal uterine bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/52/15177\">",
"           Evaluation and management of colic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/7/7288\">",
"           Evaluation and management of edema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28074\">",
"           Evaluation and management of fever in the neonate and young infant (less than three months of age)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/43/697\">",
"           Evaluation of acute pelvic pain in the adolescent female",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/13/13529\">",
"           Evaluation of diarrhea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/24/29064\">",
"           Evaluation of dizziness in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/29/43479\">",
"           Evaluation of dysuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/55/30584\">",
"           Evaluation of microscopic hematuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/37/14937\">",
"           Evaluation of oligomenorrhea in adolescence",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/9/24728\">",
"           Evaluation of otorrhea (ear discharge) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/27/12729\">",
"           Evaluation of pallor in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/41/26262\">",
"           Evaluation of proteinuria in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/31/39415\">",
"           Evaluation of sore throat in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/17/1306\">",
"           Evaluation of the child and adolescent with chronic abdominal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/39/2679\">",
"           Evaluation of the child with back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/0/4102\">",
"           Evaluation of the child with hoarseness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/46/14057\">",
"           Evaluation of the child with joint pain or swelling",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/9/23706\">",
"           Overview of the causes of limp in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26072\">",
"           Vulvovaginal complaints in the prepubertal child",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-11D04509FF-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_22_10607=[""].join("\n");
var outline_f10_22_10607=null;
